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Abstract 
 
Chromosomal instability and aneuploidy are common features of human 
malignancies, which fuel genetic heterogeneity and can lead to inaccurate 
diagnosis and treatment failure. Tetraploidy has been shown as an intermediate of 
aneuploidy and, thus, understanding the molecular mechanisms governing 
tetraploid tolerance is of great importance. A frequent tolerance mechanism 
observed in experimental systems and human tumours is loss of TP53, highlighting 
its central role in the tetraploidy checkpoint. However, despite this association, 
more than half of genome-doubled tumours are TP53 wild-type. The aim of this 
project was to understand how tetraploid cells could tolerate the polyploidy 
phenotype with a functional p53/p21 axis. Firstly, tetraploidy tolerance was 
investigated in an isogenic HCT-116 diploid and tetraploid system. The HCT-116 
tetraploids showed functional p53, in response to DNA damage and segregation 
error induction, while also displayed elevated basal level of both proteins. Despite 
this, the tetraploid clones could proliferate and showed no evidence of cell cycle 
arrest, suggesting the p53/p21 tetraploidy checkpoint response had been 
overridden.  Quantitative proteomics revealed cyclin D1 overexpression in the 
tetraploid clones. As cyclin D1 can sequester p21, their relationship was 
investigated and validated in the HCT-116 system. To further test if elevated cyclin 
D1 could affect tolerance, cytokinesis failure was pharmacologically induced in 
RPE cells, where cyclin D1 overexpression promoted tetraploidy tolerance across 
multiple assays. In addition, bioinformatics analysis revealed that D-type cyclins 
were overexpressed in TP53, CDKN1A and RB1 wild-type, genome-doubled 
testicular germ cell tumours (TGCT).  These findings indicate that D-type cyclin 
overexpression can provide tetraploidy tolerance in vitro and may be implicated in 
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Chapter 1. Introduction 
The diagnosis and treatment of many human cancers have improved significantly 
over the past twenty years, with an extensive armoury of therapeutics and clinical 
strategies available to clinical oncologists. Despite this advancement, patients with 
metastatic disease or tumours not emendable to surgical resection, remain 
incurable. Intratumour heterogeneity (ITH), which has been reported in many solid 
and haematological tumours, contributes significantly to this more than 
unsatisfactory outcome.   
 
1.1 Chromosomal instability, aneuploidy and ITH 
In 1976, Peter Nowell proposed the tumour clonal evolution model based on 
sequential selection (Nowell, 1976). The model predicts that tumours are derived 
from a single clone and, subsequently, genetic instability produces random 
intercellular aberrations that may be selected for, resulting accumulation of 
increasingly fit subclones. Nowell hypothesised this process occurred in a non-liner 
fashion, an idea that has been recently supported by studies haematological and 
solid malignancies (Gerlinger et al., 2012, Yap et al., 2012, Ding et al., 2012, Schuh 
et al., 2012, Nowell, 1976). Linear clonal evolution results in the selective genetic 
sweeps of the fittest clones, resulting in tumours with low genetic diversity (de Bruin 
et al., 2013). In contrast, non-linear branched evolutionary growth, allows the 
evolution of many independent subclones that can acquire a myriad of genetic 
lesions, producing extensive ITH.  
 
Somatic mutations represent one mechanism involved in generating genetic 
aberrations required to drive tumour evolution. Another important pathogenic 
process that can produce an aberrant genome is chromosomal instability (CIN), 
which relates to a constantly elevated rate in karyotypic change through numerical 
and structural chromosomal defects (Gordon et al., 2012).  CIN results in 
aneuploidy, which relates to a state of abnormal chromosome number and is 
frequently observed in solid and haematological malignancies (Gordon et al., 2012, 
Gerlinger et al., 2014, Greaves, 2009). However, aneuploidy is not synonymous 
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with CIN, as stable aneuploid tumours can exist (Kaneko and Knudson, 2000). 
Several studies have demonstrated that CIN and aneuploidy can provide the 
necessary genetic lesions that can increase metastatic potential and drug 
resistance. Yonkers et al demonstrated CIN in endocrine pancreatic tumours was 
an indicator of metastatic potential; highlighting that CIN can increase the 
frequency of metastatically viable subclones (Jonkers et al., 2005).  Li et al showed 
that CIN and aneuploidy provide the basis for drug resistance in cancer cell lines 
(Li et al., 2005). CIN provided the high rates of spontaneous chromosome 
alterations required for the rate of the observed drug resistance and could also 
explain the acquisition of multi-drug resistance after single-agent treatment. These 
studies demonstrate that CIN can produce the intercellular genetic variation 
required to permit phenotypes, such as enhanced drug resistance and metastatic 
potential.  
 
CIN can drive branched evolution to produce independent evolutionary trajectories, 
resulting in multiple subclones with differential karyotypes and phenotypes within a 
single lesion (Burrell et al., 2013b, Gerlinger et al., 2014). The emergence of 
spatially separated aneuploid subclones exacerbates the degree of heterogeneous 
somatic copy number alterations (SCNAs), resulting in genetic ITH. Branched 
tumour evolution, through CIN and aneuploidy, can therefore provide a diverse pool 
of clones with varying degrees of fitness under certain selection pressures. These 
clones can be selected for (e.g. drug resistant or metastatic clones), resulting in the 
poor survival outcomes and therapeutic responses observed in the clinical setting. 
 
Our laboratory has shown that CIN-positive cell lines are more resistant to targeted 
and cytotoxic anticancer agents (Lee et al., 2011). The study concluded that an 
intrinsic CIN survival state may exist which enhances resistance, as opposed to 
selection and outgrowth of low frequency, resistant subclones. The genetic 
adaptions that permit continuous segregation errors may provide tolerance to drug 
treatment and enhanced survival, which may in turn support the selection and 
outgrowth of even more optimal clones, resulting in enhanced acquired therapeutic 
resistance. Paradoxically, CIN may be associated with cell death and improved 
patient outcome. Several studies have indicated that such thing as an ‘optimal level 
of CIN’ might exist and breaching a certain threshold becomes deleterious for the 
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cell (Birkbak et al., 2011, Kops et al., 2004). Kops et al demonstrated that mild 
suppression of the mitotic checkpoint is permissive for CIN and may enhance 
tumourigenesis, whereas further weakening or complete silencing of the checkpoint 
is lethal to cancer cells (Kops et al., 2004). In addition, our laboratory showed that 
oestrogen receptor-negative breast, ovarian, gastric and non-small cell lung 
cancers with extreme CIN associated with improved prognosis, compared to 
intermediate CIN (Birkbak et al., 2011). These studies indicate that CIN needs to 
be finely tuned in order to promote disease progression and can result in 
cytotoxicity, if pushed above a threshold.   
 
Taken together, CIN results in aneuploidy and combined with branched tumour 
evolution can lead to the generation of multiple subclones within the same tumour, 
increasing the probability of drug resistance and metastasis by generating a large 
tumour gene pool to select from.  
 
1.2 Maintenance of the diploid genome  
In order to combat the harmful effects of CIN and aneuploidy, the cell has evolved 
to permit faithful replication and division of the genetic material, through a tightly 
regulated cell cycle.  
 
1.2.1 The cell cycle  
The cell cycle is comprised of four distinct and highly ordered phases, namely, gap 
phase one (G1), synthesis phase (S phase), gap phase two (G2) and mitosis (M 
phase)(Massague, 2004). S phase results in the replication of the genome, via 
semiconservative DNA synthesis from distinct regions, known as replication origins 
(Vermeulen et al., 2003). Newly formed chromatids are linked by cohesion in S 
phase, which is maintained through G2 phase, before entry into M phase. M phase 
is a complex process and is followed by cytokinesis (Nigg, 2001). In M-phase, 
sister chromatids undergo spindle attachment, before equatorial alignment, 
cohesion destruction and segregation to the spindle poles.  After nuclear 
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membrane reformation, the actomyosin contractile ring promotes abcission in 
cytokinesis, splitting the cell into two daughter cells (Nigg, 2001).    
1.2.2 The cell cycle control system  
A series of biochemical switches exist to ensure ordered progression through the 
cell cycle. Cyclin dependent kinases (CDKs) control progression by 
phosphorylating their substrates to initiate specific phases of the cell cycle. CDK 
levels remain constant throughout the cell cycle and are instead governed by 
oscillations in cyclin concentration, a process regulated through transcription and 
degradation (Fung and Poon, 2005). Cyclin oscillations are coupled to specific 
cellular signals that ensure the correct CDK is activated at the relevant stage of the 
cell cycle, allowing ordered progression through the cell cycle. CDKs and cyclins 
can be grouped based on the cell cycle stage they regulate. In G1, cyclins D and E 
activate CDK4/6 and CDK2 respectively (Sherr and Roberts, 1999). During S 
phase, cyclin A is expressed and binds CDK2, whereas cyclin D is destroyed. 
Cyclin B regulates CDK1 to govern M phase (Nigg, 2001).  
 
In addition to transcription and protein degradation, CDK-cyclin complexes can be 
regulated by cyclin kinase inhibitors (CKIs). There are two main families, the INK4 
family (p16, p14, p15, p18, p19) and the CIP/KIP family (p21, p27, p57). The 
majority of the INK4 family inhibit CDK4/6 activity exclusively, whereas p14 can 
inhibit both G1 and G2/M kinases (Canepa et al., 2007). The CIP/KIP family is 
comprised of p21, p27 and p57 and have broader specificity and can bind multiple 
CDKs (Denicourt and Dowdy, 2004). CKIs inhibit the CDK by occupying the ATP-
binding pocket, thus impairing substrate interaction (Hukkelhoven et al., 2012). 
Another level of regulation is provided by cell division cycle 25 (CDC25) 
phosphatases.  Dephosphorylation of CDKs by the either CDC25A, B or C removes 
inhibitory phosphate groups in the CDK ATP-binding loop (Nilsson and Hoffmann, 
2000). This activation step, combined with a phosphorylation event mediated by 
CDK-activating kinase (CAK) together with the binding of a relevant cyclin, permits 
transition through the cell cycle (Boutros et al., 2007).  
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1.2.3 Progression through the cell cycle: D-type cyclins and p21 in G1 phase  
Mitogenic signalling through growth factor pathways, such as the RAS/ERK 
pathway, induce the transcription and stabilisation of D-type cyclins (Musgrove et 
al., 2011). D cyclins, mediated by p21, in turn assemble with CDK4/6 in the 
cytoplasm (LaBaer et al., 1997). Binding of p21 is required for complex formation, 
activity and nuclear localisation. CDK4-Cyclin D1-p21 complexes move to the 
nucleus in a timely manner, where CAK and dephosphorylation by CDC25C fully 
activate the complex, driving mono-phosphorylation of RB (Bockstaele et al., 
2006a). The mechanistic relationship between of D-type cyclins and p21 in G1 are 
discussed in detail below.  
1.2.3.1 D-type cyclins  
There are three types of D-cyclin D1, D2 and D3. They can all interact with CDK4 
or CDK6 and promote G1 progression. All three are closely related and cyclins D2 
and D3 are 62% and 51%, respectively, identical to cyclin D1 (Musgrove et al., 
2011). The cyclin box that binds the CDK and CKI is highly conserved between the 
there homologues, further suggesting they can preform similar functions. 
1.2.3.2 p21 complexes with cyclin D1 and CDK4 
The classical roles of p21 and other KIP/CIP CDK inhibitor family members are 
described in section 1.2.1. Paradoxically, a study by LaBaer et al provided strong 
evidence for the involvement of the KIP/CIP proteins p21, p27 and p57 in CDK4/6-
Cyclin D complex formation and activation (LaBaer et al., 1997). The group noted 
that cyclin D1 and CDK4 could not be co-immunoprecipitated, in contrast to other 
CDK-Cyclin complexes. However, overexpression of p21, p27, or p57 enhanced 
CDK4 and D-type complex formation. Mutations in the either cyclin or CDK binding 
domains (CY domains) of p21 abolished complex formation, suggesting that p21 
binds both the kinase and cyclin. In addition, other studies have shown that p21 
and p27 can bind cyclins without CDKs, and can only interact with CDKs in 
presence of cyclin (Chen et al., 1996, Hall et al., 1995). In vitro biochemistry 
experiments showed low and intermediate levels of p21 aided complex formation 
and activity and correlated with p21 concentration. However, at high doses catalytic 
activity was inhibited. This observation possibly suggests that at low p21 levels a 
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1:1:1 binding relationship exits, however as ratios increase more than one p21 
molecule can bind a single CDK4/6, resulting in kinase inhibition (LaBaer et al., 
1997). This stoichiometric model of CDK4 inhibition was supported by a more 
recent study (Bockstaele et al., 2006b).  
 
Kehn et al provided further evidence for p21 and cyclin D1 interaction (Kehn et al., 
2004). The study demonstrated HTLV-1 tumour virus incudes p21 and cyclin D2, 
resulting in enhanced complex formation. In this study, purified cyclin D2, CDK4 
and p21 formed catalytically active complexes in a dose-dependent manner at the 
same stoichiometric ratios as observed by LeBaer et al. Importantly, purified p21 
could also inhibit CDK2 activity, clearly showing the CKI can inhibit CDK2, yet 
activate CDK4 at the same stoichiometry. 
 
1.2.3.3 D-type cyclins can sequester and inhibit p21 to facilitate G1 
progression  
The above studies clearly show that p21 facilitates the formation and activation of 
CDK4-CyclinD1-p21 complexes. As p21 levels rise after mitogenic signalling, it is 
likely this mechanistic process is driver of G1 progression (Cheng et al., 1999, 
Sherr and Roberts, 1999). Another important consequence of this proteomic 
interaction is the titration of p21 and p27 from CDK2, coupling early and late G1 
molecular events. Planas-Silva et al provide experimental evidence of p21 
redistribution after oestrogen addition to tamoxifen-arrested breast cancer MCF-7 
cells (Planas-Silva and Weinberg, 1997).  Oestrogen addition resulted in a cyclin 
D1 increase combined with an elevation in CDK4 and CDK2 activity. The 
heightened CDK2 activity was not due to increased CDK2, Cyclin E1, CAK or 
changes in p21/p27 levels. The authors showed that the increase in cyclin D1 could 
titrate p21 from CDK2 after oestrogen-stimulated growth.  
 
Khen at al also showed CDK2 activity increased after cyclin D2 and p21 elevation 
after HTLV-1 virus infection, despite no change in cyclin E or CDK2 (Kehn et al., 
2004). This observation further supports the notion that D-type cyclins can 
independently activate CDK2 by sequestering p21. Quintanilla-Martinez et al 
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showed cyclin D1 could sequester p27 in haematological malignancies. 
(Quintanilla-Martinez et al., 2003). The group noticed that in typical mantel cell 
lymphomas (MCL), p27 expression correlated with low ki67 staining. Paradoxically, 
more aggressive blastic MCL expressed high levels of p27 and commonly have 
t(11;14) translocations resulting in CCND1 gene overexpression. The group 
hypothesised high cyclin D1 could buffer p27 and contribute to tumourigenesis. 
Sequential IPs in blastic MCL cell lines showed cyclin D1 was in excess, compared 
to p27, and sequestered the majority of the protein, thus buffering CDK2-cyclin E1 
binding and inhibition.  
 
In contrast to the above findings, some studies have suggested CKIs are not 
required for complex formation (Bagui et al., 2003, Bockstaele et al., 2006b, Gaben 
et al., 2004). Bagui et al showed p21-/- and p27-/- mouse embryonic fibroblasts 
(MEFs) had phosphorylated RB and when p27 was overexpressed kinase activity 
was reduced in a dose-dependent manner (Bagui et al., 2003). However, although 
re-addition of p27 inhibited kinase activity it aided CDK4-CyclinD-p27 complex 
formation. Therefore, the authors concluded that a small fraction of CDK4-cyclinD 
complex exists and contributes to kinase activity, whereas most complexes contain 
CKI and their primary role is sequestering p21 and p27 from CDK2. 
 
1.2.3.4 Phosphorylation of p21/p27 and CDK redistribution    
The enzymatic activating properties of CIP/KIP CKIs may not be exclusively 
dependent on D-type concentrations alone. One group noticed differential CKI 
phosphorylation in TGF-β sensitive cells compared to the phosphorylation profile of 
cycling TGF-β-resistant cells (Ciarallo et al., 2002).  
 
James et al showed in arrested and cycling cells, CDK4 immunoprecipitates had 
similar amounts of p27 binding but in cycling cells the kinase was catalytically 
active, whereas in contact arrested cells no RB phosphorylation was observed 
(James et al., 2008). The group showed that p27’s transition from a CDK4 inhibitor 
to activator was not concentration dependent but reliant on phosphorylation at the 
Y88 and Y89 residues. This phosphorylation by the kinase Abl, switched p27 into a 
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CDK4 activator, however the modification did not inhibit CDK2 binding unlike the 
findings from Kardinal et al (Kardinal et al., 2006). Larrea et al support these 
findings and suggest that phosphorylation of p27 at T157 and T198 may aid 
complex formation before Y88 and Y89 modification, which activates CDK4 (Larrea 
et al., 2008). Therefore, these studies suggest that the CDK4 activating activities of 
p27 require phosphorylation and similar mechanisms may regulate p21. Indeed, 
more recently, Hukkelhoven et al showed that phosphorylation of p21 at Y76, in a 
RCAS-PDGF-HA/nestin system, could contribute to enhanced tumour formation in 
vivo (Hukkelhoven et al., 2012). However, unphosphorylated p21 could still form 
complexes with CDK4-CyclinD. 
 
Taken together the above studies suggest that p21 and p27 can aid CDK4-CyclinD 
complex formation and cyclin D1 plays a role in p21 sequestration, although it may 
not be essential. CKI phosphorylation likely plays a role in the activation and in vitro 
recombinant biochemistry assays suggest protein stoichiometry may also 
contribute (Figure 1.1). These findings add another layer of complexity to G1/S 
control. 
1.2.3.5 D-type cyclin expression in cancer  
CCND1 amplification occurs in breast, lung, skin and oral cancers and incidence 
rates range for 15-40% (Musgrove et al., 2011, Santarius et al., 2010). Focal 
amplifications of CCND2 or CCND3 are less commonly observed in tumours. 2% of 
gliomas harbour focal CCND2 amplifications and is considered the only cancer 
type were CCND2 involvement is classed as significant (Cancer Genome Atlas 
Research, 2008). Overexpression of cyclin D1 is more common and cannot be 
solely accounted by copy number gains, suggesting that deregulated growth factor 
signalling and protein stability networks are also responsible.  Due to the high 
frequency of D-type cyclin overexpression in human tumours and correlation with 
enhanced proliferation in human tumours and as result a range of specific CDK4/6 
specific inhibitors exist (Musgrove et al., 2011).  
 
Aside from CCND1 overexpression, D-type cyclins are frequently elevated in 
human tumours as result deregulated post-translational mechanisms (Alao, 2007, 
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Gong et al., 2014). In the normal cell cycle, cyclin D1 levels rise in early G1 until 
the G1/S boundary, where the protein is degraded to permit S phase, as cyclin D1 
can inhibit PCNA (Fukami-Kobayashi and Mitsui, 1999). Cyclin D1 has a relatively 
short half-life of ~20 minutes, allowing rapid degradation upon mitogen withdrawal. 
Diehl et al showed phosphorylation of cyclin D1 at Thr286 resulted in ubiquitin 
mediated degradation. More recent studies have shown that PARK2 and FBXO4, 
which form the PCF4 and PCF7 E3 ubiquitin ligase complexes cooperate to allow 
recognition of D and E-type cyclins (Gong et al., 2014, Bartek and Hodny, 2014, Lin 
et al., 2006). It was shown that focal deletions of PARK2 were frequent in human 
tumours (30%) and were mutually exclusive of CCND1, CCNE1, CDK4 and CDK2 
amplification and loss of complex resulted increased cellular proliferation, CDK 
activity and RB phosphorylation. 
 
For the PCF4 complex to recognise D-type cyclins, phosphorylation at Thr286 is 
required, as T286A mutations results in elevated cyclin D1 and stability (Gong et al., 
2014). The kinase GSK3-β is thought to regulate this phosphorylation site and 
overexpression in mouse fibroblasts caused cyclin D1 cytoplasmic redistribution 
and reduced proteolytic turnover (Diehl et al., 1998, Diehl et al., 1997). The kinase 
is negatively regulated by RAS signalling and therefore links the growth pathway 
activation with cyclin D1 stabilisation, as well as CCND1 induction. Yang at al also 
showed that cyclin D1-Thr286 phosphorylation was important for degradation 
during S phase (Yang et al., 2006a). However, during S phase there was no 
change in AKT, PI3K or GSK3-β activity, challenging the role of GSK3-β mediated 
phosphorylation. Nevertheless, these studies imply that D-type cyclin expression is 
tightly regulated by phosphorylation at Th286. They also provide evidence that a 
major mechanism contributing to cyclin D1 overexpression in human tumours 












Figure 1.1 Interaction between cyclin D1 and p21 in G1/S control  
1) In early G1 cyclin D and p21 are levels low. At this time, CDK2 is inhibited by 
p27 and p21 binding. 2) Mitogenic signalling induces p21 and cyclin D1 expression 
and complex formation occurs. 3) High levels of cyclin D titrate p21 and p27 from 
CDK2. p21 and p27 are constantly dissociating from CDK2. Therefore, high cyclin 
D1 levels will outcompete cyclin E1 for p21 binding. Mitogenic signalling also 
increases p21/p27 tyrosine phosphorylation. This disrupts p21/p27 Van Der Waal’s 
forces and hydrogen bonding on the alpha helix responsible for obstructing the 
CDK ATP binding pocket. This switches p21 and p27 from an inhibitory 
confirmation to an active one. 4) Activated CDK4-CyclinD-p21/p27 complexes 
hypophosphorylate RB releasing E2F1. 5) E2F1 induces cyclin E1 transcription and 
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1.2.4 Synthesis, G2 and mitotic cell cycle phases  
Primary phosphorylation of RB by CDK4-cyclinD1-p21 complexes results in cyclin 
E transcription, CDK2 activation and hyperphosphorylation of RB, leading to E2F 
dependent gene transcription of S-phase initiation genes (Figure 1.1). Cells are 
now committed to division even in the absence of mitogenic stimuli and enter S 
phase, where DNA replication takes place (Foijer and Te Riele, 2006). The 
successful completion of S phase leaves the cell with two accurate copies of the 
genome that are segregated in M phase into daughter cells. The phases of mitosis 
are outlined in Figure 1.2. Before mitotic entry, the cell firstly pauses in G2, where 
CDK1-cyclin A levels are still maintained from the preceding S phase (Goldstone et 
al., 2001).  During transition into M phase, cyclin A is degraded and cyclin B levels 
peak through transcription and protein stabilisation in G2 (Fung and Poon, 2005). 
Elevated levels of cyclin B result in more CAK activated CDK1-cyclin B complexes. 
However, the complex is still inhibited by Wee1 and Myt1-mediated 
phosphorylation, resulting in a pool of primed CDK1-cyclin B (Fung and Poon, 
2005).  In order to activate the system in a switch like fashion, CDC25 
phosphatases are activated by polo kinase, which in turn leads to preliminary 
activation of CDK1. A positive feedback loop develops, whereby CDK1 inhibits 
Wee1 and activates CDC25 phosphatases resulting in rapid activation (Potapova et 
al., 2009). Activated CDK1 now initiates early events in mitosis, including nuclear 
envelope breakdown, chromosome condensation, bipolar mitotic spindle 
organisation and assembly (Enserink and Kolodner, 2010). After CDK1 has 
performed its early roles, the cell is prepared for the metaphase to anaphase 
transition. Activation of the anaphase-promoting complex (APC/C), a ubiquitin 
ligase, promotes the degradation of securin, which in turn frees separase to cleave 
the cohesion complex resulting in its rapid disruption and chromosome segregation 
takes place (Uhlmann, 2001). Emi1 inhibits APC/C activity in S and G2 phases, 
until CDK1-dependent phosphorylation and destruction (Margottin-Goguet et al., 
2003).  
 
Before the cell commits to chromosome segregation, the spindle assembly 
checkpoint (SAC) has to be satisfied. The SAC halts anaphase onset until every 
kinetochore (a protein complex localised to chromatid centromeres that permits 
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spindle attachment) is attached to the mitotic spindle, ensuring accurate 
chromosome segregation (Musacchio and Salmon, 2007). Inhibition of APC/C by 
the SAC prevents separase activation and cyclin B degradation, holding the cell in 
metaphase (Nigg, 2001). Kinetochore assembly in prophase recruits a complex of 
proteins including MAD1, MPS1, BUB1, BUB3, BUBR1 and CENPE. Kinetochores 
vacant of microtubule binding generate a diffusible inhibitory signal that is 
dependent on the assembly of all the aforementioned proteins (Musacchio and 
Salmon, 2007). Specifically, upon binding to the kinetochore complex, MAD2 is 
activated through a conformational change, before tightly binding to cdc20 (Yu, 
2006). Cdc20 is an APC/C activator and its sequestration inhibits the system. Upon 
microtubule binding to the kinetochore, the MAD2 activation template is absent, 
relieving the SAC (Mapelli et al., 2007). Therefore, cdc20 is free to activate APC/C, 
inducing chromosome segregation. After segregation and nuclear membrane 
formation, cyclin B is destroyed by APC/C, which induces cytokinesis (Normand 
and King, 2010) .  
 
Like mitosis, cytokinesis consists of a series of highly ordered stages (Normand 
and King, 2010). Firstly, the recruitment of RhoA to the cleavage site specifies the 
cleavage plane; problems in this phase will fail cytokinesis initiation (Normand and 
King, 2010). The second stage involves the cleavage furrow ingression through 
formation of the actomyosin ring and failure at this stage can result in a lack of 
furrow initiation or regression (Normand and King, 2010). As furrow regression 
completes, the two cells remain linked by the spindle midbody. Signalling at this 
stage safely promotes abscission and permanent separation the two daughter cells 
(Normand and King, 2010). Failure at any stage of cytokinesis can result in the 
formation of bi-nucleated tetraploid cells. After successful completion of cytokinesis, 









Figure 1.2 The phases of mitosis  
Images of HCT-116 cells in the different stages of mitosis (DNA is stained with 
DAPI in blue and the mitotic spindle with anti-tubulin antibodies in green). The first 
mitotic stage is prophase, where chromosome condensation occurs and spindle 
fibres emerge from the centrosomes, before nuclear envelope breakdown. During 
prometaphase, kinetochores form at chromatid centromeres facilitating spindle 
attachment, centrosomes move to opposite poles and chromatids are aligned to the 
metaphase plate. The cell is now in metaphase with the mitotic spindle fully 
developed. The centrosomes are at opposite poles with each sister chromatid 
attached to a spindle fibre from each extremity. After satisfaction of the SAC, 
anaphase is initiated, resulting the in breakdown of cohesion proteins before 
chromosome segregation, whilst non-kinetochore spindle fibres lengthen and 
elongate the cell. During telophase, chromosomes are fully segregated to opposite 
poles, the mitotic spindle breaks down and the nuclear envelope re-forms. Finally, 
the formation of the cleavage furrow in cytokinesis occurs before abscission, 
resulting in the production of two genetically identical daughter cells. Images 
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1.2.5 Mitotic causes of chromosome missegregation and CIN 
Deviation from the strict mitotic control, described above, can lead to chromosome 
missegregation. Unfaithful chromosome segregation contributes to CIN, resulting in 
divergent and unstable aneuploidy (Ganem et al., 2009).  In order to achieve 
accurate segregation of the genome to the spindle poles and subsequent daughter 
cell generation, two pathways monitor fidelity in mitosis, the SAC and error 
correction. As discussed above, the SAC ensures all kinetochores are occupied by 
spindles through MAD2 inhibition of cdc20 and inactivation of APC/C. Once 
attachment is complete, chromosome segregation occurs. As the SAC has such a 
central role in regulating segregation it is easy to imagine that defects in system 
could lead to segregation errors (Kops et al., 2005). 
 
Alternatively, segregation errors and CIN can arise though unresolved kinetochore–
microtubule attachments. Incorrect attachments are problematic, as they can 
satisfy the SAC as all kinetochores are occupied and MAD2 signalling is supressed, 
leading to aberrant segregation, CIN and aneuploidy (Kops et al., 2005). The two 
types of aberrant spindle binding are known as syntelic and merotelic attachments. 
Syntelic attachment involves both kinetochores being attached to same spindle 
pole, and merotely occurs when one kinetochore is attached to spindle poles (Kops 
et al., 2005). Both occur frequently during mitosis and if unresolved, can lead to 
lagging chromosomes (Gregan et al., 2011). 
 
If the frequencies of erroneous attachments are high, the system can become 
saturated, resulting in uncorrected errors and lagging chromosomes. Merotely is 
particularly dangerous, in that it can resist both error correction and the SAC, as 
both kinetochores are occupied and tension is present, resulting in anaphase 
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1.2.6 DNA damage response (DDR) 
The cell employs DNA damage checkpoint pathways in order to sense errors and 
arrest the cell cycle in order to provide essential time and resources in repairing the 
damaged DNA (Kastan, 2008). DNA damage, resulting in single-strand and double-
strand breaks, DSBs and SSBs, respectively, can lead to variety chromosomal 
abnormities, including fusions, translocations and acentric fragments that can lead 
to CIN in mitosis (Thompson and Compton, 2011).  Pre-mitotic defects can lead to 
mitotic errors, such as anaphase bridges through the production of dicentric 
chromosomes, whilst acentric chromosomes can be lost or randomly segregated 
(Thompson and Compton, 2011). Therefore, pre-mitotic DNA damage can lead to 
copy number gains and losses through CIN. Indeed, our laboratory recently 
demonstrated replication stress in colorectal cancer (CRC) resulted in DNA 
damage that linked both structural and numerical CIN (Burrell et al., 2013a). The 
observation that pre-mitotic defects could result in numerical CIN may be a result of 
the DNA damage caused by structural CIN. The high frequency acentric and 
dicentric chromosomes observed after replication stress are likely to result in 
daughter cells with heightened DNA damage. Damaged chromosomes may be less 
likely to be replicated properly in S-phase and passed on to subsequent 
generations, and therefore may be lost resulting in numerical CIN. Loss of DNA 
repair proteins such as ATR and MRE11 result in high levels of CIN, as does low 
dose irradiation (IR), supporting a link between DNA damage and CIN (Deckbar et 
al., 2007, Brown and Baltimore, 2000, Buis et al., 2008). These studies show that 
defects in sensing and repair of DNA damage can lead to CIN and aneuploidy.  
 
1.2.7 Aneuploidy tolerance  
The aforementioned mechanisms demonstrate how cells can make segregation 
errors that can lead to CIN and aneuploidy. In mitosis, an aberrant SAC or 
problems in resolving kinetochore attachment can lead to lagging chromosomes 
resulting in loss or missegregation. In addition, pre-mitotic DNA damage can lead 
to structural and numerical CIN resulting in an unbalanced genome. However, 
cancer cells can have high rates of segregation errors and yet CIN and aneuploidy 
cannot be propagated (e.g. HCT-116). In order for CIN and aneuploidy to 
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propagate, chromosome missegregation must be coupled with a tolerance 
mechanism. 
 
Thompson and Compton directly investigated the relationship between CIN and 
aneuploidy, by employing a system where LacGFP was integrated into a single 
chromosome in order to monitor its segregation (Thompson and Compton, 2010a). 
Elevating the rate of segregation errors in HCT-116 cells by washout treatment with 
monastrol, an inhibitor of the Eg5 kinesin that is critical for proper spindle formation 
(Kapoor et al., 2000), inhibited colony formation in cells that missegregated the 
labelled chromosome. The reduction in viability was p38, p53 and p21-dependent 
and did not elicit a DNA damage response.  
 
Clonogenic assays showed treatment of TP53-/- cells with monastrol resulted in the 
formation of viable colonies, which showed deviation from the model chromosomal 
number, whereas p53 wild type colonies did not form. This suggests TP53-/- cells 
make segregation errors and proliferate, a hallmark of CIN (Thompson and 
Compton, 2010a). Intriguingly, TP53-/- cells not treated with monastrol maintained a 
stable diploid karyotype, suggesting that loss of a tolerance mechanism alone is 
insufficient to initiate CIN. The TP53-/- CIN-positive cells were then picked and 
subcloned, before karyotyping 50 cells from the resulting population. Karyotypes 
from these subclones often deviated from the model chromosome number, 
suggesting an elevated rate of karyotypic change (or CIN) in a previously stable 
diploid cell line (Thompson and Compton, 2010a). This result suggests the initial 
chromosomal imbalance, caused by monastrol, could maintain CIN, and gave rise 
to a diverse spectrum of aneuploid clones. A diverse pool of subclones within a 
population could be selected in the presence of a selection a pressure (e.g. drug 
treatment), highlighting the clinical importance of heterogeneous aneuploidy in 
tumours. Therefore, this study showed that elevating the segregation error rate in 
TP53-/- background leads to CIN and diverse aneuploidy, demonstrating that 
heightened rates of segregation errors in combination with a tolerance required for 
the maintenance of CIN.   
 
A scenario that may promote elevated segregation error rates in combination with 
an aneuploidy tolerance mechanism is tetraploidy. Below tetraploidy is discussed in 
Chapter 1 Introduction 
33 
 
detail, firstly examining routes to tetraploidization, before discussing tolerance and 




There are two different classes of polyploid cells, namely, allopollyploids and 
autopolyploids. Allopolyploids can be formed by fusion of diploid gametes, resulting 
from improper meiosis, from two hybrid organisms (Storchova and Pellman, 2004, 
Otto, 2007). Allopolyploidy is particularly important in evolution, as different 
genomes are combined and also undergo a degree of structural change and can 
contribute to the formation of new species (Storchova and Pellman, 2004). 
Autopolyploids are derived from a genome-doubling event of the same genome 
and can lead to whole organism polyploidy or can be confined to a population cells 
in euploid organism (Storchova and Pellman, 2004).  
 
Tetraploidy is an autopolyploid state referring to the specific doubling of the diploid 
complement (2N), in contrast to aneuploidy which is not a 2N multiple. Polyploidy 
observed in normal mammalian tissue plays a beneficial role to the cell and 
organism (Davoli and de Lange, 2011a). However, polyploidy, and mainly 
tetraploidy, observed in tumours can lead to CIN aneuploidy and tumour evolution. 
Polyploid cells can be formed by three major mechanisms in animals; cell fusion, 
developmental endoreplication and mitotic errors (Storchova and Pellman, 2004). 
These processes are discussed in detail below in the context of normal 
development and disease.  
 
1.3.1 Polyploidy and CIN in normal cellular physiology  
Although polyploidy is well documented in plants, a wide variety of animal tissues 
are polyploid including the blood, liver, intestinal, brain, and skin, highlighting an 
important role in normal development (Davoli and de Lange, 2011a).  
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Cell fusion can create polyploid cells in normal development. Skeletal muscle fibres 
are formed though fusion of thousands of myoblasts. Initially, low numbers of 
myoblast fuse to form nascent myotubes, before further fusion events produce 
mature myotubes (Horsley and Pavlath, 2004). Macrophages also undergo cell 
fusion, although in contrast to myoblasts, it is a relatively rare event confined to 
specific instances such as chronic inflammation (Bruzzaniti and Baron, 2006). 
Fusion results in giant cells or osteoclasts that have an increased capacity to 
consume and degrade foreign bodies.  
 
Endoreplication can be divided into two subcategories comprised of the endocycle 
and endomitosis (abortive mitosis). Endocycling involves the complete absence of 
mitosis, resulting in S phase and growth phase alternations with no division. Cells 
that undergo endomitosis, enter M phase but fail to complete the process and exit 
early from mitosis with either mono or bi-nucleate cells, depending on the point of 
exit (Fox and Duronio, 2013).  They are both programmed, normal physiological 
mechanisms that generate polyploid cells and occur in a variety of mammalian 
tissues.  
 
Differentiation of trophoblast stem cells (TS) to giant cells (TG) results in 
endocycling and polyploidization with ploidy profiles of up to 64N (Ullah et al., 
2008). During differentiation, fibroblast growth factor 4 deprivation and increases in 
p57 expression attenuate cyclin B expression and CDK1 activity and blocks mitotic 
entry. This endocycling process is thought to benefit the cell by accelerating cellular 
growth, by shortening the cell cycle while increasing the chromosome complement. 
Megakaryocytes are thought to undergo endoreplication as repeat cycles can result 
in cells with ploidy profiles up to 128N. Many single cells would be required to 
produce the same number of platelets as a polyploid megakaryocyte. Increasing 
platelet production form a single cell is beneficial as less energy is required for 
membrane, due to lower surface area, synthesis and cell division. Therefore one 
polyploid megakaryocyte can produce and equivalent number of platelets at a 
reduced energy cost. (Ravid et al., 2002). 
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1.3.2 Pathogenic polyploidy in cancer   
Polyploidy and CIN has been observed in normal tissues and is discussed in 
section 1.3.1. However, tetraploidy has also been shown to be an intermediate of 
aneuploidy, by promoting and supporting CIN and leading to tumour evolution and 
drug resistance (Dewhurst et al., 2014). Although the mechanisms that can 
produce normal or pathogenic polyploid cells are the same, there are some key 
differences between programmed and sporadic polyploidy.  
 
Normal endoreplication is associated with permanent departure from the cell cycle 
and is synonymous with terminal differentiation (Fox and Duronio, 2013). Therefore, 
if the cell is not cycling, CIN and branched tumour evolution cannot occur. The liver 
is an interesting case, where proliferation and CIN are tolerated and rarely lead to 
cancer (Duncan et al., 2010). Even joint loss of TP53 and RB1 fail to produce 
tumours, suggesting that the liver has the capability to suppress tumour formation 
in the presence of CIN and aneuploidy (Fox and Duronio, 2013). Therefore, when 
polyploidy is programmed, it rarely leads to tumourigenesis as mechanisms are in 
place to prevent it. However, in tissues where non-programmed genome-doubling 
occurs, cell cycle re-entry is permitted and tetraploidy tolerance is provided, such 
that the resulting proliferating tetraploid cells can facilitate tumourigenesis and 
tumour evolution. Mechanisms involved in the formation of pathogenic tetraploid 
cells are described below.  
 
1.3.2.1 Pathogenic cell fusion  
Cell fusion can be a pathogenic event leading to fused cells with tumourigenic 
potential and CIN. Hu et al demonstrated the HPV16 virus E5 gene product acts as 
fusion protein (Hu et al., 2009). Microscopy and fusion assays demonstrated that 
viruses expressing the E5 protein could fuse human keratinocytes. The model 
proposed involves viral infection followed by a transient increase in E5 protein, 
permitting cell fusion before lowering expression. The fusion event will normally 
produce a p53 apoptotic response, however expression of E6 (p53 inactivation) 
and E7 (RB inactivation) suppress the response, resulting in a tetraploid cell with 
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deregulated DDR and cell cycle. This molecular phenotype may provide the 
background for CIN and carcinogenesis.  
 
Another study showed fibroblasts over-expressing the E1A and HRAS oncogenes 
are fused by the MPMVE virus, displayed high levels of CIN and aneuploidy, and 
has increased tumourigenic potential in murine models (Duelli et al., 2007). The 
study highlighted that it was specifically the fusion event that resulted in CIN, as 
non-fused diploid cells containing MPMVE and oncogene over-expression did not 
display elevated CIN. Fusing cells at different cell cycle stages could be the cause 
of elevated CIN. For example, if an S phase cell was fused with a late G2 cell, 
incomplete replication could cause extensive DNA damage in M phase. Therefore, 
it is possible that cell fusion can cause CIN independently of any mutations.  
 
1.3.2.2 Mitotic failure  
Another common route to tetraploidy is characterised by the deregulated 
progression through mitosis and can be a result of two main events, namely, 
cytokinesis failure and mitotic slippage. 
 
1.3.2.2.1 Cytokinesis failure  
Failure in cytokinesis results in bi-nucleate cells that may enter S phase and a 
subsequent normal mitosis resulting in two mono-nucleated 4N daughter cells 
(Davoli and de Lange, 2011b). Emi1 and MAD2 have been implicated in 
cytokinesis failure (Sotillo et al., 2007, Margottin-Goguet et al., 2003, Lehman et al., 
2006). Both proteins are negative regulators of the APC/C ubiquitin ligase (mitotic 
control discussed in section 1.2.2) and are both frequently overexpressed in human 
tumours. Fittingly, experimental overexpression of either of these two APC/C 
regulators can result in cytokinesis failure and the formation of bi-nucleate cells 
(Margottin-Goguet et al., 2003, Sotillo et al., 2007). Interestingly, prolonged 
overexpression of several APC/C inhibitors results in the stabilisation of 
downstream substrates, possibly hampering the correct coordination of cytokinesis 
(Meraldi et al., 2002, Mundt et al., 1997, Wheatley et al., 1997).  




Shi and King estimated that 94% of bi-nucleate cells formed through furrow 
regression would show evidence of chromosome non-disjunction (Shi and King, 
2005). Chromatin in the cleavage furrow may couple chromosome non-disjunction 
and cytokinesis failure. However, Shi and King et al showed, chromosome bridging 
or lagging (CBL) occurred in only 53% of cells that become bi-nucleate by furrow 
regression, suggesting CBL couldn’t fully account for the formation of all tetraploids 
(Shi and King, 2005). In addition, 15% of mono-nucleate cells completed 
cytokinesis even in the presence of CBL. Therefore, the presence of CBL is neither 
necessary nor sufficient to induce cytokinesis failure and bi-nucleation. In contrast 
to this study, others have found chromatin remaining in the spindle midzone can 
result in furrow regression and failed cytokinesis, for example, lagging or acentric 
fragments are present in the midzone (Mullins and Biesele, 1977, Davoli and de 
Lange, 2011a). In addition, the NoCut pathway in yeast can sense chromatin in the 
midzone and inhibit cytokinesis, which if unresolved, may lead to abscission failure 
and polyploidy (Norden et al., 2006). Interestingly, Aurora A kinase plays a 
fundamental role in the NoCut pathway, further highlighting overexpression can 
inhibit cytokinesis. There is clearly a debate on whether chromatin present in a 
cleavage furrow or a chromosome non-disjunction is a major mechanism for 
cytokinesis failure (Weaver et al., 2006). Nevertheless, cytokinesis failure can 
occur by a variety of mechanisms and result the formation of G1 tetraploid cells.   
 
1.3.2.2.2 Mitotic slippage  
Mitotic slippage is another mechanism that can result in the formation of G1 
tetraploid cells (Aylon and Oren, 2011). The mechanism, again, involves APC/C 
inhibition, but in this case, the metaphase to anaphase transition fails and cells do 
not complete any further mitotic stages before entering G1. During prolonged SAC 
activation and inhibition of APC/C, cyclin B degradation can still occur via gradual 
proteasome-mediated degradation. As transcription is inhibited in mitosis, 
eventually cyclin B levels fall below a threshold, inactivating CDK1, and the cell 
“slips” out of mitosis (Blagosklonny, 2007). This route of tetraploidization produces 
mono-nucleate 4N cells, as chromosome segregation has not occurred.  




Elhajouji et al showed that treatment with the spindle poison nocodazole, which 
causes SAC activation through spindle depolymerisation and thus constant MAD2 
signalling, resulted in the formation of mono-nucleate tetraploid cells by mitotic 
slippage (Elhajouji et al., 1998). Rossio et al showed MAD2 overexpression in 
yeast resulted in mitotic slippage, with a concomitant reduction in cyclin B and 
securin (Rossio et al., 2010). Furthermore, the study conducted by Sotillo et al also 
noted MAD2 overexpression resulted in the formation of mono-nucleate in addition 
to bi-nucleate cells (Sotillo et al., 2007). This suggests that MAD2 overexpression 
can result in mitotic slippage, as well as cytokinesis failure. Loss of the 
Adenomatous Polyposis Coli (APC) that governs β-catenin and WNT signalling has 
been shown to associate with tetraploidization. Dikovskaya et al demonstrated that 
APC loss in cell lines resulted in increased spindle defects and a compromised 
SAC, thus, leading to mitotic slippage and tetraploid cell formation (Dikovskaya et 
al., 2007). Taken together, these studies show that aberrant expression of mitotic 
regulators can deregulate mitotic process resulting in slippage and cytokinesis 
failure and the formation of tetraploid cells.  
 
1.3.2.3 DNA damage and pathogenic endocycling  
A study by Davoli et al showed that a persistent DNA damage signal could result in 
the formation of viable tetraploid cells (Davoli et al., 2010). In early tumourigenesis 
and in the absence of p16 and p53, telomere shortening goes beyond the ‘Hayflick 
limit’, exacerbating shortening and induces massive CIN. During this time, short 
telomeres and shelterin dysfunction result in persistent activation of ATR/ATM and 
CHK1/2. These pathways inactivate CDK1-cyclin B activity, which inhibit entry into 
mitosis, and cause a prolonged G2 arrest. During this arrest, mitosis-independent 
destruction of geminin occurs, permitting the expression of cdt1, origin firing and 
genome duplication (Davoli et al., 2010). Post-crisis telomerase activation or 
telomere function restoration leads to the reduction of the DNA damage signal and 
the 8N cell can enter mitosis, producing two daughter tetraploids (Chin et al., 2004, 
Davoli et al., 2010).  
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Persistent DNA damage can also induce endocycling via other sources. Loss of the 
DNA damage processing and sensing proteins XRCC3, NBS1, Rad17 or 
overexpression of RPA result in endoreplication, supporting the hypothesis that 
persistent DNA damage can result in the formation of tetraploid cells (Reina-San-
Martin et al., 2005, Yoshihara et al., 2004, Wang et al., 2003).  Moreover, tumours 
lacking the homology-directed repair protein BRCA2 in p53-negative breast cancer 
are frequently polyploid, further supporting aberrant DNA damage pathways and 
polyploidy (Gretarsdottir et al., 1998).  A final source of persistent DNA damage 
may arise from replication stress driven by oncogene overexpression, as shown by 
several studies, which results in induction of DNA damage and tetraploidization 
(Bartkova et al., 2005, Di Micco et al., 2006).  
 
In the examples above, p53 loss was required to either permit the formation of a 
tetraploid after DNA damage-mediated endocycling, or to resist G1 arrest after 
cytokinesis failure. Therefore, loss of p53 plays an important role in the formation 
and survival of tetraploid cells. The role of p53 in supressing the proliferation of 
tetraploid cells after an aberrant mitosis is discussed below.  
 
1.4 Tetraploid control systems  
Mammalian cells have evolved systems to perturb the proliferation of tetraploid 
cells, formed through mitotic defects or cytokinesis failure (Aylon and Oren, 2011). 
As previously discussed, mitotic failure can result in the formation of G1 4N 
tetraploid cells. The observation of p53-dependent G1 arrest after tetraploidization 
has fuelled the idea of a tetraploidy checkpoint. The tetraploidy checkpoint may 
serve as final control mechanism to abort polyploid cells. 
 
1.4.1 The tetraploidy checkpoint  
Early evidence suggesting that cells could detect the formation of tetraploid cells 
was provided before the discovery of classical cell cycle checkpoints. In 1967, 
Smith et al purified lymphocytes from peripheral blood and showed cytochalasins, 
derived from moulds, could prevent cytokinesis and produce arrested bi-nucleated 
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cells (Smith et al., 1967). Thereafter, in 1972, Wright and Hayflick noted the same 
effect in lung fibroblasts (Wright and Hayflick, 1972). Transformation with SV40 and 
continuous cytochalasin treatment resulted in persistent nuclear division and lead 
to multi-nucleated cells. The authors concluded that “once a normal human diploid 
cell becomes bi-nucleate, intrinsic cell mechanisms come into play preventing 
further division – perhaps SV40 cells can escape this control” (Wright and Hayflick, 
1972).  
 
Subsequently, it was discovered that SV40 inactivates p53 and provided early 
evidence the transcription factor was central in the control of bi-nucleate cell 
survival (Ahuja et al., 2005). Further work in the 1990’s generated 4N cells by 
mitotic slippage after nocodazole treatment. In support of the earlier findings, this 
4N G1 arrest was mediated by p53 and p21, resulting in decreased RB 
phosphorylation and was DNA damage-independent (Di Leonardo et al., 1997, 
Khan and Wahl, 1998). Andreasen et al attempted to investigate whether the G1 
arrest after mitotic slippage was SAC-dependent or a more general “tetraploidy 
checkpoint” exists (Andreassen et al., 2001b). Treating REF-52 cells with 
dihydocytochalasin B (DCB) to promote cytokinesis failure, before drug washout, 
resulted in a permanent 4N G1 arrest, p53/p21 induction and decreased CDK2/RB, 
all indicative of a G1 arrest. In contrast, T-antigen transformed cells and REF-52 
cells expressing a dominant negative form of p53 failed to arrest and progressed 
through the cell cycle. The authors obtained similar results with transient 
nocodazole treatment (Andreassen et al., 2001b). As tetraploid cells were formed 
by either mitotic slippage or cytokinesis failure, it was conclude that a general 
tetraploid checkpoint exists and was not dependent on specific signalling 
mechanisms in mitosis, such as SAC.  
 
Conversely, two studies that shortly followed Andreasens’ work questioned such a 
checkpoint, while the presence of normal human tetraploid hepatocytes also 
complicates matters (Duncan et al., 2010, Wong and Stearns, 2005, Uetake and 
Sluder, 2004). A key weakness of the above studies is the pharmacological 
induction of tetraploidy, because the observed p53-driven G1 arrest of 4N cells 
may be a result of an off-target drug effect (e.g. DNA damage) rather than the 
formation of a tetraploid cell. Indeed, Lohez et al reported that lowering the dose of 
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DCB treatment was not sufficient to form tetraploid cells but still caused a diploid 
cell cycle arrest, suggesting the drug could cause cell cycle inhibition independently 
of tetraploidization (Lohez et al., 2003).  In contrast, Uetake and Sluder showed 
that further lowering the DCB dose produces bi-nucleate tetraploid cells but they 
were able to proliferate, implying the absence of a tetraploid G1 arrest (Uetake and 
Sluder, 2004). Wong et al also suggested tetraploid cells created by cell fusion can 
cycle, and fusion of cytoplasts (enucleated cells) and diploid cells producing 2N 
cells with centrosomes could also proliferate (Wong and Stearns, 2005). These 
studies argue against the presence of a tetraploidy checkpoint that directly senses 
chromosome or centrosome number and arrest may be an off-target 
pharmacological effect.  
 
Even so, Uetake and Sluder’s study showed that bi-nucleate cells formed by the 
addition of DCB did arrest, whereas diploids did not. Furthermore, Shi and King’s 
study showed that naturally occurring tetraploids, resulting from chromosome non-
disjunction and subsequent cytokinesis failure, had differential fates depending on 
p53 status (Shi and King, 2005). Therefore, although in some systems tetraploid 
cells can proliferate, clearly tetraploids are more sensitive to G1 p53-dependent 
arrest, although it is unlikely that aberrant chromosome number is directly sensed.   
 
1.4.2 Molecular mechanisms of the tetraploidy checkpoint  
A possible trigger for the tetraploidy checkpoint is the tumour suppressor LATS2 
kinase (Large Tumour Suppressor Kinase 2). Aylon et al showed that 
overexpression of LATS2 could reduce the ubiquitination of p53, by MDM2 
inhibition (Aylon et al., 2006). In addition, treatment with nocodazole mediated 
LATS2 translocation to the nucleus, inhibiting MDM2 and stabilising p53. 
Consequently, p53 bound to the LATS2 promoter and induced p53 even further. 
Cell cycle analysis showed that p53 activation occurred during mitosis, before 
mitotic slippage, and gradually increased to an inhibitory threshold once the cell 
was in G1 (Aylon et al., 2006). This study provides evidence that microtubule 
damage and the ensuing SAC activation activate LATS2 to safeguard the cell in the 
event of a slippage event. 




A recent study by Ganem et al showed that LATS2 was also implicated in 
activating p53 in response to a tetraploidization event (Ganem et al., 2014). 
Treatment of RPE cells with DCB-induced cytokinesis failure and p53/p21 
expression, exclusively in the tetraploid cells. After DCB treatment, G1 tetraploid 
cells were sorted utilising the Fucci system (a system that allows identification of 
cell cycle phase) and screened in a siRNA library to identify genes that could 
promote survival. The screen identified that large tumour suppressor kinase 2 
(LATS2) knockdown permitted the proliferation of tetraploid cells. It was discovered 
that centrosome amplification in the genome-doubled cells activated RAC kinase, 
which in turn inhibited RhoA, leading to LATS2 activation. As LATS2 is a negative 
regulator of MDM2, p53 was stabilised while YAP and TAZ transcription was 
reduced. This mechanism provides evidence for a tetraploidy checkpoint and can 
explain why DCB treatment under different conditions can yield different responses. 
Lowering the dose of the drug or growing cells on fibronectin shortens the length of 
G1. As the p53 response provided by this system is gradual, as also in the case of 
(Aylon et al., 2006), the threshold for inhibition may not be reached in these 
conditions, resulting in cell cycle progression of newly formed tetraploids. Moreover, 
tetraploid mouse hepatocytes also showed activation of LATS2, p53 and p21, 
whilst the response was absent in p53-null mice (Ganem et al., 2014). This finding 
provides strong evidence for hippo pathway activation in vivo. This discovery, in 
combination with fact that two different mechanisms of tetraploid induction using 
different compounds induced a p53-mediated G1 arrest (implying the arrest is due 
to tetraploidy and not alteration of a specific drug target), strongly suggests the 
presence of tetraploidy checkpoint and argues against the response being a 
pharmacological off-target effect. 
 
In addition to cell cycle arrest, tetraploids may also have to resist apoptosis. 
Castedo et al showed that newly formed tetraploids undergo a p53/BAX dependent 
apoptosis (Castedo et al., 2006b). Expression arrays showed that newly formed 
tetraploids were characterised by a mild elevation in p53 target genes and 
underwent enhanced spontaneous apoptosis, which could be rescued by silencing 
PUMA or overexpressing BCL-2 (Castedo et al., 2006b). Therefore, apoptosis 
presents another hurdle for newly formed tetraploid to overcome.  






Figure 1.3 Tetraploid checkpoint pathway  
After tetraploidization and centrosome amplification, a hyperactivation of the small 
G-protein RAC1 occurs. RAC1 antagonizes Rho, which is a negative regulator of 
the LATS2 kinase. The activation of LATS2 results in YAP cytoplasmic 
sequestration and TAZ degradation, inactivating the pro-proliferative Hippo 
pathway transcription factors, resulting in cell cycle arrest. In addition, LATS2 is 
negative regulator of MDM2 through protein degradation, leading stabilised p53, 
which induces p21 expression, resulting in a G1 arrest. p53 can also induce 
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1.5 Consequences of tetraploidy  
If a newly formed tetraploid manages to overcome the tetraploidy checkpoint, the 
cell can continue to proliferate and divide. The consequences of overriding the 
tetraploidy checkpoint and continued proliferation are discussed below. 
 
1.5.1 Tetraploidy and tumourigenesis  
Fujiwara et al performed a series of experiments to investigate whether tetraploid 
cells can initiate tumourigenesis (Fujiwara et al., 2005). Treating TP53+/+ or TP53-/- 
mammary mouse epithelial cells (MMECs) with DCB-generated generated bi-
nucleate tetraploid cells. TP53+/+ cells underwent one round of division but failed to 
propagate, whereas TP53-/-  tetraploids proliferated and showed increased CIN 
compared to diploid cells. These data imply that MMECs do not have a G1 
tetraploidy checkpoint but fail after the first division, possibly as result of enhanced 
CIN. When TP53-/- tetraploid cells were injected into mice, 25% of mice 
spontaneously formed tumours, whereas TP53-/- diploids did not form any tumours. 
Therefore, this study directly demonstrated that tetraploid cells could form tumours 
and this case, more frequently than diploids with the same genetic background.  
 
In support of this seminal work, Sotillo et al’s study showed that transient MAD2 
overexpression which resulted in tetraploid cell formation via mitotic failure, also 
increased tumour formation (Sotillo et al., 2007). Importantly, this study 
demonstrated that transient MAD2 overexpression and subsequent 
tetraploidization can be the stimulus for tumourigenesis, as continued MAD2 
overexpression was shown to not be required, unlike other oncogenes. Specifically, 
transient MAD2 overexpression could produce tetraploid cells, which facilitate 
tumour progression regardless of MAD2 expression. Duelli et al also noted the 
virally fused tetraploid cells formed tumours in mice, whereas infected diploids 
carrying the same oncogene overexpression did not (Duelli and Lazebnik, 2007).  
 
Together, these studies provide evidence that a tetraploidization event can promote 
tumourigenesis, highlighting the importance of functional tetraploidy checkpoint.  
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1.5.2 Tetraploidy CIN and DNA damage  
A substantial body of studies exists to suggest that tetraploid cells are 
intermediates of CIN and aneuploidy (Ganem et al., 2009, Dewhurst et al., 2014, Lv 
et al., 2012, Duelli and Lazebnik, 2007, Fujiwara et al., 2005). Therefore, it is 
expected that when a tetraploid cell evades the tetraploidy checkpoint and initiates 
tumourigenesis, the resulting tumour would be genetically complex.  
 
Ganem et al investigated the mechanistic basis of elevated CIN in tetraploid cells 
(Ganem et al., 2009). Tetraploid cells, formed through cytokinesis failure or mitotic 
slippage, will have duplicated centrosomes and this can lead to multipolar 
chromosome segregation resulting in aneuploidy (Ganem et al., 2009). However, 
Ganem et al found that multipolar segregation was infrequent and highly toxic to 
cells, presumably due to massive CIN, and therefore could not explain elevated 
CIN and aneuploidy in tumours. On the contrary, the group showed that cells with 
extra centrosomes underwent bi-polar segregation as result of centrosome 
clustering. However, even though segregation was bi-polar, the frequency of 
lagging chromosomes was greater in cells with amplified centrosomes. It was 
shown that cells with amplified centrosomes pass through a multipolar spindle 
intermediate stage before clustering, which can lead to increased merotelic and 
syntelic attachment and lagging chromosomes (Ganem et al., 2009).  Therefore, 
unique spindle geometry, as result of centrosome amplification, can result in 
relatively mild segregation errors resulting in non-catastrophic aneuploidy and CIN.  
 
Janssen et al showed pharmacologically-induced whole chromosome segregation 
errors could lead to chromosomal damage during cytokinesis, resulting in DNA 
damage and activation of the p53-mediated DDR and cell cycle arrest (Janssen et 
al., 2011). The resulting DSBs lead to structural aberrations and chromosome 
translocations in daughter cells. Loss of p53 increased the frequency of structural 
chromosomal aberrations, highlighting its important role in maintaining genome 
stability. Crasta et al support the hypothesis that segregation errors can lead to 
DNA damage (Crasta et al., 2012). A proportion of lagging chromosomes induced 
by transient nocodazole treatment formed micronuclei (MN) and a reduction in 
helicase proteins caused replication stress and incomplete DNA replication upon 
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mitotic entry, which led to massive DNA damage and chromothripsis (extensive 
local structural chromosomal rearrangement) (Crasta et al., 2012). The resulting, 
translocations could persist as MN or upon nuclear envelope breakdown could be 
segregated and integrated into the nucleus.  
 
Taken together these studies highlight how tetraploidy might lead to elevated CIN 
and DNA damage, resulting in aneuploid tumours. Centrosome amplification in 
tetraploids can lead to multipolar intermediates, leading to lagging chromosomes 
that can be incorporated in correctly into daughter cells (numerical CIN). A 
heightened rate of lagging chromosomes could also lead to increased 
chromosomal translocations through the generation of DSBs at cytokinesis, and the 
formation of MN the can result to massive genetic rearrangement by chromothripsis. 
Hence, tetraploid cells with extra centrosomes may be more prone to CIN and DNA 
damage then diploids and this can drive tumourigenesis and genetic evolution. As 
discussed previously, these mechanisms of CIN resulting in aneuploidy are 
dependent on a relevant tolerance mechanism, such as loss of p53, which may be 
provided by the tetraploid cell.  
 
1.5.2.1 Tetraploidy is an aneuploidy intermediate  
Building on these findings, direct evidence linking tetraploidy as an aneuploidy 
intermediate has been provided from in vitro and in vivo longitudinal studies. In 
addition to tumour formation, Fujiwara et al noted mouse tetraploid tumours 
showed an array of abnormalities including extra centrosomes, non-reciprocal 
translocations, di-centric and double minute chromosomes. All tumours examined 
showed regional amplification of chromosome 9, a region overexpressed in human 
breast cancers (Fujiwara et al., 2005).  
 
Further supporting this hypothesis, ovarian tumours are generally aneuploid and 
cancer risk increases with age and correlates with elevated tetraploid ovarian 
epithelial cells (Chuaire-Noack et al., 2010). Based on this observation, Lv et al 
investigated whether tetraploidy could act as a precursor to aneuploidy (Lv et al., 
2012). The group created and continually passaged spontaneously immortalised 
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mouse ovarian cells and investigated ploidy at different passage numbers by flow 
cytometry. The majority of cells at passage 9 were diploid however, over time, 
genome-doubling occurred and at passage 36, cells were either tetraploid or 
aneuploid. Chromosome compositions, detected by fluorescent in situ hybridization 
(FISH), showed that early passage cells were exclusively diploid but became 
increasingly tetraploid, which correlated with an elevated fraction of aneuploid cells. 
Early and late passage cells were injected into mice and only the late genome-
doubled aneuploid cells formed tumours. These data suggest that mouse ovarian 
diploid cells can give rise to tetraploids that become aneuploid and are more 
tumourigenic.  
 
Finally, Davoli et al showed that tetraploid cells generated through telomere-
induced endoreplication were more tumourigenic in vitro and in vivo (Davoli and de 
Lange, 2012). Tetraploid cells formed colonies more readily in soft ager assays and 
when these cells were injected into mice, they were more tumourigenic. Analysis of 
cell lines derived from tetraploid tumours revealed sub-tetraploid karyotypes, 
indicating chromosomal loss. In contrast diploid tumours remained stable and 
showed a near diploid karyotype. Therefore this study provides support for 
tetraploid cells being more tumourigenic and can act as an aneuploidy intermediate.   
 
1.5.2.2 Connecting tetraploidy, CIN and aneuploidy  
The above studies demonstrate tetraploidy can precede aneuploidy, possibly 
through CIN driving mechanisms such as proposed by Ganem at al (Ganem et al., 
2009). However, these studies do not link CIN with tetraploidy and aneuploidy 
directly.  
 
A recent study in our laboratory has linked tetraploidy as an intermediate of CIN 
and aneuploidy (Dewhurst et al., 2014). Chromosomally stable HCT-116 diploid 
and low frequency tetraploid cells were single-cell cloned and passaged for 18 
months. Clonal FISH assays measured the cell-cell variation in chromosomal 
number (percentage of cells deviating from the colony mode) in order to investigate 
ploidy and numerical CIN.  




Tetraploid colonies showed significantly greater chromosomal variation than 
diploids at both early and late passages. Although twice as many segregation 
errors were present in the tetraploids than the diploids, this simply reflected the 
DNA duplication, as the segregation error rate was the same, and could not solely 
explain the heightened cell-cell variation observed. When the colony modes 
(colony-colony variation) were investigated, all tetraploid clones produced 
aneuploid colonies, whereas only one aneuploid colony was found across all 
diploid clones. The high frequency of aneuploid colonies formed from tetraploid 
clones suggested that tetraploid cells can tolerate aneuploidy resulting in selection 
and outgrowth, producing modal chromosome numbers other than four. In contrast, 
all but one diploid clones had modal colony number of two, suggesting that 
although aneuploid cells are formed they are rarely viable, hindering aneuploid 
colony formation. Taken together, these data suggested that tetraploid cells could 
tolerate CIN and aneuploidy, whereas diploids could not. Direct proof of enhanced 
tetraploid tolerance to segregation errors was provided by live cell imaging 
experiments, which showed that after segregation errors, 58% of diploids died or 
arrested compared to just 16% of tetraploids (Dewhurst et al., 2014). 
 
Importantly, the genetic complexity of the diploid and tetraploid clones was 
assessed at different time points over an 18-month period. The weighted genome 
insatiably index (wGII), which estimates the proportion of the genome with aberrant 
copy number compared with median ploidy weighted on per-chromosome basis, 
was used to asses CIN for in vitro clones and CRC tumours (TCGA public dataset).  
All diploid clones showed a low wGII similar to the early passage tetraploid clones 
but became increasing unstable and aneuploid overtime, recapitulating the genetic 
complexity in human CRC tumours.  
 
In summary, this study demonstrated that in cancer cells that make segregation 
errors, tetraploid clones make twice as many, show elevated cell-cell variation, can 
form aneuploid colonies and tolerate segregation errors. Furthermore, tetraploid 
clones exhibited increasing levels of wGII in a longitudinal assay, which correlated 
with a reduction in ploidy, implying that the aneuploidy observed was a result of 
ongoing CIN. Other studies have suggested that in combination with a tolerance 
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mechanism, an increase in segregation error rate is required to promote CIN 
(Thompson and Compton, 2010a, Ganem et al., 2009). Although the rate per 
chromosome did not increase in this study, a doubling on a per cell basis from a 
basal rate of 19% was clearly sufficient. Therefore, this study directly links 
tetraploidy with elevated CIN, which may explain the presence of aneuploid CRC 
tumours. 
1.5.2.3 Tetraploidy and aneuploidy in human tumours   
Evidence that tetraploidy precedes aneuploidy has also been shown in human 
tumours (Maley et al., 2006, Olaharski, 2006, Galipeau et al., 1996, Dewhurst et al., 
2014).  
 
Galipeau et al followed a cohort of 90 patients with initially diploid Barretts 
oesophagus for at least twelve months (Galipeau et al., 1996).  If tumours were still 
diploid at the first follow up, 11% of patients’ tumours progressed to aneuploidy. 
However, in patients whose first follow-up biopsy was tetraploid, 73% progressed 
to aneuploidy, providing evidence that tetraploidy is an aneuploidy intermediate in 
human tumours. The study also found p53 loss proceeded tetraploidy, providing 
further evidence for a tetraploidy checkpoint. Providing further support, Olaharski et 
al showed in cervical cancer cells derived form 143 women that tetraploidy 
preceded aneuploidy (Olaharski, 2006).  In CRC, the study by Dewhurst et al also 
showed that genome-doubling was a relatively early event, preceding the majority 
of copy-number losses and CIN and was predictor of poor outcome (Dewhurst et 
al., 2014). 
 
The aforementioned studies clearly demonstrate that tetraploid cells form tumours 
and these tumours can be CIN and aneuploid and highlight the importance of the 
tetraploidy checkpoint in halting the proliferation of tetraploid cells. Failure to do so 
can result in tumour formation and progression, resulting in aneuploidy and ITH. A 
diverse pool of subclones increases the probability of clones able to metastasise 
and resist therapy, leading to poor survival rates. 
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1.5.3 Tetraploid drug resistance  
The elevated rate of karyotypic change, caused by the tetraploidy-to-aneuploidy 
transition, can increase the probability of tumour subclones harbouring genetic 
alterations that can confer resistance to anti-cancer therapeutics (Jonkers et al., 
2005, Li et al., 2005). It is, therefore, likely that progression from tetraploid 
intermediates to highly aneuploid cells contributes to the therapeutic failure 
observed in the clinical setting.  
 
In addition to drug resistance generated through the aneuploidization of tetraploid 
precursors, tetraploid cells can be intrinsically drug resistant (Castedo et al., 2006b, 
Castedo et al., 2006a, Kuznetsova et al., 2015). Castedo et al generated tetraploid 
CRC HCT-116 and RKO cell lines and tested their drug sensitivity to a range of 
compounds. Tetraploids showed relative resistance to a panel of DNA damaging 
agents (cisplatin, camptothecin and oxaliplatin) compared to diploids, while also 
exhibiting a reduced apoptotic response (Castedo et al., 2006a). It was discovered 
that elevated levels of p53 in tetraploid cells enhanced transcription of the 
downstream target p53-ribonucleotide reductase (p53-R2), required for the 
conversion of ribonucleotides into deoxyribonucleotides and facilitates DNA repair 
(Castedo et al., 2006a). Therefore, p53-R2 overexpression in tetraploid cells, as 
result of constitutive p53 activation, could enhance DNA repair after treatment with 
DNA damaging agents, leading to therapeutic resistance (Castedo et al., 2006a). A 
more recent study by Kuznetsova et al also showed that tetraploid cells were more 
resistant to cytotoxic therapy than their diploid counterparts (Kuznetsova et al., 
2015). However, in this study the mechanism of resistance was through 
cytoplasmic sequestration of p53.  
 
In addition cytotoxic chemotherapeutic drug resistance, tetraploidy has been 
implicated in resistance to targeted therapies. Balsas et al cultured human multiple 
myeloma cells for 18 months whilst gradually increasing the dose of the 
proteasome inhibitor bortezomib, to create resistant cell lines (Balsas et al., 2012). 
The resulting cell lines were up to 6-fold more resistant to bortezomib whereas, 
unexpectedly, the cell lines did not display mutations in bortezomib’s target PSMβ5, 
but rather overexpression of the proteasome subunit. Further analysis revealed that 
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resistant cells had undergone a genome-doubling event and this was the source of 
elevated PSMβ5. In agreement with a general up-regulation of proteins (through 
genome-doubling), resistant cell lines displayed cross-resistance to other 
chemically unrelated proteasome inhibitors (Balsas et al., 2012). This study 
demonstrated that genome-doubling can promote resistance to targeted therapies, 
by elevating the expression of the target proteins and leading to selection and 
outgrowth of the resistant tetraploid clone.  
 
In summary, the aforementioned studies demonstrate that not only can tetraploidy 
lead to aneuploidy, which in turn elevates genetic diversity and a heightened 
probability of resistant subclones, but also that the tetraploid state can be inherently 
resistant to therapy.  
 
1.5.4 Summary 
The above studies show how tetraploidy can lead to CIN, aneuploidy and ITH. 
Polyploidization can be a normal event is some human tissues, such as the liver, 
providing a physiological benefit. However, these cells are either terminally 
differentiated or have mechanisms to suppress potentially oncogenic effects of 
polyploidy.  In contrast, the tetraploidization of cells by failed mitosis, cytokinesis or 
induction of endocycling can give rise to highly malignant cells. A G1 arrest 
normally follows un-programmed tetraploidy, however this can be overridden by 
loss of tumour suppressors such as TP53 and CDKN1A. Tetraploid cells can 
readily form tumours that become heterogeneously aneuploid through CIN. 
Tetraploidy per se and the resulting CIN and aneuploidy can lead to therapeutic 
resistance. Therefore, genome-doubling in human tumours contributes to the ITH 
observed in the clinic, impacting on patient survival by fuelling metastasis and anti-
cancer drug resistance.  
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1.6 Study aims 
This thesis describes the work undertaken to understand mechanisms of tetraploid 
tolerance.  
 
Based on previous studies, it is of great importance to gain a greater understanding 
of how tetraploidy is tolerated. The isogenic HCT-116 tetraploid system, used by 
Dewhurst et al, would firstly be investigated. Uniquely, this system was not 
produced by pharmacological intervention and possessed non-coding mutations in 
TP53 and CDKN1A. Understanding mechanisms of tetraploidy tolerance 
independent of p53 pathway mutations is important, as it could lead to the 
identification of novel targets and mechanisms amenable to therapeutic modulation. 
The primary aim of this thesis was to uncover tetraploidy tolerance mechanisms 
independent of p53/RB pathway mutations. This was addressed using global 









Chapter 2. Materials & Methods 
2.1 Materials 
Table 2.1 Pharmacological agents 
Agent Supplier 
5-Fluorouracil Sigma-Aldrich 
Oxaliplatin  Sigma-Aldrich 
Epigenetic library  Selleckchem 
Reversine  Sigma-Aldrich 
Dihydrocytochalasin B Sigma-Aldrich 
Nocodazole  Sigma-Aldrich 
Cycloheximide  Sigma-Aldrich 
 
Table 2.2 Primary and secondary antibodies 
Antibody Species Catalogue number Supplier 
His-tag Mouse ab18184 Abcam 
p53 Mouse sc-126 Santa Cruz 
p-53 S15 Rabbit 9248 Cell Signalling 
p21 Rabbit 2947 Cell Signalling 
GAPDH Rabbit ab9385 Abcam 
PARP Rabbit 9542 Cell Signalling 
Cleaved PARP Rabbit 5625 Cell Signalling 
RB Mouse 9309 Cell Signalling 
pRB 807/811 Rabbit 9308 Cell Signalling 
PDCC6IP Rabbit 2171  Cell Signalling 
KIFC1 Rabbit 12313 Cell Signalling 
Cyclin A1 Mouse sc-271682  Santa Cruz 




Antibody Species Catalogue number Supplier 
Cyclin B1 Rabbit sc-752 Santa Cruz 
Cyclin D1 (WB) Mouse 556470 BD Biosciences 
Cyclin E1 Mouse sc-247 Santa Cruz 
CDK4 Rabbit sc-260 Santa Cruz 
CDK2 Rabbit sc-163 Santa Cruz 
Cyclin D1 (IF) Rabbit ab16663 Abcam 
Cyclin D1 Thr-286 Rabbit 3300 Cell Signalling 
Actin Mouse ab49900 Abcam 
ERK Rabbit 9102 Cell Signalling 
p-ERK (p44/42) Rabbit 4370 Cell Signalling 
Histone H2B Goat sc-8652 Santa Cruz 
 
Table 2.3 siRNA Sequences  
All siRNAs were ordered from Dharmacon and have the ON-target plus modification 
Gene Sequence  Catalogue number  
Control-1 UGGUUUACAUGUCGACUAA D-001810-01-05 
Control-2 UGGUUUACAUGUUGUGUGA D-001810-02-05 
TP53-2 GUGCAGCUGUGGGUUGAUU J-003329-15 
CDKN1A AGACCAGCAUGACAGAUUU J-003471-12 
 
Table 2.4 Q-PCR primer sequences 
Gene Forward sequence  Reverse sequence 
TP53 TGACTGTACCACCATCCACTA AAACACGCACCTCAAAGC 
CDKN1A CCATGTGGACCTGTCACTGT GGCGTTTGGAGTGGTAGAAA 
CCND1 TGTTTGTTCTCCTCCGCTC GAGGAGCTGCTGCAAATGG 
GAPDH CTTCAACAGCGACACCCACT GTGGTCCAGGGGTCTTACTC 
ACTB  TGGATCAGCAAGCAGGAGTATG GCATTTGCGGTGGACGAT 




2.2 Methods  
2.2.1 Cell culture 
HCT-116 cells were obtained from the European Collection of Animal Cell Cultures 
(ECACC) by Cancer Research UK (CRUK). RPE-Fucci cells were kindly provided 
by Dr Laurent Sansregret (CRUK). These cell lines, as well as their diploid and 
tetraploid derivatives, were grown in Dulbecco’s Modified Eagle Medium (DMEM) 
with 4.5g/L D-glucose, 1mM L-glutamine and 1mM sodium pyruvate (Gibco, Life 
Technologies), containing 10% foetal bovine serum (FBS) (LabTech) and 1X 
penicillin/streptomycin (Sigma-Aldrich) at 37°C in a 5% CO2 atmosphere.  
 
2.2.1.1 Clonogenic assays 
Clonogenic assay were performed as described (Franken et al., 2006). Cells were 
seeded, after seeding density optimisation, at low densities in 6-well tissue culture 
plates or 100mm culture dishes (BD Biosciences). Cells were incubated for 16 
hours to allow for cell attachment, before addition of test compounds. Cells were 
allowed to form colonies for a minimum of 10 days. Plates were washed with PBS, 
before staining with crystal violet (0.05% w/v) and methanol (20% v/v) for 30 
minutes. Plates were then washed with 20% methanol and colonies were counted 
by image capture before calculating the surviving fraction with the Mathematica® 
software. For RPE clonogenic assays, cells were seeded at low density after the 
cell sorting process (section 2.2.17).  
 
2.2.2 Short-term viability assay 
Short-term 72 hours proliferation assays were performed using CellTitre-Blue®, 
according to manufacturer’s instructions (Promega). Briefly, cells were seeded into 
96-well tissue culture plates and incubated for 16 hours. Drug treatments were 
performed in a dose curve and incubated with cells for 72 hours. 20µl of Cell 
TitreBlue® was mixed with 100µl media and incubated for one hour, before 
fluorescence was measured in a Perkin Elmer Envision 2102 multi-label reader 
(Ex550/Em590). All fluorescence values were normalized to DMSO control.   





2.2.3 Epigenetic screen  
Two diploid and two tetraploid cell line pairs were screened using the Selleckchem 
epigenetics compound library, comprising of 51 epigenetic modulators. Cells were 
plated into 96-well culture plates before 16 hours incubation to allow cell 
attachment. The library was used on each clone, in triplicate, at 5µM for 72 hours. 
Sensitivity was assessed by the CellTitre-Blue® assay (see section 2.2.2). 
Response data was estimated as the value of each replicate divided by the mean 
of the control wells for each cell line. Diploid and tetraploid cell lines were 
compared using a Wilcoxon test, a non-parametric statistical test that does not 
assume normality and is used to compare two sets of scores that come from the 
same participants.  
 
2.2.4 siRNA transfections 
The final concentration of siRNA used for all experiments was 40nM. For a single 
6-well tissue culture plate transfection, 3µl of 20µM siRNA was mixed with 197µl of 
Opti-MEM (Gibco) in a 1.5ml microtube. At the same time, 4µl of transfection 
reagent (RNAiMax Thermo Fisher) was incubated with 196µl Opti-MEM for five 
minutes. After this period, both solutions were mixed and incubated for a further 30 
minutes at room temperature. During this time, cells were plated at density of 
1.1x106 cells in 1,100µl of DMEM media. 400µl transfection was then added 
dropwise to each well.  
 
For 96-well plates, 10µl of 400µM siRNA diluted in DMEM was added to each well. 
RNAiMax was diluted to concentration of 0.15µl/10µl of Opti-MEM and 10µl of mix 
was added per well and incubated for 30 minutes at room temperature. Cells were 
seeded at a density of 5,000/80µl to each well, to achieve a final volume of 100µl. 
 




2.2.5 Western blotting  
Cells were grown until 60-80% confluent, before being washed in PBS and 
trypsinised (Trypsin-EDTA 0.25%, phenol red; GIBCO). Trypsin was inactivated 
with FCS-containing media before cells were pelleted by centrifugation at 1,000rpm 
for five minutes. Cells were washed with PBS and pelleted before being 
resuspended in cell lysis buffer (Abcam ab152163; constituents: 0.216% Beta 
glycerophosphate, 0.19% sodium orthovanadate, 0.001% leupeptin, 0.38% EGTA, 
10% Triton-X-100, 3.15% Tris-HCl, 8.8% sodium chloride, 0.29% sodium EDTA, 
1.12% sodium pyrophosphate decahydrate). Lysates were quantified for protein 
content by Bradford assay (Bradford, 1976). Equal amounts of protein were mixed 
with loading buffer (BioRad) and loaded into 10 or 15-well NuPAGE® Novex® 4-
12% Bis-Tris Gels (Invitrogen NP0321BOX), before subjected to electrophoresis at 
200V for 45 minutes with MOPS running buffer (Invitrogen). Gels were transferred 
to poly-vinylidene (PVDF; GE Healthcare) membranes before semi-dry transfer in 
20% methanol-containing transfer buffer (Invitrogen) at 125mA for one hour. 
Membranes were blocked in blocking buffer consisting of 5% non-fat milk TBS-T 
(Tris-Buffered-Saline-Tween: 50mM Tris-Cl, pH 7.5. 150mM NaCl, 0.1% tween). 
Membranes were incubated with primary antibodies for 16 hours at 4oC in 5% BSA 
(bovine serum albumin) in TBS-T. Membranes were washed three times in TBS-T 
before incubation with the appropriate HRP-conjugated secondary antibody (Dako) 
for one hour in blocking buffer at room temperature. Membranes were washed a 
further three times in TBS-T before detection with Immobilon Chemiluminescent 
HRP substrate (Merck Millipore).  
 
2.2.6 Indirect immunofluorescence  
Cells were grown on 22/22mm glass coverslips pre-treated with poly-lysine to 
enhance cell attachment. After the desired incubation time, cells were washed with 
PBS before fixing and permeabilisation using PTMEF (4% formaldehyde, 20mM 
PIPES, 10mM EGTA, 1mM MgCl2) for 10 minutes. Coverslips were then PBS-
washed before blocking in 3% BSA in PBS at room temperature for one hour. Next, 
coverslips were incubated with 150µl of primary antibody optimally diluted in 
blocking buffer for 1.5 hours at room temperature. Coverslips were then washed 




three times before addition of 150µl of secondary antibodies (goat anti-rabbit 
AF594, Molecular Probes) diluted at 1/500 in blocking buffer, protected from light 
for one hour. Finally, coverslips were washed three times and mounted on glass 
slides with Vectashield mounting medium (Vecta H-1000) and sealed with clear nail 
varnish. Images were acquired on an Olympus Delta Vision RT microscope 
(Applied Precision) equipped with a CoolSnap HQ camera. Images were 
deconvolved using conservative settings for 8 cycles. Images were analysed using 
softWoRX Explorer (Applied Precision LLC). 
 
 
2.2.7 Quantitative PCR   
RNA was extracted from cells using the RNeasy Qiagen kit, according to the 
manufacturer's instructions. RNA concentrations were quantified on a NanoDrop 
instrument (Thermo Scientfic) and adjusted to 10ng/µl before cDNA synthesis using 
the first-strand cDNA synthesis kit (GE healthcare), according to the manufacturer’s 
instructions. Real-time quantitative polymerase chain reaction (qPCR) primers were 
designed using Primer-BLAST (Ye et al., 2012). Multiple qPCR primers were 
ordered for genes of interest and primers that produced a single product in the melt 
curve were deemed acceptable for use.  QPCR was performed using SYBR® 
GreenER with premixed ROX (Invitrogen) according to the ΔΔCT method, namely, 
values were firstly normalised to GAPDH or β-actin, before secondary 
normalisation to parental HCT-116 values. Three replicates were performed per 
clone on an Applied Biosystems 7900 real time PCR machine using 96-well plates.  
 
2.2.8 Protein Immunoprecipitation  
Cell pellets were lysed on ice in KLB lysis buffer (50mM Tris pH 7.4, 150mM NaCl, 
0.1% Triton X-100, 0.1% Nonidet P-40, 4mM EDTA, 50mM sodium fluoride, 0.1mM 
sodium orthovanadate, 1mM dithiothreitol. Lysates were centrifuged at 13,000rpm 
for 15 minutes at 4oC before quantitation by Bradford assay. Sample 
concentrations were adjusted so all samples were of equal concentrations in 250µl 
of lysis buffer and 30µl were removed for inputs. 1µg of primary antibody was 




added before incubation at 4oC for 16 hours, with rotation. 30µl of protein G beads 
(Sigma-Aldrich) were added and incubated at 4oC for one hour, with rotation. 
Protein G beads were washed three times in lysis buffer before dissociation with 
sample buffer. Equal volumes were subjected to western blotting to identify protein 
interactions.    
 
2.2.9 In vitro kinase assays  
Any procedures that involved handling of 32P were carried out by Dr Emanuela 
Maria Cuomo (UCL). Endogenous CDK4 and CDK2 were immunoprecipitated, as 
described in section 2.2.8. No EDTA was present in buffers as the compound is a 
magnesium chelator and can inhibit the reaction. After incubation of protein G 
beads in antibody-bound lysates, samples were washed three times in KLB lysis 
buffer. After washing, beads were re-suspended in kinase buffer before incubation 
with 32P labelled ATP and full length GST-RB, which served as the substrate for the 
kinase activity, for 30 minutes. After this time, the reaction was terminated by 
addition of 4x Laemmli buffer (BioRad) before separation by SDS-PAGE and 
radiography. 
 
2.2.10 Apoptosis array 
The apoptosis array was carried out according to the manufacturer’s instructions. 
The array is a Reverse Phase Protein Array (RPPA), consisting of a nitrocellulose 
membrane spotted with antibodies against 35 human apoptosis markers. Cells 
were lysed and incubated before expression was detected by chemiluminescence. 
After quantification by densitometry the fold change between conditions was 
calculated.  
2.2.11 Cycloheximide assay 
2x105 diploid and 1.7x105 tetraploid cells were seeded into 6-well tissue culture 
dishes and incubated for 16 hours. Media was removed before addition of fresh 
media containing 50µg/ml cycloheximide for the desired time-course. After the 
indicated time of incubation, media was aspirated before immediate lysis in KLB 




lysis buffer at 4oC. Lysates were analysed by western blotting. Cyclin D1 stability 
was calculated by normalising cyclin D1 protein levels to GADPH loading control. 
Normalised values were then expressed as a percentage of untreated control.   
 
2.2.12 ERK assay 
2x105 diploid and 1.7x105 tetraploid cells were seeded into 6-well tissue culture 
dishes and incubated for 16 hours. Media was removed before addition of fresh 
media containing no serum for 24 hours. Serum-free media was removed before 
addition of fresh media containing 10% serum and was incubated for the desired 
length of time. Finally, media was aspirated before immediate lysis in KLB lysis 
buffer, at 4oC. 
 
2.2.13 Nocodazole trap assay  
Cells were seeded into 10cm dishes and treated with nocodazole (1µM), for 16 
hours. After this period, cells were harvested and washed with PBS before fixing 
with 70% ethanol and stored at 4oC for 24 hours. Fixed cells were then prepared for 
DNA profile analysis.  
 
2.2.14 Flow cytometry 
2.2.14.1 DNA profiles 
Cells were trypsinised and washed with PBS before fixing with 70% ethanol and 
stored at 4oC for 24 hours. Cells were washed before staining with propidium iodide 
(Sigma-Aldrich) and RNA digestion with RNase (Life Technologies). DNA profiles 
were obtained after setting laser voltages for untreated diploid HCT-116 cells.  
 
2.2.14.2 Antibody-based FACS 
Cycling cells were trypsinised, washed and pelleted before fixation with 2% 
formaldehyde and incubated at 4oC. Cells were washed twice in 0.1% BSA before 




blocking in the same solution for one hour at room temperature. After this time, 
cells were washed with blocking buffer and 0.5% Triton X-100 (Sigma-Aldrich) to 
permeabilise the cell nuclei, before a final wash in blocking buffer. At this time, cell 
pellets were divided into fresh tubes. One set was stored at 4oC whereas the other 
set, 100µl of blocking buffer containing primary antibody at the appropriate 
concentration was then incubated at 4oC for 16 hours.  Next, pellets were washed 
twice in blocking buffer. Both sets of pellets (untreated and primary antibody 
treated) were then resuspended in 100µl of buffer containing DAPI (1µg/ml) and 
the corresponding fluorescent secondary antibody (1/500) and incubation for one 
hour at room temperature protected from light. This procedure results in primary, 
secondary and DAPI versus secondary and DAPI treated replicates. After this 
period, stained cell pellets were washed twice before resuspension in PBS. 
Samples were analysed on a Fortessa flow cytometer (BD Biosciences), before 
analysis with FlowJo software.  
 
2.2.15 Subcellular fractionation  
Cells were grown into 10cm tissue culture dishes until 70-80% confluent, before 
being washed in PBS and pelleted by centrifugation at 1,000rpm for five minutes 
and transferred to 1.5ml microtubes. Pellets were then lysed in buffer A (10mM 
HEPES pH 7.9, 10mM KCL, 0.1mM EDTA, 0.1mM EGTA, 1mM dithiothreitol [DTT]) 
supplemented with protease and phosphatase inhibitors on ice for 15 minutes. 
After this time, Tergitol-type NP-40 (NP-40) was added to the solution to achieve a 
final concentration of 0.6%. Lysates were centrifuged at 1,000rpm for five minutes, 
before the cytoplasmic supernatant was removed and stored in fresh microtubes on 
ice. The remaining pellet was then resuspended in buffer C (20mM HEPES pH 7.9, 
400mM NaCl, 0.1mM EDTA, 0.1mM EGTA, 1mM DTT) supplemented with 
protease and phosphatase inhibitors (1 tablet per 10ml; Roche Complete Protease 
inhibitors and Roche PhosStop), before shaking at 1,100rpm (4oC) for 15 minutes. 
After this time, the nuclear supernatant was removed and stored in fresh 
microtubes.  
 




2.2.16 Viral CCND1 overexpression in HCT-116 and RPE-Fucci 
Any procedures that involved handling of virus were performed by Sally Dewhurst 
(CRUK), who prepared the CCND1 and control lentivirus. 293FT cells were 
cultured in standard DMEM supplemented with 1mM sodium pyruvate. Cells were 
plated at a density of 6x106 and cultured for a further 16 hours in antibiotic-free 
media. The transfection mix (10µg CCND1 DEST vector, 7µg psPAX2 [packaging 
vector], 3 µg pMD.2G (envelope vector), 0.5ml Opti-MEM + lipofectamine 2000) 
was then added to the cells and media was replenished after 24 hours. Another 24-
28 hours later, viral supernatants were harvested before filtering through a 0.45µm 
HV filter (Millipore). For infection, 2ml of fresh media containing 8µg/ml polybrene 
(infection reagent) was added to cells cultured in a 6-well tissue culture plate. Next, 
50-200µl of viral supernatant was added to each well and incubated for 3 days, 
before puromycin selection.  
 
2.2.17 Cytokinesis failure - DCB assay   
On day 0, RPE-Fucci, RRE-Fucci Control and RPE-Fucci CCND1 cells were 
seeded into separate 15cm tissue cultures dishes. After 24 hours, cells were 
treated with dihydrocytochalasin-B (DCB, Sigma-Aldrich) for 16 hours. After this 
period, cells were washed for five minutes, five times, before trypsinisation and 
DNA staining with 10µg/ml Hoescht for one hour at 37oC. Samples were then 
washed in PBS before aliquoted into sorting tubes after being strained to ensure 
single-cell suspensions. Samples were sorted using an Influx BD cell sorter (BD 
Biosciences). The Fucci markers were excited were excited at 561 (emission 
610/20 mCherry), 488 (emission 530/40 Venus) and 405 (Hoescht emission 
460/50). mCherry+ve/Venus–ve G1 tetraploid cells were sorted and kept on ice 
before washing, counting and seeding at a density of 4,000 cells/well. The 96-well 
plates were pre-loaded with siRNA and transfection reagent for desired gene 
silencing (method described in section 2.2.4). For clonogenic assays, cells were 
seeded at low density in 6-well plates (method described in section 2.2.1.1). After 
incubation for the desired timeframe, the 96-well assays were treated with S-Trityl-
L cysteine (STLC) for 12 hours.  STLC inhibits Eg5 and arrests cells in prophase 
(Skoufias et al., 2006). In this assay, to determine if cells have progressed though 




the G1/S boundary and overcome arrest, cells in G2/M are scored as proliferating. 
In the absence of STLC, cycling cells will be in G2/M, but some may also have 
progressed through the cycle, back to G1, and would not be counted as 
proliferating competent. Therefore, pre-treatment with STLC before analysis will 
arrest all cycling cells in M-phase and allow more reliable detection of proliferating 
cells. After 72 hours (total for the whole assay), plates were fixed with 4% 
paraformaldehyde (PFA) and stored at 4oC, until required. Next, plates were 
washed with PBS and stained with DAPI (1µg/ml) and permeabilised with 0.5% 
Triton X-100 for five minutes at room temperature. Plates were imaged using the 
Cellomics Arrayscan Vti machine with a 10x numerical aperture objective. The 
percentage of G2/M cells was calculated using the Target Activation Cellomics 
Bioapplication (TACB) and was then compared to RPE-Fucci and relative fold-
change values were calculated.  
 
2.2.18 Microarray profiling 
RNA was extracted using the RNeasy extraction kit following the manufacturer’s 
instructions, before RNA quality testing by Qubit (Life technologies). Purified RNA 
was sent to the Cancer Research UK Manchester institute for analysis using 
Affymetrix Human Gene 1.0 ST arrays. Probir Chakravarty, Dr Tejal Joshi, Dr 
Nicolai Birkbak and Nicholas McGranahan performed the data analysis.  
 
Data was normalised using the frozen Robust Microarray (fRMA) method (McCall 
et al., 2010), summarising probes sets at gene level. Genes that showed 
differential expression between diploids and tetraploids were identified using the 
Student’s t-test with a significance threshold of p<0.05. Significant genes were 
further filtered by selecting those that showed a ≥ 2-fold change.  
 
2.2.19 SILAC 
SILAC was performed in collaboration with the CRICK proteomic facility with Dr 
Bram Snijders and Dr Vesela Encheva. The facility staff performed proline 
incorporation checks and subsequent methods.  




2.2.19.1 SILAC isotopes  
Unlabelled, hydrochloride forms of L-arginine and L-lysine (R0K0) obtained from 
Sigma-Aldrich (light isotopes). Hydrochloride forms of L-arginine [13C6, 15N4] and 
L-lysine [13C6, 15N2] (R10K8) were obtained from CK Isotopes (Heavy isotopes). 
2.2.19.2 Labelling of cells 
DC14 and TC13 (passage five and 42) were cultured in DMEM supplemented with 
light or heavy isotopes. Each clone at both early and late passages was cultured in 
‘heavy’ or ‘light’ media, as replicate experiments that could be inversely correlated 
after analysis. DMEM media supplemented with 150mg/L L-Proline (Sigma-Aldrich). 
Cells were passaged for a minimum of eight population doublings in T175 tissue 
cultures flasks.  After this time, cells were trypsinised and counted. 3x106 cells were 
aliquoted into 1.5ml microtubes, before lysis with 300µl 8M urea/Tris pH 8.5 on ice. 
Samples were then sonicated for 10 seconds and cooled on ice, before mixing at a 
1:1 ratio. Next lysates were quantified by Bradford assay before separation by 
SDS-PAGE. Gels were stained with EZ blue (Sigma), before de-staining and 
storage in water.  
 
2.2.19.3 In-gel digestion (for protein quantitation) 
Polyacrylamide gel slices were prepared for mass spectrometric analysis using the 
Janus liquid handling system (Perkin-Elmer). Briefly, the excised protein gel pieces 
were placed in individual wells of 96-well microtiter plates and destained with 50% 
acetonitrile, 50mM ammonium bicarbonate, reduced with 10mM DTT, and alkylated 
with 55mM iodoacetamide (all reagents from Sigma-Aldrich). After alkylation, the 
proteins were digested with 6ng/µl trypsin overnight at 37°C. The resulting peptides 
were extracted in 2% formic acid, 1% acetonitrile.  
 
2.2.19.4 In-solution digestion (for phosphoproteomics) 
Cells were lysed in 9M urea, 20mM HEPES, pH 7.8, supplemented with 100 
units/ml of benzonase and sonicated to reduce viscosity (3mm probe, 50% 




amplitude, three 15 second bursts, on ice). Between 4-5mg of protein per sample 
were used as estimated by Bradford protein assay. Lysates were reduced with 
10mM DTT for 30 minutes at room temperature, followed by alkylation with 20mM 
iodoacetamide (Sigma-Aldrich) for 30 minutes at room temperature in the dark. 
Lysates were digested initially with LysC (Promega) for 2 hours at 37⁰C. The 
lysates were then diluted with 100mM ammonium bicarbonate, 5% acetonitrile to a 
final urea concentration of less than 2M. The samples were digested 1:100 enzyme 
to protein ratio (w/w) with trypsin (Promega) overnight at 37⁰C. The next day, two 
additional aliquots of trypsin were added and incubated at 37⁰C four hours each.  
After the digestion, the samples were acidified with TFA (Thermo Fisher Scientific) 
to final concentration of 1% (v/v). All insoluble material was removed by 
centrifugation and the supernatant was desalted with Sep-Pak C18 cartridges 
(Waters) and lyophilized for 2 days. 
 
2.2.19.5 SCX fractionation of phosphopeptides  
Peptides were resuspended in 90µl of 10mM ammonium formate pH 2.9 and 25% 
acetonitrile, sonicated and all insoluble material was removed by centrifugation. 
Separation was performed using Agilent 1200 (Agilent) HPLC at a flow rate of 
1ml/min. The peptides were loaded on 20cm Polysulfoethyl-Asp SCX column 
(4.6mm inner diameter, 5µm particle size, PolyLC). Solvent A was 10mM 
ammonium formate pH=2.9, 25% acetonitrile, and the solvent B was 500mM 
ammonium formate pH=6.8, 25% acetonitrile. The samples were run on a linear 
gradient 0-80% B in 10 minutes. The total run time including column conditioning 
was 30 minutes. A total of six fractions were collected every two minutes between 
1-13 minutes after injection (one fraction=2ml). The collected fractions were 
vacuum dried and used for phosphopeptide enrichment. 
 
2.2.19.6 TiO2 enrichment of phosphopeptides 
Dried fractions were solubilised in 1ml of loading buffer (80% acetonitrile, 5% TFA, 
1M glycolic acid), sonicated and mixed with 5mg of TiO2 beads (Titansphere, 5µm 
GL Sciences Japan). Samples were incubated for 10 minutes with agitation 




followed by a one minute 2,000 × g spin to pellet the beads. The supernatant was 
removed and the beads were washed with 150µl of loading buffer. This was 
followed by two wash steps, first with 150µl 80% acetonitrile, 1% TFA and second 
with identical volume of 10% acetonitrile, 0.2% TFA. After each wash beads were 
pelleted by centrifugation (one minute at 2,000 × g) and the supernatant discarded. 
The remaining solution and beads were dried in a vacuum centrifuge for 30 
minutes followed by two elution steps at high pH. For the first elution step, the 
beads were mixed with 100µl of 1% ammonium hydroxide (v/v), incubated for 10 
minutes with agitation and pelleted at 2,000 × g for one minute. For the second 
elution step the beads were mixed with 100µl of 5% ammonium hydroxide (v/v), 
incubated for 10 minutes with agitation and pelleted at 2,000 × g for one minute. 
The two elutions were combined, vacuum dried and desalted using C18 Stage Tips 
(Rappsilber et al., 2007). Briefly, each Stage Tip was packed with one C18 
Empore™ high performance extraction disk and conditioned with 100µl of 100% 
methanol, followed by 200µl of 1% TFA. The sample was loaded on the 
conditioned Stage Tip, washed six times with 200µl of 1% TFA and eluted with 50µl 
of 80% acetonitrile, 5% TFA. The desalted peptides were vacuum dried in 
preparation for LC-MS/MS analysis. 
 
2.2.19.7 LC-MS/MS 
For MS analysis, peptides were resuspended in 0.1 %TFA and loaded on 50-cm 
Easy Spray PepMap column (75µm inner diameter, 2µm particle size, Thermo 
Fisher Scientific) equipped with an integrated electrospray emitter. Reverse phase 
chromatography was performed using the RSLC nano U3000 (Thermo Fisher 
Scientific) with a binary buffer system at a flow rate of 250nl/min. Solvent A was 
0.1% formic acid, 5% DMSO, and solvent B was 80% acetonitrile, 0.1% formic acid, 
5% DMSO. The diGly enriched samples and the in-gel digested samples (RNA 
polymerase IP, CSB IP and chromatin proteome) were run on a linear gradient of 
solvent B (2- 40%) in 150 minutes, total run time of 180 minutes including column 
conditioning. The phospho-enriched samples were run on a linear gradient of 2-
35% B in 150 minutes, total run time of 186 minutes. The nanoLC was coupled to a 




Q Exactive mass spectrometer using an EasySpray nano source (Thermo Fisher 
Scientific).  
 
The Q Exactive was operated in data-dependent mode acquiring HCD MS/MS 
scans (R=17,500) after an MS1 scan (R=70,000) on the ten most abundant ions 
using MS1 target of 1 × 106 ions, and MS2 target of 5 × 104 ions. The maximum ion 
injection time utilized for MS2 scans was 120 milliseconds, the HCD normalized 
collision energy was set at 28, the dynamic exclusion was set at 10 seconds, and 
the peptide match and isotope exclusion functions were enabled. 
 
The phospho-enriched samples were also analysed using a LTQ Orbitrap Velos 
(Thermo Fisher Scientific), where the HPLC conditions were as described above. 
CID and Multi Stage Activation (MSA) fragmentation were used in separate runs to 
increase the total number of identified phosphopeptides. The LTQ Orbitrap Velos 
was operated in data-dependent mode acquiring 10 CID or MSA MS2 scans 
(R=17,500) after an MS1 scan (R=60, 000). MS1 target was set at 1 × 106 ions, 
and MS2 target at 3 × 104 ions. The CID normalized collision energy was set at 35 
with 10 millisecond activation time and a maximum ion injection time for MS2 scans 
at 50 milliseconds. The dynamic exclusion was set at 20 seconds and singly 
charged peptides and peptides with unassigned charge states were excluded from 
fragmentation.  
 
2.2.19.8 Quantification of incorporation and L-arginine ->L-proline conversion 
The percentage of incorporation of the heavy (R10K8) amino acids was assessed 
after the cells have doubled six times in the heavy medium. The cells were lysed 
and separated on SDS-PAGE and analysed by LC-MS/MS, as described 
previously. The data was searched using MaxQuant/Andromeda, but an additional 
label for heavy L-proline was established to assess the percentage of conversion of 
heavy L-arginine to heavy L-proline. Ratios of MaxQuant-derived intensities for 
peptides containing R10K8 versus R0K0 peptides were used to determine the 
percentage of incorporation (R10K8/ R0K0). The same strategy was used to 
calculate the level of L-arginine->L-proline conversion (R10K8P6/R10K8P0). 





2.2.19.9 Data processing and analysis 
Raw data files were analysed with MaxQuant software (version 1.3.0.5), as 
described previously (Cox et al., 2009). Parent ion and tandem mass spectra were 
searched against UniprotKB Homo sapiens database (August 2012). A list of 247 
common laboratory contaminants provided by MaxQuant was also added to the 
database. For the search, the enzyme specificity was set to ‘trypsin’ with maximum 
of two missed cleavages. The precursor mass tolerance was set to 20 parts per 
million (ppm) for the first search (used for mass re-calibration) and to 6ppm for the 
main search. Carbamidomethylation of cysteines was specified as fixed 
modification, oxidized methionine and N-terminal protein acetylation were searched 
as variable modifications. Phosphorylated serine, threonine and tyrosine were 
added to the list of variable modifications when samples enriched for 
phosphorylated peptides were searched. The datasets were filtered on posterior 
error probability to achieve 1% false discovery rate on protein, peptide and site 
level. 
 
2.2.20 Bioinformatics  
Dr. Nicolai Birkbak performed all bioinformatics analyses. 
 
2.2.20.1 Copy number analysis  
Raw TCGA SNP data for testicular germ cell tumours (TGCT) and matched normal 
samples was downloaded from the TCGA on 2015-08-04, and processed, as 
described (Birkbak et al., 2012). Briefly, Affymetrix SNP data was pre-processed 
using the CRMAv2, CalMaTe and TumorBoost algorithms within the AROMA 
framework (Bengtsson et al., 2009, Bengtsson et al., 2010, Ortiz-Estevez et al., 
2012). Allele-specific copy number was determined using ASCAT v2.3 (Van Loo et 
al., 2010). 
 




2.2.20.2 Expression analysis  
Pre-processed RNA-seq data, normalized using the RSEM method and 
summarized to gene level, was downloaded from the TCGA. RNA-seq data was 
log2 transformed, and expression levels of CCND1, CCND2, CCND3 and CDKN1A 
was compared using Pearson’s correlation.  
 
2.2.20.3 Genome-doubling algorithm  
A modification of the genome-doubling algorithm used by Carter et al was used to 
assess the likelihood of genome doubling in the TCGA TGCT samples (Carter et al., 
2012). A P-value threshold of 0.001 was used for samples with ploidy ≤3, but for 
samples with a ploidy of 4, P ≤ 0.05 was used, and all samples where ploidy 
exceeded 5 were classified as genome doubled.  
 
Briefly, the rationale behind the analysis was based on the notion that if genome-
doubling occurs then homologous chromosomes must have two copies across the 
genome. If subsequent loss of genetic material occurs from one chromosome then 
the copy number will be odd (i.e. one), this being the minor allele. The copy number 
of the other allele (major) will still be even (i.e. two). Therefore, if the majority of the 
major allele is even, this implies the tumour would have undergone a genome-
doubling event as all chromosomes would have doubled at the same time. This is 
in contrast to tumours that may have increased their ploidy by specific gains of 
chromosomes. In this context, the major allele will not necessarily be even across 
the majority of the genome, as the major allele will be odd (one) and only fraction 
(the minor) even. Using this principle the algorithm calculated the probability of 
genome-doubling from TCGA SNP comparative genome hybridisation CGH data. 
 
2.2.20.4 Whole exome sequencing DNA sample preparation 
DNA extraction was carried out using the Qiagen DNeasy Blood and Tissue 
extraction kit, following the manufacturer’s instructions. DNA quality was assessed 
using a QuBit instrument (Life Technologies). DNA preparation and sequencing 
was carried out by the Advanced Sequencing Facility at Cancer Research UK 




London Research Institute. Paired-end sequencing was carried out as described 
(Gerlinger et al., 2012). Briefly, DNA was fragmented into 250-300bp (base pairs) 
fragments, before adaptors were ligated to each end. Adaptor-ligated templates 
were purified with Agencourt AMPure SPRI beads (Beckman Coulter), and 
amplified by ligation mediated PCR. DNA was then hybridised to SureSelect 
Biotinylated RNA library (BAITS) and bound to streptavidin beads. Each sample 
was loaded into an Illumina Genome Analyser II, and paired-end sequencing was 
performed to at least 30X coverage. Raw image files were processed with 
HCS1.4.8 software using default parameters to call bases. 
 
2.2.20.5 WES alignment and variant calling analysis 
Alignment and variant calling was carried out by Harshil Patel (Bioinformatics and 
Biostatistics, London Research Institute). Raw reads were aligned to the human 
hg19 genome assembly using BWA 0.5.9 (Li and Durbin, 2009), with a maximum 
mismatch threshold of 4 within 101bp; all other parameters were left as default. 
Alignments were post-processed to remove reads that mapped to multiple genomic 
loci and those that could have arisen from PCR duplication (using Picard tools 1.81, 
(Picard). The Genome Analysis ToolKit (version 2.3-9-ge5ebf34, (DePristo et al., 
2011) was used to perform indel realignment and indel left alignment. After filtering, 
a median exome coverage of 76X was observed per sample. Base-level nucleotide 
counts were obtained using the deepSNV package (Gerstung et al., 2012), with a 
minimum base quality threshold of 20, and subsequent variant calling was 
performed across all samples simultaneously using scripts written in Python. 
Variants with a minimum nucleotide count of 5 and an allele frequency less than 
0.1 were excluded from further analysis. Variant annotation was performed with 
ANNOVAR release 2012Oct23 (Wang et al., 2010). 
 
2.2.20.6 WES downstream filtering 
All variant calls in all samples were filtered as follows: The number of times a 
variant appeared in diploid and tetraploid samples was added as a filter. Mutations 
occurring in any diploid sample were removed. Unique tetraploid mutations were 




then filtered for the number of samples they occurred in. Different amino acid 
substitutions in the same gene, occurring in the same tetraploid sample, were not 
counted as two different samples. The predicted consequence of each mutation 
was assessed using the tools SIFT-predictor, PolyPhen-predictor and Mutation-
taster contained in the ANNOVAR variant calling package (Wang et al., 2010). 
 
2.3 Statistics  
Western blotting densitometry was quantified using ImageJ software. For grouped 
diploid versus tetraploid comparisons mean values were compared and tested for 
significance using the unpaired student’s t-test in Prism software, unless otherwise 


















Chapter 3. Investigating the molecular basis of 
tetraploidy tolerance 
3.1 Introduction 
Cell cycle checkpoints maintain the integrity of the diploid genome and protect 
against the oncogenic effects of CIN and aneuploidy (Davoli and de Lange, 2011a). 
Classic examples of these pathways are the SAC and DNA damage checkpoints.  
 
The SAC senses unattached chromosomes in anaphase, resulting in APC/C 
inhibition and mitotic arrest until all chromosomes have been properly attached. 
Loss of SAC can result in segregation errors and an unbalanced genome 
(Musacchio and Salmon, 2007). DNA damage checkpoints act as safeguards 
against damaged DNA progressing through the S and M phases of the cycle, to 
ensure errors are not duplicated and that proper segregation is achieved (Davoli 
and de Lange, 2011a). Progression past these checkpoints can result in CIN, 
cytokinesis failure and tetraploidy (Hayashi and Karlseder, 2013).  
 
The tetraploidy checkpoint has been proposed as the ‘last resort’ checkpoint and is 
deigned to clear polyploid cells, contributing to the maintenance of the diploid 
genome. Studies have shown newly formed tetraploid cells to undergo a p53-
dependent G1 arrest and termed this phenotype the ‘tetraploidy checkpoint’ 
(Andreassen et al., 2001a, Andreassen et al., 2001b). The stimulus for p53 
activation is not fully understood but, despite conflicting studies, it is generally 
accepted that tetraploid cells are susceptible to p53-dependent arrest, although the 
response is not likely to directly sense the polyploid genome (Ganem and Pellman, 
2007, Uetake and Sluder, 2004). Combined with studies showing correlation 
between tetraploid tumour cells and p53 mutations, a strong case for the role of 
p53 in the regulation of polyploid cell survival is emerging (Ramel et al., 1995, 
Galipeau et al., 1996). This chapter is aimed at understanding the status and 
dynamics of p53, as well as drug resistance, in the isogenic HCT-116 
diploid/tetraploid system (Figure 3.1).  
 






Figure 3.1 Tetraploid isogenic system  
To generate the isogenic tetraploid system, parental HCT-116 cells were stained 
with DAPI and analysed by flow cytometry. Cells were selected based on ploidy 
status (2N or 8N), before being subjected to cell sorting and single-cell cloning. 
This produced diploid clone (DC) DC8 and tetraploid clones (TC) TC3 and TC4. 
The same procedure was performed on DC8 after 37 weeks (p37) to produce a 
second generation of clones. This is an important step, as it shows that tetraploid 
cells can spontaneously arise from a single diploid precursor in vitro within the 37-
week time frame.  
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3.2 p53/p21 response in tetraploids  
TP53 mutations have been shown to correlate with polyploidy in murine and human 
tumours and a likely reason for this observation is its integral role in the tetraploidy 
checkpoint (Galipeau et al., 1996, Ramel et al., 1995, Aylon and Oren, 2011). 
Mutations in TP53 are likely to allow newly formed tetraploid cells to bypass the G1 
checkpoint, permitting proliferation and survival and, therefore resulting in CIN and 
aneuploidy (Andreassen et al., 2001b, Dewhurst et al., 2014). Previous work on the 
TP53 and CDKN1A status of the tetraploid clones revealed no coding mutations, 
suggesting that the tetraploid clones overcome the tetraploidy checkpoint in a p53-
independent manner (Dewhurst et al., 2014). To investigate the status of the p53 
and p21 pathway, multiple components of this pathway were investigated by 
mutational analysis, functional assays of the p53 response and cell cycle analysis.  
 
3.2.1 Mutational analysis by WES  
Whole exome sequencing (WES) was performed on all diploid and tetraploid 
clones at early (p5) and late (p50) passages (Figure 3.2A). Whole genome 
sequencing (WGS) was not employed in this study, as the primary aim was to 
identify coding DNA alterations that disrupt protein function. Early and late passage 
clones were analysed to investigate if specific mutations were selected over time. 
WES revealed no mutations were shared exclusively in the tetraploid clones, 
compared to the diploids, suggesting that tolerance to tetraploidy, in this system, is 
not provided by a single ubiquitous somatic event. Hierarchical clustering was 
performed to analyse the profile of non-synonymous mutations in the diploid and 
tetraploid clones (Figure 3.2A). The analysis showed diploid and tetraploid clones 
did not cluster, implying that the two ploidy states cannot be separated based on 
their mutational profiles. The clones also failed to cluster specifically in relation to 
passage number.   
 
Exome sequencing confirmed previous findings, showing no mutations in TP53 or 
CDKN1A. The sequencing data also demonstrated the absence of RB1 mutations; 
another gene commonly mutated in tetraploid cells, as it renders the G1 checkpoint 
inactive and permits the survival of tetraploid cells (Davoli and de Lange, 2011a). In 




addition, a further 15 genes known to be associated with the G1/S checkpoint were 
specifically analysed (Figure 3.2B). Only MYC and PCNA mutations were 
exclusively present in the tetraploid clones, although MYC was only mutated in 
TC16 (p5 and p50), with PCNA only mutated in late passage TC35 cells (p50). This 
mutational pattern implies lack of mutations converging on different parts of the 
tetraploidy checkpoint.  
  





Figure 3.2 Mutational analysis by WES 
Intronic and synonymous mutations were removed from the total number of 
mutations, resulting in 4,138 non-synonymous SNVs. These mutations were 
observed in 3,287 genes. Mutated genes present in HCT-116 parental cells alone 
or present in all clones were removed, leaving 2,360 genes. Genes were subjected 
to hierarchical clustering, with genes on the Y-axis and samples on the X-axis. (B) 
G1/S pathway. Gene products in black were not mutated in the diploid and 
tetraploid clones. Gene products in red were mutated specifically in the tetraploid 



























































































3.2.2 DDR in tetraploids  
Even though TP53 and CDKN1A were not mutated, the axis could still be 
repressed by genetic, epigenetic, transcriptomic or post-translational abnormalities 
in other components of the pathway and provide tolerance to the tetraploid 
phenotype.  
 
To test whether the p53 and p21 pathways were fully functional in our tetraploid 
clones, cells were treated with 5-FU, a member of the fluoropyrimidine family of 
compounds. Fluoropyrimidine were first developed in the 1950’s, based on the 
observation that rat hepatomas metabolised uracil more readily than normal tissue, 
indicating that enhanced pyrimidine synthesis may be semi-selective target for 
cancer therapy (Longley et al., 2003a). 5-FU is a common anti-cancer agent used 
in treatment of breast, head and neck and CRC (Longley et al., 2003a). Specifically, 
5-FU is an analogue of uracil with a fluorine atom substitute in place of hydrogen at 
the C-5 position (Figure 3.3A). In the clinical setting, response rates to single-agent 
therapy with 5-FU in advanced CRC are approximately 10-15%, however this can 
be improved to 40-50% if combined with oxaliplatin or irinotecan (Longley et al., 
2003b). There are three major mechanisms of action of 5-FU, all of which cause 
severe cellular toxicity, which is induced at lower doses in cancer cells in 
comparison to normal cells due to the former’s greater requirement for RNA 
synthesis, DNA synthesis and DNA repair (Longley et al., 2003a). In practice, this 
confers a degree of cancer cytotoxic selectivity.  
  




3.2.2.1  5-FU treatment induces tetraploid p53 and p21  
The DNA and RNA damage caused by 5-FU activates p53 and p21, causing arrest 
and apoptosis (Longley et al., 2003a). 5-FU treatment for sixteen hours, before 
harvesting and analysis by western blot, induced p21, p53 and p53 Ser-15 
phosphorylation. Induction of p53 protein levels and phosphorylation, as well as the 
up-regulation of p53 target genes are indicative of a fully functional transcriptional 
response (Figure 3.3B). Untreated tetraploid p53 and p21 levels were generally 
elevated in the tetraploid clones. This observation suggests that the tetraploid cells 
have constitutively high levels of p53 and p21, perhaps indicating a persistent level 
of cellular stress. The lack of p53-Ser15 phosphorylation under non-treated 
conditions, despite corresponding elevated total protein levels, suggests the 
mechanism of increased p53 up-regulation is not due to the DNA damage 
response. Tetraploid clones TC16, TC17 and TC35 displayed reduced p53-Ser15 
phosphorylation, which may indicate a dampened DDR and resistance to 5-FU 
exposure.  
 
3.2.2.2 Tetraploid clones show enhanced resistance to 5-FU 
Previous research has suggested that tetraploid cells are more resistant to 
cytotoxic chemotherapeutics and IR (Castedo et al., 2006a, Castedo et al., 2006b, 
Sharma et al., 2013, Balsas et al., 2012). To investigate whether our tetraploid 
clones displayed drug resistance, cells were treated with a range of 5-FU doses for 
72 hours, before viability was quantified. A three-day proliferation assay showed 
that diploids and tetraploids were generally equally sensitive to short-term 5-FU 
exposure, further validating an active DDR (Figure 3.3C). To investigate if there 
was a difference in cytotoxic drug sensitivity over a prolonged period of time, 
diploid and tetraploid clones (early and late passages) were exposed to 5-FU for 
12-16 days.   
 
  





Figure 3.3 Response to drug treatments  
(A) Chemical structure of 5-FU (B) Western blot analysis shows activation of the 
p53/p21 pathway after 5-FU treatment. Cells were treated with 5µM 5-FU for 16 
hours. (C) Clones were treated with a range of 5-FU doses (0-10µM) for 72 hours 
before being assessed for cell viability. Error bars represent standard deviations of 
3 replicates.   
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Firstly, early passage clones (p14-16) were tested over a dose range, revealing a 
difference in sensitivity at the 5µM dose. After quantification and normalisation of 
colonies, it was clear that the tetraploids were more resistant than diploid clones 
(Figure 3.4A & Figure 3.5A). TC13 was the most resistant, with a surviving fraction 
of 37%, while the other tetraploid clones ranged from 1.9%-9.6%. In contrast, DC14 
and DC25 showed no colony formation and the surviving fraction of DC8 was only 
0.6%. These data suggest even at an early passage (p10-14), the tetraploid clones 
are more resistant to 5-FU.  
 
The tetraploid clones can tolerate chromosomal segregation errors and, as a result, 
become genetically diverse over time (Dewhurst et al., 2014). This event 
recapitulates the genetic complexity observed in CRC tumours, which may result in 
drug resistance. To test if late passage clones were more drug resistant than early 
clones, possibly as a result of CIN tolerance, late passage diploid and tetraploid 
clone were exposed to 5µM 5-FU for 16 days and allowed to form colonies. The 
control colonies were slightly too large and in some cases single colonies could not 
be accurately counted, however the overexposure allows the easy visualisation of 
5-FU resistant tetraploid clones (Figure 3.4B). In order to increase the accuracy of 
colony counting, cells were seeded at lower densities of 150 and 200 cells per well 
and incubated for 12 days and these conditions produced smaller colonies that 
could be reliably counted (Appendix). 
 
Quantification showed that, in general, the late passage tetraploids were more 
resistant to 5-FU treatment. Three tetraploid clones (TC13, TC17 and TC35) were 
extensively more resistant to 5-FU than diploids, however TC16 was more sensitive 
than DC14 and DC25 but similar to DC8 (Figure 3.5B). All diploid and tetraploid 
clones showed a greater level of resistance in the late passage experiment. A 
possible explanation for this observation could be that HCT-116 cells are 
microsatellite unstable (MIN), thus the cumulative acquisition of mutations in the 
diploid clones could explain the elevated resistance in the late clones. These data 
suggest that tetraploid cells are intrinsically more resistant to 5-FU and the effect 
seen in the late passage clones could be the combined effect of MIN and the 
inherent resistance.  
 





Figure 3.4 Long term 5-FU treatment of early and late passage clones 
(A) Clones were seeded at 250 cells per well and incubated for 14 days with the 
indicated concentration of 5-FU. Colonies were stained with crystal violet, before 
counting and quantification. (B) Clones were seeded at 300 cells/well and 
incubated for 16 days with the indicated concentration of 5-FU. Colonies were 
stained with crystal violet and before counting and quantification. 




Oxaliplatin is commonly used in combination with 5-FU and can increase response 
rates. Oxaliplatin is a derivative of cisplatin and has a similar mechanism of action 
(Graham et al., 2004). After IV administration of oxaliplatin, the drug is activated by 
displacement of oxalate ligand giving rise to OH- groups that can form adducts with 
DNA and create intra- and interstrand cross-links. These cross-links interfere with 
DNA replication and transcriptional machinery, resulting in cell death by apoptosis. 
To test if the tetraploid clones were resistant to oxaliplatin, late passage diploids 
were treated with the drug in a ten-day clonogenic assay at doses ranging from 5-
0.3µM (Figure 3.5C). Treatment of diploids and tetraploids with oxaliplatin revealed 
no differential sensitivity at any dose. 
 
In summary, although short term proliferation assays in this CRC cell line model did 
not exhibit a difference in sensitivity to 5-FU, longer term clonogenic assays 
revealed elevated resistance to 5-FU in early and late tetraploid clones, suggesting 
that tetraploidy in CRC might contribute to clinical drug resistance and therapy 
failure, or perhaps select for tetraploid, genome-doubled recurrences. The finding 
that tetraploids and diploids are equally sensitive to oxaliplatin may explain why 
combination of 5-FU and oxaliplatin is more effective in the clinical setting and 
implies that single-agent oxaliplatin therapy might be more effective at clearing 
resistant tetraploid clones.  
  






Figure 3.5 Quantification of clonogenic assays  
(A) Early passage; three replicates from one experiment. Error bars represent 
standard deviation (SD) of three replicates (B) Late passage; colonies from three 
replicates were counted and the surviving fraction (SF) was calculated (SF = 
treated colonies/cells seeded x plating efficiency [PE]). Quantification was 
performed by automated Wolfram Mathematica software. Error bars represent SD. 
(C) Diploid clones (DC8, DC14 and DC25) and tetraploid clones (TC13, TC16, 
TC17 and TC35) were treated with oxaliplatin in a clonogenic assay for 10 days. 
Diploid and tetraploid clones were grouped. Results from three independent 




































































3.2.3 p53 response to segregation errors   
The observed elevated basal p53 and p21 levels in (Figure 3.3B) are not likely to 
be a result of the DDR, as no p53-Ser15 phosphorylation was observed, 
suggesting other routes of p53 activation could be contributing to increase protein 
levels. Previous work has shown that the tetraploid clones make twice as many 
segregation errors relative to the diploids (a function of genome-doubling) and are 
more resistant to cell cycle arrest and death (Dewhurst et al., 2014). As no 
mutations were found in p53, it was hypothesised that the increased segregation 
error rate may contribute to elevated p53 and p21 and resistance to apoptosis is 
provided downstream of p53. 
 
3.2.3.1 Reversine induced segregation errors elevate tetraploid p53 and p21 
To test whether p53 and p21 could be induced by segregation errors in the 
isogenic system, the MPS1 kinase inhibitor, reversine, was used to inhibit the SAC 
and promote whole chromosome mis-segregation (Figure 3.6A) (Lan and 
Cleveland, 2010). MPS1 is required to recruit SAC proteins to unattached 
kinetochores and thus contributes to SAC activation and APC/C inhibition. 
Therefore the absence of MPS1 can result in chromatid segregation before 
microtubule attachment and cause lagging chromosomes.  Indeed, loss of MPS1 
has been shown to cause rapid aneuploidy and cell death (Janssen et al., 2009). 
Reversine is a potent inhibitor of MPS1 (IC50 3nM) and, therefore, provides a useful 
chemical tool to pharmacologically induce segregation errors and investigate the 
p53 response to segregation errors and aneuploidy (Santaguida et al., 2010).   
 
Reversine treatment induced p53 and p21 in the tetraploids and PARP cleavage in 
all clones (Figure 3.6B). Although there was clonal variation in p53 and p21 
induction, there was no specific strong down-regulation of both tumour suppressors 
in the tetraploid clones (Figure 3.6B). In contrast, there was a consistent reduction 
of PARP cleavage exclusively in the tetraploid clones.   
 
These results demonstrate that p53 and p21 can be induced by segregation errors 
in both the diploids and tetraploids, however PARP cleavage is suppressed, 




suggesting reduced apoptosis only in the tetraploids after reversine treatment. 
These findings support the aforementioned hypothesis, suggesting that the 
doubling in segregation error rate might partly explain the elevated p53 and p21 
protein levels in tetraploids and resistance to apoptosis might occur downstream of 
p53. 
  







Figure 3.6 p53/p21 response to reversine and apoptosis array 
(A) Reversine chemical structure. (B) Western blot analysis of p53/p21 response in 
all clones after 200nM reversine treatment for 72 hours.  (C) Modified western blot 
analysis of apoptosis array. Cells were treated with 250nM for 72 hours. Dots 
represent a range of proteins involved in apoptosis (for protein names and 
quantification see Figure 3.7).  
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3.2.3.2 Reversine apoptosis array 
The decrease in tetraploid PARP cleavage post-reversine treatment, despite the 
elevated p53 and p21 levels, suggests that the mechanisms that provide tolerance 
to segregation errors are located downstream of p53. It is possible that tetraploids 
exhibit reduced PARP cleavage because of overexpression of anti-apoptotic 
proteins or defects in the apoptotic pathway. To test this, an apoptosis array was 
performed on DC14 and TC16, as these clones showed a substantial difference in 
post-reversine PARP cleavage.  
 
The array consists of a nitrocellulose membrane spotted with antibodies against 35 
apoptosis human cell markers (Figure 3.6C). Cells were lysed and incubated, 
before expression was detected by chemiluminescence. After quantification by 
densitometry the fold change between conditions was calculated. The basal levels 
of p53, p27 and p21 were all greater in the tetraploid clones, consistent with earlier 
findings (Figure 3.3B & Figure 3.7A). However, the analysis revealed increases in 
multiple forms of phosphorylated p53, in contrast to previous results (Figure 3.3B). 
This is likely due to non-specific binding, possibly un-phosphorylated p53, as the 
increase was also seen in the reversine-treated samples and previous data in this 
chapter has shown the compound does not induce the DDR (p53-Ser15) (Figure 
3.4A). However, in the cases of p53-Ser46 and p53-Ser392, basal activation 
cannot be ruled out. The analysis also revealed up-regulation of the anti-apoptotic 
proteins cLAP-1 and livin and also the tumour necrosis factor receptor (TNFR), 
however these ratios were likely artefacts of extremely low expression 
compromising reliable quantification (raw data in Appendix). Reversine treatment 
induced p21, p27, p53 and cleaved caspase-3 in DC14 (Figure 3.7B), however 
caspase cleavage was absent in TC16, supporting the hypothesis of a supressed 
apoptotic response in the tetraploids (Figure 3.7C). Induction of p53, p27 and p21 
in TC16 was subtle and this probably reflects higher basal levels of these stress 
proteins. There was no reduction in expression of anti-apoptotic or overexpression 
of pro-apoptotic proteins in the tetraploid clones, implying that apoptotic resistance 
to segregation errors after p53 induction may be attributed to other mechanisms. 
  





Figure 3.7 Quantification of apoptosis arrays  
Duplicate apoptosis array protein spots were quantified by densitometry and ratios 
between samples were calculated. (A) Fold change in TC16 untreated apoptotic 
protein expression relative to DC14. (B) Fold change in DC14 apoptotic protein 
expression relative after reversine treatment relative to untreated. (C) Fold change 
in TC16 apoptotic protein expression relative after reversine treatment relative to 
































































































































































































































































































































































































































































































































































































































Taken together, these data suggest that the tetraploid clones have substantially 
higher basal p53 and p21 levels and importantly the pathway is active. The axis 
can be activated by DNA damage, although this route is unlikely to be contributing 
to the basal elevation, as no p53-Ser15 was observed. Reversine-induced p53 and 
p21 were apparent in the all clones, providing evidence that segregation errors can 
activate the pathway. These results suggest that the heightened rate of segregation 
errors in the untreated tetraploid clones, compared to the diploids, might contribute 
to the enhanced p53/p21 levels. The p53/p21 response could not induce PARP 
cleavage as effectively in the tetraploids, providing a potential mechanism that 
might explain the increased frequency of cell survival after an endogenous 
segregation error (Dewhurst et al., 2014). The apoptosis array demonstrated an 
induction of p53 and cell cycle inhibitor proteins and a reduced apoptotic response 
in the tetraploid clones, as represented by reduced PARP cleavage, although the 
mechanism contributing to decreased tetraploid apoptosis could not be determined 
in the assay.  
 
Although, collectively, the data suggest that the tetraploid clones are tolerating 
segregation errors by a dampened apoptotic response, the cells still have 
enhanced levels of p21. Increased segregation errors and other tetraploidy 
associated cellular stressors are likely to be contributing to elevated p21. 
Heightened levels of p21, comparable to diploid levels after 5-FU and reversine 
treatment would be expected to cause cell cycle arrest (Kaeser et al., 2004). 
Therefore, it is tempting to speculate that the tetraploids may have developed a 
mechanism to cycle in the presence of elevated p21 which, combined with a 
decreased apoptotic response, produces a molecular network able to circumvent a 








3.3 Cell cycle characterisation of tetraploids  
Although the tetraploid clones proliferate slightly slower (Dewhurst et al., 2014), 
how they cycle with an activated tetraploidy checkpoint is an important question 
and will give further clues on how they tolerate tetraploidy. As the tetraploidy 
checkpoint induces p21, the mechanism that allows continued proliferation in 
presence of the cell cycle inhibitor is likely to be the mechanism that permitted the 
initial override of the checkpoint. To confirm the tetraploids were cycling in the 
presence of high p21, RB phosphorylation status and cell cycle dynamics were 
assessed. 
 
3.3.1 Basal p53 and p21 expression is elevated in the tetraploid clones  
The basal levels of p53 and p21 were validated and quantified by western blotting 
(Figure 3.8A). The analysis confirmed a 2.3 (p= ≤ 0.01) and 3.5 -fold (p= ≤ 0.001) 
increase in the tetraploids compared to diploids in p53 and p21, respectively 
(Figure 3.8B and C). There is a relative p53 and p21 increase compared to GAPDH 
in the tetraploids, suggesting specific protein overexpression.  
Of technical note, quantification of total tetraploid protein on a per cell basis by 
Bradford assay also showed a near doubling (1.98-fold; p ≤ 0.001), compared to 
diploids (Appendix). All proteins in this study were analysed against proteins that 
show no relative difference between the diploid and tetraploid clones. Therefore, 
tetraploid loading controls take protein doubling into account and, therefore, any 
further increase relates to specific protein overexpression.  
mRNA levels determined by quantitative PCR (Q-PCR) revealed no difference in 
TP53 levels between the diploid and tetraploid clones (Figure 3.8D and E). This 
finding is consistent with the post-translational regulation of p53 (Dai and Gu, 2010) 
and suggests up-regulation in the tetraploid clones is a result of protein stabilisation. 
In contrast, CDKN1A levels were generally elevated in the tetraploid clones (Figure 
3.8F). When all the diploids were compared to the tetraploids, there was an 
average 1.7-fold increase in CDKN1A mRNA (Figure 3.8G). The CDKN1A gene is 
a transcriptional target of p53 (Mirza et al., 2003). To investigate the extent of p53-




mediated induction of p21, siRNA was used to silence p53, before analysis of p21 
protein expression by western blot (Figure 3.8H). Loss of p53 completely abolished 
p21 expression in the tetraploids and diploids, suggesting that the elevated p21 
levels observed were exclusively p53-driven. Taken together these data suggest in 
tetraploid clones p53 is stabilised resulting in increased p21 transcription and 
protein expression.  
  






Figure 3.8 Validation and quantification of p53 and p21 protein and mRNA levels  
(A) Basal p53 and p21 levels in diploid and tetraploid clones analysed by western 
blotting with densitometry quantification (B and C). Representative example of 
three independent experiments. (D) TP53 mRNA measured by Q-PCR. N=3 (E) 
Combined comparison of diploids and tetraploids. (F) CDKN1A mRNA measured 
by Q-PCR. N=3. (G) Combined comparison of diploids and tetraploids. (H) siRNA 
knockdown of p53 in all clones. Lysates were analysed by western blotting and 
probed for p53 and p21; GAPDH was used as a loading control. Error bars = SD. 




































































































































































































































































































3.3.2 Tetraploid p21 is elevated in both cytoplasmic and nuclear subcellular 
locations  
Phosphorylation of p21 at Thr145 in the cytoplasm by AKT signalling results in p21 
cytoplasmic sequestration and is considered oncogenic, as p21 can no longer 
inhibit CDK2. This event is also permissive for an anti-apoptotic function, by 
inhibiting cytoplasmic pro-apoptotic regulators (Abbas and Dutta, 2009).  
 
To investigate if the elevated tetraploid p21 was being sequestered in the 
cytoplasm, cell fractionations were performed (Figure 3.9). Consistent with previous 
data, p21 was elevated in the tetraploid clones. However, there was no specific 
enrichment in the cytoplasm, demonstrating that p21 was not being sequestered in 
the cytoplasm and thus permitting CDK2 activity and cell cycle progression. 
Analysis of p53 revealed that the transcription factor was predominantly nuclear, in 
agreement with p21 gene induction. This result also suggests that apoptosis is not 










Figure 3.9 p21 and p53 subcellular localisation  
Cycling cells were fractionated into nuclear and cytoplasmic fractions. This was 
achieved by different lysis buffers optimised to rupture cell or nuclear membranes 
specifically.  Fractionated lysates were separated by SDS-PAGE before immuno-
blotting. PARP was used as a purity control, GAPDH as a loading control. 



























































3.3.3 Phospho-RB status is similar between diploid and tetraploid clones 
To determine whether the tetraploid clones had a similar proliferation profile 
compared to the diploids and were cycling without arrest in the presence of high 
p21/p53, RB-pSer807/811 was analysed by western blotting (Figure 3.10). 
Phosphorylation of RB at pSer807/811 is considered a marker of progression from 
G1 to S phase of the cell cycle and cellular proliferation status (Elangovan et al., 
2008). The amount of total RB protein was shown to be elevated in the tetraploid 
clones. However, when RB-pSer807/811 was normalised to the steady state levels 
of the protein, RB-pSer807/811 was in fact slightly reduced in the tetraploid cells, 
although this was not statistically significant and could be attributed to clonal 
variation (Figure 3.10C). These data suggest there is no major difference in RB-
pSer807/811, indicating tetraploid clones are cycling in presence of elevated p21.  
  





Figure 3.10 Phospho-RB status 
(A) RB-Ser807/881 and steady state RB levels analysed by western blot; GAPDH 
was used as a loading control. (B) RB levels in individual clones and (C) Pooled 
clones were quantified by densitometry. Error bars represent SD. Representative 




























































































3.3.4 Tetraploid clones do not display elevated G1 arrest despite raised p21 
levels  
In order to expand on previous findings and further investigate the cellular 
proliferation and absence of G1 arrest in a p53/p21-high background, a nocodazole 
trap assay was carried out (Figure 3.11). Nocodazole is a spindle poison that 
prevents microtubule polymerisation and spindle attachment resulting in SAC 
activation and mitotic arrest (Kallas et al., 2011, Matson and Stukenberg, 2011). 
Cells can be ‘trapped’ in mitosis by treatment with nocodazole for 16 hours, before 
analysis by flow cytometry, which should reveal a single G2/M peak. If a G1 arrest 
is occurring, the G2/M phase peak will decrease, as a fraction of cells will be 
represented in the arrested G1 peak. The diploid and tetraploid clones were 
subjected to the mitotic trap assay and only a minor G1 arrest was detectable 
(Figure 3.11A and B). There was no significant difference (p= 0.0676) between the 
average percentage of diploids remaining in G1 (2.6%) and tetraploids (3.4%) after 
treatment. These data provide additional evidence for tetraploid proliferation in the 
presence of elevated p21 and p53. 
  





Figure 3.11 Analysis of G1 arrest  
(A) DNA content profiles of the diploid and tetraploid clones after treatment with 
nocodazole for 16 hours before PI staining and analysis by flow cytometry. (B) 
Table showing percentage of cells in G1 -/+ nocodazole treatment. Representative 
example of two independent experiments. 
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3.4 Population based p21 expression analysis  
The levels of p21 protein appear to be elevated in the tetraploid clones as 
confirmed by western blot (Figure 3.10A). However, this approach could not 
distinguish between all cells expressing equal levels of p21 or distinct 
subpopulations differentially expressing p21. In order to confirm this, as well as to 
investigate the distribution of p21 within the population and throughout the cell 
cycle, p21 immunodetection coupled with flow cytometry was performed. 
Representative examples of the analysis are displayed in Figure 3.12. Analysis of 
individual clones TC16, TC17 and TC35 showed consistently greater ’p21 high’ 
populations, whereas TC13 displayed a p21-positive fraction similar to the diploid 
clones (Figure 3.13A). A grouped comparison revealed no significant difference (p= 
0.0989) in the percentage of cells that express p21 between the diploid (48%) and 
tetraploid clones (60%) (Figure 3.13B).  The relative intensity of p21 per cell was 
calculated by measuring the median p21 intensity value of all gated cells. The 
average fold change of p21 intensity was 2.3 times greater in the tetraploid cells 
(p= <0.0001) (Figure 3.13C, D). These data support the western blot analysis, 
confirming p21 up-regulation in the tetraploid clones. This implies that the same 
number of cells express p21 in diploid and tetraploid clones, but on average there 
was more protein per cell in tetraploids, as there is no clear indication of an ‘extra 
high’ p21 subpopulation.  
 
DNA staining with DAPI was combined with p21 immunodetection, to allow 
determination of the distribution of p21 throughout the cell cycle. In order to analyse 
p21 in relation to cell cycle phase, the total percentages of all cell cycle phases 
were summed and defined as 100%. G1, S and G2/M fractions were then 
expressed relative to this total, ensuring a defined comparison of cell cycle phases. 
Cell cycle fractions were not expressed as percentages relative to the whole cell 
count, as a proportion of cells existed outside the gated areas, meaning the gated 
cells would not equal 100% and skew the analysis. There were fewer G1 p21-
positive cells in the diploid clones compared to the tetraploids, although this was 
not statistically significant (p = 0.2815) (Figure 3.13E, F). This result may suggest 
that tetraploid clones cycle slightly slower through G1, however the nocodazole 
 





Figure 3.12 p21 expression analysis 
p21 expression was investigated in the diploid and tetraploid clones. Cells were 
incubated with a p21 primary antibody followed by a FITC-conjugated anti-p21 
secondary antibodies. Stained cells were subjected to flow cytometry and p21 
intensity was quantified. Shown are the population density plots. The gated area 
represents p21-positive cells. The p21-positive threshold was set at intensities 
above the signal produced the secondary antibody alone. Representative example 
of two independent experiments. 
 




trap experiment excludes a significant G1 arrest (Figure 3.11). Tetraploid cells 
expressed more p21 in the G1 phase of the cell cycle. The percentage of cells in S 
phase was significantly greater (1.8-fold, p≤0.01) in the tetraploid clones (7.5% and 
13.7% for diploids and tetraploid respectively), possibly suggesting a longer 
synthesis phase (Figure 3.13 E and F). As a result of the elevated percentage of 
p21 positive tetraploids in G1 and S phase, the G2 fraction was significantly smaller 
(p≤0.05) in the tetraploids (30.2%) compared to the diploids (42.7%) (Figure 3.13, 
E and F). These data support a slower progression through the cell cycle in 
agreement with previous proliferation curves (Dewhurst et al., 2014).  
 
The p21 median intensity was also calculated for each phase of the cell cycle. 
Interestingly, the tetraploid clones showed greater p21 intensity in all phases of the 
cell cycle (Figure 3.13G).  The greatest difference was evident in G1, with tetraploid 
clones expressing 2.2 times more p21 (p≤0.01). Importantly, elevated p21 was also 
observed in the S and G2/M phases with a significant 1.8-fold change (p≤0.01 and 
≤0.001 respectively) (Figure 3.13G). Collectively, these data support the previous 
finding of elevated p21 in the tetraploid clones and also implies they can progress 
from G1 through to G2/M despite increased p21. 
  





Figure 3.13 Cell cycle quantification of p21 flow cytometry analysis  
(A) The percentage of p21-positive cells across all cell cycle phases. (B) Diploid 
and tetraploid group comparison of percentage of positive p21 cells. (C) Median 
intensity of p21-positive cells across all cell cycle phases. (D) Grouped median p21 
intensity across all phases of the cell cycle. (E,F) Percentage of diploids and 
tetraploids in all phase of the cell cycle. (G) p21 median intensity in all phases of 
the cell cycle. Data displayed, N=2. Error bars indicate the SD of two independent 
experiments.  Unpaired student’s-t-tests * = p<0.05, ** p= <0.01  *** p=0 <.001 **** 



















































































































































































3.5 Discussion and Conclusions  
The primary aim of this chapter was to investigate the p53 and p21 status in the 
tetraploid clones, as they are both important components of the tetraploidy 
checkpoint. Drug treatments inducing DNA damage and segregation errors 
revealed the p53 and p21 axis to be active in the tetraploid clones. The basal levels 
of p53 and p21 in the tetraploid clones were substantially elevated, suggesting the 
tetraploid clones are cycling with high levels of both proteins that would normally 
induce cell cycle arrest and death in diploids. Therefore, these data provide 
evidence the tetraploid clones can activate the tetraploidy checkpoint response, as 
evidenced by the up-regulation of p21 expression, while a mechanism bypassing 
the inhibitory effects p53 and p21 must be in place to provide continuous and initial 
tetraploidy tolerance. In addition, the tetraploid clones were more resistant to 5-FU, 
a finding that may help explain drug resistance in the clinic.  
 
The HCT-116 cell system was used, as it is chromosomally stable which allowed 
the effects of tetraploidy on CIN and aneuploidy to be studied. However, HCT-116 
cells are MSI, which means there is a high mutational burden and clones can drift 
genetically by somatic mutation. This can cause issues when trying to understand 
molecular phenotypes as they may change simply as a function of genetic drift.  
The high mutational burden also challenges the initial identification of relevant 
mutations from NGS data. 
 
Exome sequencing failed to identify common mutations present in the tetraploid 
clones including TP53, CDKN1A or RB1, suggesting a tolerance mechanism 
independent of inactivating mutations in G1/S control components. Activation of 
p53 and p21 could be achieved by DNA damage and segregation error induction 
and protein levels in tetraploid clones were high. This result supports the 
sequencing data, confirming the expression of a wild-type p53 and not an inactive 
mutant. As exogenously induced segregation errors by reversine could elevate p53 
and p21 protein expression, the previously observed increased rate of endogenous 
segregation errors in the tetraploid clones (Dewhurst et al., 2014), might partly 
explain elevated levels of p21 and p53. This observation is in agreement with 
Thompson and Compton, who showed that induction of segregation errors in HCT-




116 cells induced a p53 response (Thompson and Compton, 2010b). Despite this 
experimental association, further work is required to conclusively show 
endogenous segregation errors are responsible for p53 induction. A possible 
strategy to address this question involves reducing the tetraploid segregation error 
rate, and investigating if p53 levels fall.  
 
In addition, it is likely that other tetraploidy associated mechanisms are also 
contributing to elevated p53 and p21 levels. Ganem et al recently proposed that 
Hippo signalling was responsible for a graded p53 response after tetraploidization, 
where LATS2 activation inhibits MDM2, thus stabilising p53 (Ganem et al., 2014). 
Therefore as extension of the current work, it would be of great interest to analyse 
components of the Hippo pathway in the HCT-116 tetraploidy system, in order to 
determine whether the pathway contributes to the observed elevations of p21 and 
p53. If Hippo signalling were responsible for p53 and p21 elevation, this would 
suggest the HCT-116 tetraploids are proliferating with a constitutively activated 
tetraploidy checkpoint.  
 
In addition, Thompson and Compton also demonstrated p38 activation after 
segregation error induction in HCT-116 cells, possibly suggesting that the response 
to aneuploidy is triggered by ROS (Bragado et al., 2007, Thompson and Compton, 
2010b). Therefore, an intriguing extension to this study would involve analysis of 
p38 and ROS levels in the tetraploid clones. A more extensive DNA damage 
analysis could also be performed in the tetraploids, by investigating the DNA 
damage pathway activation after a segregation error induction (e.g. ATM, CHK1/2). 
The combination of these studies with the analysis of Hippo signalling and 
segregation errors outputs, could clarify further which pathways and processes are 
active upstream the of p53 and p21 pathway in the tetraploid clones.  
 
Castedo et al showed that tetraploid cells undergo apoptosis after tetraploidization 
in a BAX dependent manner, highlighting another obstacle newly formed 
tetraploids have to overcome (Castedo et al., 2006b). The HCT-166 tetraploid 
clones in this study were less sensitive to reversine-induced apoptosis suggesting 
that one possible mechanism of tolerance may be a dampened apoptotic response 




downstream of p53, although the mediator of this phenotype was not detected in an 
apoptosis array.  
 
However, although tetraploids exhibited a compromised apoptotic response, they 
still possessed high levels of p53 and the cell cycle inhibitor p21. TP53 mRNA 
levels were similar between all clones, suggesting post-translational modification of 
p53 is responsible for the heightened protein expression. In agreement with 
CDKN1A being a transcriptional target of p53, p21 mRNA levels were significantly 
elevated in the tetraploid clones. In addition, knockdown of p53 resulted in the 
complete loss of p21 protein expression, suggesting p21 expression is exclusively 
driven by p53-dependent CDKN1A induction. 
 
Another mechanism that can suppress the inhibitory effect of p21 is cytoplasmic 
sequestration. Phosphorylation of p21-Thr145 inhibits translocation to nucleus. Due 
to the absence of a satisfactory p21-Thr145 antibody, the cellular localisation of 
p21 was assessed by compartment fractionation experiments. There was no 
cytoplasmic enrichment of p21 in the tetraploid clones, compared to the diploids, as 
p21 was greater in both the nucleus and cytoplasm. Of note, p53 was 
predominantly nuclear, also ruling out cytoplasmic sequestration of the transcription 
factor. These data show that p53 and p21 are elevated in the nucleus of the 
tetraploid clones, which would result in cell cycle arrest in normal cells. In contrast, 
a recent study showed CIN positive HCT-116 and RPE tetraploid cells sequestered 
p53 in the cytoplasm (Kuznetsova et al., 2015).  
 
Analysis of cell cycle progression by RB-Ser807/811 phosphorylation status, 
nocodazole trap experiments and flow cytometry revealed the tetraploids could 
progress through the cell cycle without G1 arrest, despite expressing high p21 in all 
cycle phases.  A possible explanation for the variability seen in the RB-Ser807/11 
analysis was the use of unsynchronised cells. Populations of cells within the 
different clones may have been at different cell cycle phases at the time of lysis, 
which may explain the relatively variable result. To address this issue, cells could 
be synchronised in M phase and released, before phospho-RB analyses at 
different G1/S time points, permitting a more reliable comparison between clones. 
RB can be phosphorylated at many sites and a more extensive RB-phosphorylation 




panel, such as Ser795, Ser608/612 and Ser780, could be used to further 
investigate tetraploid G1/S progression (Rubin, 2013). Nevertheless, these data 
combined with the confirmation of an active p53 pathway and high basal protein 
levels, suggest that tetraploidy-associated stress is promoting constitutive p53/p21 
pathway activation and the tetraploid clones are resisting G1 arrest and apoptosis.  
 
Taken together, the data presented in this chapter, show that tetraploidy tolerance 
in the HCT-116 isogenic system is not provided by mutating a member of the 
p53/p21/RB pathway, and implies the involvement of a more complex mechanism. 
This molecular phenotype provides a unique opportunity to study novel tetraploidy 
tolerance mechanisms bypassing a functional p53/p21 axis. Consistent with this, a 
pan-cancer analysis of nine tumour subtypes revealed 43% of TP53 wild-type 
tumours were genome-doubled compared to 58% in TP53 mutant tumours 
(McGranahan et al., 2015). In addition, the analysis showed that although there is a 
significant co-occurrence between mutant TP53 and genome-doubling, 65% of all 
genome-doubled tumours were TP53 wild-type. This suggests that other 
mechanisms of tolerance do exist in the clinical setting and understanding their 
molecular basis is important, as it may provide opportunities for therapeutic 
intervention together with an understanding of how chromosome segregation errors 
are propagated and how intercellular heterogeneity and cancer evolution is 
accelerated.  
 
Tetraploid cells treated with 5-FU were found to be more drug resistant. Similarly, 
Castedo et al showed that their tetraploid HCT-116 clones were more resistant to 
cisplatin, oxaliplatin and camptothecin, through up regulation of p53R2, a protein 
that facilities DNA repair (Castedo et al., 2006a, Castedo et al., 2006b). In addition, 
Kuznetsova et al showed elevated drug resistance to a wide range of cytotoxic 
anticancer agents in tetraploid HCT-116 and RPE cells (including 5-FU), although 
differences were small. In this study, although early diploids and tetraploid clones 
were equally sensitive at lower doses, tetraploid clones treated with 5µM and 10µM 
5-FU, specifically TC13, were more resistant than diploids. This may suggest that 
in the tetraploid clones there are more highly resistant 5-FU subclones, compared 
to diploid cultures. These subclones may require higher drug doses to completely 
clear them and prevent outgrowth during treatment, resulting in greater tetraploid 




surviving fractions. This provides evidence for the intriguing concept that 5-FU 
treatment might select for the reoccurrence of tetraploid tumours as a result of 
elevated resistance. As tetraploid cells can support CIN and aneuploidy, this could 
result in further drug resistance and more aggressive disease.  
 
When late passage clones were tested, although the tetraploid clones also 
demonstrated elevated resistance, the diploid clones were also more resistant. This 
may suggest the possibility that tetraploid clones are inherently more resistant to 5-
FU and elevation seen in the late passage diploid and tetraploids are a function of 
MIN and the accumulation of somatic mutations during clonal evolution. To improve 
this part of the study, dose response curves could be constructed ranging from 1-
5µM to demonstrate a dose-dependent relationship and completely rule out the 
possibility of an off-target effect at higher doses. As there was no differential 
sensitivity to oxaliplatin and the drug completely cleared diploid and tetraploid 
clones at the same dose (5µM), this might explain why combination with 5-FU is 
more active than single-agent therapy (Longley et al., 2003a).  
 
Understanding the molecular of basis of resistance may explain why tetraploid 
resistance is only observed after 5-FU treatment. It is possible that tetraploids have 
a greater nucleotide pool and are therefore less sensitive to depletion of RNA and 
DNA precursors, such as 5-FU, but are equally sensitive to DNA damage by 
oxaliplatin. To investigate this hypothesis, other antimetabolite drugs that deplete 
nucleotide pools could be tested (e.g. gemcitabine) in order to investigate if a 
similar phenotype is observed. Additionally, resistant 5-FU colonies could be 
expanded, before survival analysis by clonogenic assay and oxaliplatin treatment to 
confirm class specific drug resistance.  
 
Although the apoptosis array did not highlight any major pathway aberrations, all 
the clones should be analysed, as there may be mechanistic clonal variation. 
Apoptotic pathway aberrations may converge at different points, promoting 
resistance to cell death after segregation errors in the tetraploid clones (Taylor et 
al., 2008). For example, some tetraploid clones could overexpress BCL-2, whilst 
others may underexpress BAD, resulting in compromised apoptotic pathways 
(Taylor et al., 2008). Reversine treatment failed to induce BAX or BAD, suggesting 




that caspase-3 cleavage might be induced by an alternative pathway or perhaps 
the current assay is not sensitive enough. The integration of fluorescent secondary 
antibodies would allow a more sensitive and reliable detection and quantification. 
Thorough western blot analysis and other apoptosis assays could also be used to 
further dissect the apoptosis pathway downstream of p53.  
 
This chapter provides evidence that tetraploids have an elevated and functional 
checkpoint, which suggests that they should be undergoing a G1 arrest. Several 
lines of investigation show that there is no tetraploid G1 arrest and future work is 
needed to address how the tetraploid clones are overriding high p21 levels. Global 
analysis of the transcriptome and proteome may highlight molecular mechanisms 
capable of overriding the activated p53/p21 pathway. 
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Chapter 4. Quantitative proteomics of diploid and 
tetraploid cells  
4.1 Introduction  
The previous chapter has shown that p21 levels are elevated in the tetraploid 
clones and yet despite this they are still proliferating. In an attempt to understand 
how this may be occurring and to unearth further clues as to how the tetraploidy 
tolerance is provided in our system, RNA expression analysis and quantitative 
proteomics were performed. These powerful techniques allow the quantification 
and detection of differences in mRNA and protein expression.  
 
These techniques have been previously combined to investigate differences in 
expression in aneuploid cells (Pavelka et al., 2010, Stingele et al., 2012). Pavelka 
et al showed that protein expression in yeast correlated with increased copy 
number and that aneuploidy could produce phenotypic variation, in comparison to 
isogenic euploid cells (Pavelka et al., 2010). Stingele et al generated human 
aneuploid trisomic and tetrasomic cell lines and quantitatively determined changes 
in DNA copy number, mRNA and protein expression (Stingele et al., 2012). mRNA 
levels reflected DNA copy number, however, proteins were reduced towards diploid 
levels. This was particularly apparent for protein complex subunits and kinases. 
This suggests that protein subunits were regulated at the protein level to maintain 
the correct stoichiometric ratios, while kinases were post-translationally regulated 
to maintain diploid kinase signalling. The group also noted down-regulation of DNA 
and RNA metabolism pathways and up-regulation of metabolic and autophagy 
pathways (Stingele et al., 2012). Furthermore, the group expanded these findings 
and showed that tetraploid cells generated from HCT-116 cells, via cytokinesis 
failure, resulted in aneuploidy and the transcription profile elicited the same 
changes as trisomic cells, suggesting aneuploidy produces uniform response 
(Durrbaum et al., 2014).  
 
Taken together these studies suggest that, in aneuploid cells, a large proportion of 
regulation to permit survival is achieved at the protein level. This chapter aimed to 




apply RNA profiling and quantitative proteomics to identify potential differences in 
mRNA and protein levels between diploid and tetraploid clones.  This may provide 
important information on how cells manage tetraploidy and increased CIN. Three 
proteomic experiments were performed, comparing diploid and tetraploid clones, at 
both early and late passage time points. The global phosphoproteome was also 
compared in in the early clone pair.  
 
4.2 mRNA expression analysis  
Firstly, RNA was extracted from exponentially growing diploid and tetraploid clones 
and analysed using Affymetrix Human Gene 1.0 ST arrays. Surprisingly, only a 
limited number of transcriptional differences were identified between the diploid and 
tetraploid clones (Figure 4.1A). As there were no striking differences between 
clones and differences were not exclusive to ploidy state, these genes were not 
followed up. Therefore in the genome-doubled tetraploid system, mRNA expression 
may have scaled directly with DNA content, producing no detectable gene 
expression differences and regulation of expression as at the protein level. This 
would be consistent with the approximate doubling of total protein content 
(Appendix). This finding is in agreement with previous studies, which suggest that 
mRNA levels scale with DNA content and regulation is at the protein level (Stingele 
et al., 2012). Therefore SILAC was conducted to compare the proteome of diploid 












Figure 4.1 Diploid versus tetraploid mRNA expression analysis  
(A) Combined expression analysis of all diploid and tetraploid clones, early and late 
passage. Genes labelled in red show significant expression changes by ‘hypothesis 
testing’. For genes to score as a ‘hit’, the difference in expression should be >2-fold 
at p≤0.01.  
  




















































4.3 Stable Isotope Labelling of Amino acids in Cell culture 
(SILAC) 
To investigate whether the gene expression was regulated at the proteome level, 
Stable Isotope Labeling of Amino acids in Cell culture (SILAC) was performed. It 
was hypothesised that proteomic regulatory mechanisms may result in differential 
protein expression, which could provide tetraploidy tolerance and permit 
proliferation in the presence of high p21. Two experiments were carried out 
comparing diploid and tetraploid clones, at both early and late passage. Proteomic 
differences at both early and late time points may indicate proteins that are 
required for survival, whereas investigating differences at specific timepoints may 
also provide information on transient changes and evolved adaptations.  
 
4.3.1 SILAC principle  
SILAC is a relatively new technique, first published in 2002 (Ong et al., 2002, 
Blagoev et al., 2003). The principle allows quantitative proteomic comparisons 
between multiple samples, as opposed to standard mass spectrometry. 
Populations of cells are grown in ‘heavy’ and ‘light’ tissue culture media that 
provides the basis for comparison.  The ‘light’ condition is a normal growth medium 
with standard amino acids present, whilst the ‘heavy’ media contains arginine and 
lysine with 2H, 13C and 15N isotopes. Cells are grown in ‘light’ or ‘heavy’ media for a 
minimum of five population doublings, allowing incorporation of the isotopes into 
the proteome. This results only in a change of proteome mass and no other 
chemical changes (Mann, 2006). After five population doublings, fully labelled 
populations of ‘heavy’ and ‘light’ cells exist and are mixed 1:1, before separation by 
SDS-PAGE. The proteins in the SDS-PAGE gel are digested by trypsin, which 
cleaves proteins on the carboxy-terminal of arginine and lysine, producing a 
peptide mixture (Ong et al., 2002). Peptides are further separated by high 
performance liquid chromatography (HPLC) and eluted in order of hydrophobicity, 
before electrospray ionisation in the mass spectrometer ionisation chamber. In this 
study, a ‘time of flight’ (TOF) analyser was used to separate peptides by their mass. 




before peptide sequencing. The mass to charge (m/z) ratio is plotted on the 
chromatogram, as this corrects for the effect of ionisation on the peptide. At this 
point the relative abundances of the ‘light’ and ‘heavy’ samples are calculated. The 
‘heavy’ peptides in the sample have slightly greater m/z ratio than the ‘light’ species 
on the mass spectrum, permitting relative quantification between the two samples 
(Figure 4.2). The peptides are identified by another MS analysis known as ‘tandem 
MS’ or MS/MS. The peptide, known as the precursor ion, is fragmented to product 
ions by cleavage of amide bonds. The mass of the product ions (single amino 
acids) is then determined and matched to a database that reveals the peptide 
sequence and thus identifies the protein (Steen and Mann, 2004). 
  





Figure 4.2 Principle of the SILAC labelling strategy 
Cells are cultured in ‘light’ or ‘heavy’ media for a minimum of five population 
doublings. In the ‘heavy’ condition the mass spectrums show how a peptide 
species becomes labelled. At first the entire fraction is ‘light’. Midway through the 
labelling process the fraction of ‘heavy’ and ‘light’ peptides is equal and after 5> 
doublings 99% of proteins should be a ‘heavy’ species. This allows for sensitive 
and valid quantification of relative protein abundances between the two samples. 
After labelling cells are mixed at 1:1 ratio and separated by SDS-PAGE, before 
HPLC, mass spectrometry, peptide ratio calculations and peptide identification. 
m/z, mass/charge ratio.  
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4.4 SILAC analysis of DC14 vs TC13 
For technical reasons it was not practical to analyse the whole isogenic system by 
SILAC. Therefore, a representative diploid-tetraploid pair was selected and any 
differences discovered were validated across all clones. After labelling, ‘heavy’ 
labelled cells were checked for lysine and arginine incorporation (Figure 4.3). It 
immediately became apparent that there was a problem with the ‘heavy’ labelled 
cells. Although lysine and arginine labelling was sufficient, secondary ‘heavy’ 
proline peaks were apparent on the mass spectrum (Figure 4.3). The ‘heavy’ 
isotope incorporation checks revealed high Arg→Pro conversion rates of 
approximately 28-30%, causing problems for data analysis. ‘Heavy’ labelled proline 
will produce a fraction of peptides that contain ‘heavy’ arginine, lysine and proline 
producing three peaks for a single peptide on the mass spectrum (‘Light’ + ‘Heavy’-
arg-lys + ‘Heavy’ arg-lys-pro;  Figure 4.4). Abundance of ‘heavy’ labelled peaks will 
be underestimated as the proline satellite peaks will contain a proportion of the 
overall peptide, which cannot be factored into the quantification process ( Figure 
4.4). 
 
This problem is relatively common (Van Hoof et al., 2007), however conversion of 
~30% is very high and a solution to reduce this level was required in order to 
progress. One option involves changing the labelling system so the need for 
metabolic incorporation is bypassed, for example, isotope affinity tags (ICAT). At 
the time, this would require specialist technical assistance and further prolonged 
assay development and so was not deemed viable. Van hoof et al suggest the use 
of isotope ‘trickery’ to compensate for peak reduction. Applying isotopically labelled 
15N4-13C6 -Arginine to ‘light’ media would fuel conversion to ‘heavy’ proline in the 
‘light’ condition controlling for conversion, resulting in comparable peaks (Van Hoof 
et al., 2007). However, this method assumes conversion will be a constant between 
cell lines and can complicate analysis.  
  






Figure 4.3 Examples of proline conversion satellite peaks 
(A and B) Isotope incorporation check mass spectrum (MS1 spectra) 
demonstrating the presence of ‘heavy’ proline satellite peaks. Samples analysed 
were heavy samples only, i.e. not mixed with light samples. Peaks outlined in red 
on the left are the expected monoisotopic peaks containing ‘heavy’ arginine only 
(R), whereas peptides containing ‘heavy’ arginine and proline (R+P) are shifted to 
the right, outlined in blue.  
TCT5894A9RW3_AC_A2 #3402-3456 RT: 32.10-32.38 AV: 13 NL: 4.06E7
F: FTMS + p NSI Full ms [300.00-2000.00]











































TCT5894A12RW3_AC_D2 #3249-3401 RT: 31.79-32.58 AV: 34 NL: 2.08E7
F: FTMS + p NSI Full ms [300.00-2000.00]





































































Simpler methods involve reducing the ‘heavy’ arginine content to lower the 
conversion of arginine to proline, or increase the amount of proline in the media to 
shift the reversible reaction in the favour of arginine production. A slight reduction in 
arginine concentration may not have been effective in this study due to the high 
conversion rates calculated. However, Bendall et al demonstrated that the addition 
of exogenous proline to SILAC media reduced ‘heavy’ proline monoisotopic peaks 
in a dose-dependent manner and completely abolished conversion when cells were 
treated with >100mg/L (Bendall et al., 2008).  
 
The Bendall method was therefore adopted in an attempt to overcome the high 
proline conversion rate in the isogenic HCT-116 cell lines ( Figure 4.4C). ‘Heavy’ 
SILAC media was supplemented with multiple doses of exogenous L-proline and 
used to culture diploid parental HCT-116 cells. After five doublings, cells were lysed 
and separated by SDS-PAGE before proline incorporation checks. Scatter plots 
displayed in Figure 4.5 show the ratio of peptides containing ‘heavy’ arginine and 
lysine versus ‘heavy’ arginine-lysine-proline peptides. The median ratio of peptides 
containing a single proline was used to calculate the conversion rate, as peptides 
with multiple proline residues have greater ratios due to signal dispersion. The 
analysis was expected to reveal negative ratios (Log2 scale), as ‘heavy’ proline 
peptides are usually a small fraction of the total. 
 
Addition of exogenous proline at a range of doses appeared to supress the proline 
conversion observed. Untreated HCT-116 cells had a conversion rate of 20-30%, 
consistent with earlier checks for DC14 and TC13. However, addition of 100mg/L of 
proline reduced conversion to <1% and 400mg/L almost entirely abolished 
conversion. The scatter plots in Figure 4.5 clearly show that as the proline 
concentration is increased, the conversion rate falls and the number of ‘heavy’ 
containing peptides is decreased to almost undetectable levels. From these data it 
was decided that 150mg/L would be used for future SILAC experiments to abolish 
proline satellite peaks, permitting accurate quantification of peptides. 
  






 Figure 4.4 Proline satellite peaks and arginine metabolism 
‘Heavy’ arginine conversion to ‘heavy’ proline can hinder a reliable comparison 
between ‘heavy’ and ‘light’ samples. The chromatogram in (A) shows the 
abundances of a peptide in a ‘heavy’ and ‘light’ sample are equal. If a fraction of 
‘heavy’ proline exists and is incorporated into the peptide, three species of peptide 
will be detected as opposed to the expected two. (B) This hinders reliable 
detection, as the ‘heavy’ monoisotopic peak used to calculate a ratio relative to the 
‘light’ condition is underrepresented, as a fraction of the peptide is now present in 
the third ‘heavy’ lysine, arginine and proline peak. (C) Addition of exogenous 
proline solves this problem, by reducing the synthesis of proline from ‘heavy’ 
arginine and favouring the reverse reaction.  
  















Figure 4.5 Addition of exogenous L-proline & ‘heavy’ prolinecontaining peptides 
Standard DMEM media was supplemented with increasing concentrations of L-
proline. After five population doublings, cells were lysed and separated by SDS-
PAGE, before trypsin digestion and analysis by mass spectrometry. Ratios of 
‘heavy’ Lys-Arg/Lys-Arg-Pro peptides were calculated and plotted. The median 
conversion ratio of single proline containing peptides (the most abundant and 
reliable species) was used to calculate the overall proline conversion and was 
expressed as a percentage. Dashed line: median conversion ratio of single proline 
peptides.  
Peptides containing a single proline residue
Peptides containing a two proline residues
Peptides containing a three proline residues
Peptides containing a four or more proline residues
DMEM + 0mg/L L-Proline
DMEM + 100mg/L L-Proline



























































































































































































































































































































































































































































































































































4.4.1 Analysis of DC14 and TC13 
With the issue of proline conversion solved, the SILAC procedure was repeated 
under the optimised conditions. After culturing for more than five population 
doublings, cells were harvested, counted and mixed at a ratio of 1:1, in different 
combinations (Table 4.1). Mixes were lysed with 8M urea before quantification and 
separation by SDS-PAGE. All the mixes resulted in good separation and defined 
protein bands with minimal smearing, suggestive of protein quality adequate for MS.  
 
4.4.2 Control for experimental variation  
The first pair selected for analysis was mix 1 that contained DC14p5 labelled 
‘heavy’ and ‘light’ (Figure 4.6A). This analysis allowed the detection of intrinsic 
variance within the experimental process. In theory, all proteins would ideally return 
to a ratio of Log2=0 (1:1), as the same samples have been compared. In reality, 
some variation would be present due to quantification errors and slight differentials 
in expression between samples. Figure 4.6A shows the scatter plot for mix 1 and 
demonstrates a tight distribution and a limited spread. When the ratio distributions 
were compared between all samples, it was clear that the control had a much 
tighter distribution, implying intrinsic variance to be satisfactory (Figure 4.6B). This 
provided confidence that the changes seen in the experimental samples were a 
result of differential expression and not artificially induced by the technique or 
‘heavy’ and ‘light’ medias.   












Table 4.1 SILAC mixing combinations 
Components of each clone mix, with mix 1 acting as the control. Mixes 3 and 9 are 
reverse labelling repeats of early clones. Mixes 8 and 14 are late reverse repeats. 
Yellow box: control mix. Green boxes: experimental comparisons.  
  
	  	   ‘Heavy’	  Media	  
‘Light’	  
Media	  
	  	   DC14p5	   DC14p42	   TC13p5	   TC13p42	  
DC14p5	   Mix	  1	   2	   Mix	  3	   4	  
DC14p42	   5	   6	   7	   Mix	  8	  
TC13p5	   Mix	  9	   10	   11	   12	  
TC13p42	   13	   Mix	  14	   15	   16	  





Figure 4.6 Control mix and ratio distributions across all mixes 
(A) SDS-PAGE separation of mix 1 stained with Coomassie blue to check protein 
quality. The gel was processed for mass spectrometry analysis and sample ratios 
plotted in a scatter plot. The raw ‘heavy’/’light’ ratios were normalised to the median 
ratio and plotted on a Log2 scale. (B) Distributions of ratios for all mixes. Mix 1 
demonstrated a tighter distribution than the experimental mixes as it served as 









































































































































































































































































































































































































































































































































































































































































































































































































































































































DC14p5 (H) vs DC15p5 (L)




4.4.3 Sample correlation analysis 
Each mix was performed in duplicate and each replicate was labelled in the reverse 
combination, for example, mix 3 (DC14p5 [L] + TC13p5 [H]) versus mix 9 (DC14 
[H] +TC13p5 [L]). This was carried out to ensure reproducibility and that ‘light’ and 
‘heavy’ media had no effect in protein expression. Figure 4.7A shows the 
correlations between mix 3 and 9 (early samples) and Pearson correlation 
coefficient of -0.25 was calculated. Figure 4.7B shows the correlation of mixes 8 
and 14 (late samples) and possessed a Pearson correlation coefficient of 0.44. 
Therefore, the reverse experiments showed a satisfactory negative correlation, 










Figure 4.7 Mix correlation plots and protein gels 
(A) Correlation between early diploid and tetraploid repeat experiments. Labelling 
was reversed for each repeat to ensure differential media formulations did not 
affect the result. (B) Correlation between late diploid and tetraploid samples. (H) 
Heavy, (L) Light.  
VS
50 75 50 75ug ug
VS
50 75 ug 50 75 ug
A
B
TC13p5 (H)/DC14p5 (L) DC14p5 (H)/TC13p5 (H)









































































































































































































































































































































































































































































































































































































4.4.4 Comparison of protein groups between diploids and tetraploids 
As the experimental controls gave the expected results, the data could be analysed 
to find proteomic differences between the diploid and tetraploid samples. The data 
was first analysed to identify classes of proteins that showed differential expression 
levels. Figure 4.8 shows a scatter plot comparing protein groups from mix 8 and 14 
(late clones) and demonstrated a strong expected negative correlation between 
them. Late clones were analysed as they provided a stronger negative correlation 
between repeats than early samples.  Protein groups depleted in the tetraploid cell 
line appeared to be related to ribosomal subunits and associated proteins, possibly 
suggesting down-regulation of protein translation. These data also showed that the 
tetraploid clones had enrichment of chromatin components and nuclear proteins. 
As tetraploid cells with a 4N DNA content were predicted to have elevated levels of 
the majority of these proteins, this protein enrichment suggested that the technique 
has been successful and that valid biological differences were being detected. 
Interestingly, histone methyltransferase complex components, including histone-
lysine N-methyltransferase (MML) and chromobox protein homolog 5 (CBX5), 
showed enrichment in the tetraploid cell line. This finding may be suggestive of an 
increased demand for epigenetic regulators as a result of genome-doubling.  
 
To test this hypothesis, the diploid and tetraploid pair analysed by SILAC and two 
others (DC8, DC14, TC13, TC16) were screened in an epigenetic inhibitor library 
(Figure 4.9). Clones were subjected to library containing 51 epigenetic modulators 
for 72 hours at 5µM dose. The screen revealed tetraploids were significantly 
sensitive (p ≤ 0.01) to two histone deacetylase inhibitors, PCI-34051 and valproic 
sodium salt. In addition, tetraploids showed significant resistance to 2-
methoxyestradiol. However, although these differences in sensitivity were 
significant, the actual differences were minor and in the case of valproic sodium 
salt, survival was above 80% in all samples. TC13 was generally more resistant to 










Figure 4.8 Late clone protein group 2D analysis 
Scatter plot displaying classes of proteins that differ between late DC14 and TC13 
produced by Perseus software. The 2D analysis function is an algorithm that 
quantifies relative up and down-regulation of cellular pathways. Red dots and text 
represent pathways of interest that show differential regulation between diploids 





















































































































Figure 4.9 Epigenetic drug screen 
Diploid and tetraploid clones were seeded into 96-well assay plates containing 5µM 
of compound. Cells were incubated in the presence of drug for 72 hours, before 
measurement of metabolic activity by cell titre blue. Treated samples were 
normalised to DMSO control.    
Relative growth compared to control
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4.4.5 List of differentially abundant proteins in diploids and tetraploids 
Profile plots were generated in order to obtain a list of proteins that were 
differentially expressed between diploid and tetraploid samples (Figure 4.10). 
Profile plots were chosen as the best way to analyse the MS data, as they display 
data clearly across all samples analysed. Tetraploid enrichment ratios were 
manually set at approximately Log2=2 for ‘heavy’ labelled tetraploid samples, and 
approximately Log2=-2 for mixes with ‘light’ labelled tetraploids. As the ratio 
calculation is always ‘heavy’/’light’, this setting would identify proteins enriched in 
tetraploids (Figure 4.10A). The opposite settings were applied to find depleted 
proteins in the tetraploids (Figure 4.10B). Proteins displaying expression ratios that 
exceed these settings were likely to be impurities. Ratios for mix 1 were set at zero 
in order to ensure that the proteins selected did not show variation in the control 
condition, increasing the likelihood that hits were a result of biological differences 
and not induced artificially. These filters were applied and the software identified a 
manually set number of proteins that most closely followed the set ratio profiles. 
The MS data were interrogated for a total of 50 proteins enriched or depleted in 
tetraploid cells (early and late). A selection greater than 50 was not useful, as many 
proteins whose ratios fall within the box plots would start to be included and would, 
therefore, not be significantly deregulated. Proteins present in both early and late 
passage clones were taken forward, as de-regulation at both time points enhances 
the probability of the aberrations contributing to chronic tolerance, as opposed to 


























Figure 4.10 Profile plots for top 50 enriched or depleted proteins 
(A and B) Profile plots displaying 50 proteins that are enriched or depleted across 
all samples. Peptides must have been detected at least twice in all samples in 
order to be considered. The y-axis represents fold change and the samples (mixes) 
are plotted on the x-axis. Ratio values set are displayed in tables below plots and 
were set manually. Enrichment and depletion ratios set at approximately log2 2 or – 
2. This degree of expression change is considered relevant and is common setting 










Proteins that were identified as enriched or depleted in the early and late tetraploid 
cells are listed in Table 4.2.  Firstly, the enriched protein list was analysed against 
the gene ontology database, grouping proteins according to their function, and a 
degree of overlap was observed (Table 4.3). The analysis revealed fourteen 
biological processes that could be enriched in the tetraploid cells relative to their 
diploid counterparts. Although a degree of overlap was observed, due to nature of 
the gene ontology phylogenetic structure, mitotic control, cell cycle, chromatin 
regulation and DNA packaging all emerged as plausible differences that could aid 
the tetraploid phenotype. Validation of these findings across all the clones in the 
isogenic system is required, to ensure that the differences are not a result of 
intrinsic clonal variation. Down-regulated proteins were also analysed by the GO 
database and only a small overlap was observed Table 4.4.  
























































Table 4.2 List of genes identified by the mass spec profile plots 
50 proteins identified from the enrichment or depletion profile plots. Enrichment and 
depletion ratios were set at log2 of 2 and -2.  





Table 4.3 Gene ontology analysis from top 50 enriched tetraploid proteins 
The 50 enriched tetraploid proteins detected by SILAC were entered into the gene 
ontology database. Proteins that showed pathway convergence are displayed. Blue 









































































































































































































Symbol% %% %% %% %% %% %% %% %% %% %% %% %% %% %% %% %% %%
CDCA5% !! !! !! !! !! !! !! !! !! !! !! !! !! !! !! !! !!
PEX3% !! !! !! !! !! !! !! !! !! !! !! !! !! !! !! !! !!
KIF4A% !! !! !! !! !! !! !! !! !! !! !! !! !! !! !! !! !!
HELLS% !! !! !! !! !! !! !! !! !! !! !! !! !! !! !! !! !!
CHAF1B% !! !! !! !! !! !! !! !! !! !! !! !! !! !! !! !! !!
MSH2% !! !! !! !! !! !! !! !! !! !! !! !! !! !! !! !! !!
CNN2% !! !! !! !! !! !! !! !! !! !! !! !! !! !! !! !! !!
ATG9A% !! !! !! !! !! !! !! !! !! !! !! !! !! !! !! !! !!
SLC29A1% !! !! !! !! !! !! !! !! !! !! !! !! !! !! !! !! !!
IGF2R% !! !! !! !! !! !! !! !! !! !! !! !! !! !! !! !! !!
KIF20A% !! !! !! !! !! !! !! !! !! !! !! !! !! !! !! !! !!
PLP2% !! !! !! !! !! !! !! !! !! !! !! !! !! !! !! !! !!
ABCF2% !! !! !! !! !! !! !! !! !! !! !! !! !! !! !! !! !!
DNAJC1% !! !! !! !! !! !! !! !! !! !! !! !! !! !! !! !! !!
TPX2% !! !! !! !! !! !! !! !! !! !! !! !! !! !! !! !! !!
KIF22% !! !! !! !! !! !! !! !! !! !! !! !! !! !! !! !! !!
MSH6% !! !! !! !! !! !! !! !! !! !! !! !! !! !! !! !! !!
INCENP% !! !! !! !! !! !! !! !! !! !! !! !! !! !! !! !! !!
 




Gene/Gene	   Set	  

























Gene	  Symbol	   	  	   	  	  
MGST2	   	  	   	  	  
PFKP	   	  	   	  	  
NQO1	   	  	   	  	  
ALDH1A3	   	  	   	  	  
SORD	   	  	   	  	  
CPS1	   	  	   	  	  
BDH1	   	  	   	  	  
ALDH16A1	   	  	   	  	  
AGL	   	  	   	  	  
ASPH	   	  	   	  	  
ECH1	   	  	   	  	  
MAOB	   	  	   	  	  
CAM2KD	   	  	   	  	  
CPS1	   	  	   	  	  
ASPH	   	  	   	  	  
NDRG1	   	  	   	  	  
CLIC4	   	  	   	  	  
 
Table 4.4 Gene ontology analysis from top 50 depleted tetraploid proteins  
The 50 depleted tetraploid proteins detected by SILAC were entered into the gene 
ontology database. Proteins that showed pathway convergence are displayed. Red 
shaded squares indicate pathway involvement.   
  




4.4.6 Investigation and validation of SILAC ‘hits’ 
The 50 enriched or depleted proteins identified by the profile analysis were 
manually reviewed by checking protein function, via the human gene compendium 
database. Proteins, with functions that could provide benefit to the tetraploid clones, 
were checked for correlation in the two repeat experiments to confirm validity of the 
profile plot results. Peptide detection coverage was also considered when following 
up ‘hits’, as this relates to confidence in protein identification and quantification. 
 
4.4.6.1 ALIX (PDCD6IP)  
Programmed cell death interacting protein (PDCD6IP/ALIX) was identified as being 
enriched in early and late tetraploid cells by approximately 2-fold (Figure 4.11). 
ALIX is a mammalian protein with many cytosolic roles, such as endocytosis. The 
protein was first identified as the binding partner of the Ca2+ regulator ALG-2, which 
is required for induction of apoptosis (Odorizzi, 2006). Studies have shown that 
ALIX cooperates with ALG-2 to activate apoptosis and overexpression of ALIX 
results in cell death. Conversely, the mutated form of ALIX acts an anti-apoptotic 
regulator (Odorizzi, 2006).  Overexpression in the tetraploid system may be a result 
of an ALIX-dependent stress response. All members of the isogenic cell system 
were analysed for ALIX expression by western blot. Western blotting in Figure 4.11 
clearly shows more ALIX protein in TC13, validating the SILAC result. 
Encouragingly, GAPDH showed no variation across all samples in the SILAC result, 
and western blot analysis confirmed no relative variation between ploidy states and 
clones (Figure 4.11B). However, rather than an up-regulation in the tetraploid clone, 
there is down-regulation only in DC14 and all other clones showed expression 
similar to the tetraploids, suggesting DC14 has abnormal expression and the 
difference is probably due to clonal variance (Figure 4.11C). As this was not a 
general phenotype of all diploids, the ALIX protein was not investigated any further.  
  

















Figure 4.11 PDCD6IP (ALIX) and GAPDH plots and validation 
Profile plots for displaying protein ratios each SILAC sample. (A) PDCD6IP and (B) 
GAPDH. (C) Western blot validation of PDCD6IP for all clones. GAPDH loading 
control.   














The tumour suppressor N-myc downstream-regulated gene 1 (NDRG1) was found 
to have reduced expression in early and late tetraploid cells by approximately 3-fold 
relative to DC14 (Figure 4.12). NDRG1 is an α/β hydrolase and has been 
implicated in suppression of metastasis in colon, prostate and breast cancer (Bae 
et al., 2013). Elevated NDRG1 expression has been shown to be predictive of 
cellular stress and the protein can be induced by p53 (Bae et al., 2013). 
Experiments in human DLD-1 colorectal cancer cell lines have demonstrated 
NDRG1 is required for p53-dependent apoptosis (Bae et al., 2013). The SILAC 
result indicated lower expression of NDRG1 in the tetraploid cell line, which may 
support the tetraploid phenotype by suppression of the p53 response (Figure 
4.12A). Western blot analysis of all clones suggested that the SILAC technique had 
quantified the abundances correctly in DC14 and TC13 (Figure 4.12B). Western 
blotting revealed that NDRG1 may be depleted in TC13, however again the 
depletion was likely due to clonal variation and not ploidy specific. 
  





Figure 4.12 NDRG1 scatter plots and validation 
A) SILAC scatter plot displaying NDRG1 expression ratio. B) NDRG1 western blot 





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The kinesins KIF4A, KIF20A and KIF22 were present in the enrichment list for the 
tetraploid cell line and a manual review of the SILAC data revealed KIFC1 to be 
also enriched by approximately 50%, suggesting kinesins may provide an important 
role in tetraploid cells (Table 4.2 and Figure 4.13A.)  
 
KIFC1 has been described to participate in an important role in centrosome 
clustering (Kwon et al., 2008). The kinesin has been shown to be an essential 
factor for centrosome clustering in tetraploid cells with abnormal numbers, but is 
dispensable in normal diploid cell lines (Kwon et al., 2008). This rendered KIFC1 
into an attractive therapeutic target, as inhibition of KIFC1 should selectively kill 
cancer cells with amplified centrosomes and spare normal diploid cells, reducing 
toxicity. It has been shown by Sally Dewhurst that tetraploids have supernumerary 
centrosomes, compared to diploids (Appendix). Therefore overexpression might 
facilitate centrosome clustering, permitting survival. The SILAC data showed that 
KIFC1 is upregulated in the tetraploid cell line (Figure 4.13B). However, western 
blot analysis of all clones showed that the SILAC result did not validate and 









Figure 4.13 Kinesin scatter plots and validation 
(A) Scatter plot for mix 3 showing enriched kinesins. (B) Correlation plot for mix 3 
versus mix 9 displaying KIFC1 enrichment in both samples. (C) Western blot 




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































4.4.6.4 Cyclin D1 
Manual analysis of the data, investigating proteins that showed good inter-replicate 
experiment correlations, revealed cyclin D1 could be elevated in the tetraploid 
samples. In ‘mix 3’ versus ‘mix 9’ cyclin D1 was approximately 2-fold greater in 
TC13 relative to DC14 (Figure 4.14A, B). In the later passage samples, cyclin D1 
showed slight increase in ‘mix 14’ but was not detected in the duplicate control 
experiment. Western blot analysis of all clones in the isogenic system revealed 
cyclin D1 was elevated in four out of six clones (Figure 4.14). Quantification by 
densitometry and comparison of the diploid and tetraploid averages revealed a 4.9-
fold increase in tetraploid cyclin D1 protein expression. Although cyclin D1 was 
detected by SILAC, the signal intensity was low which can hinder quantification and 
may explain the discrepancy between the two techniques.  
 





Figure 4.14 Cyclin D1 scatter plots and validation 
(A) Correlation scatter plot displaying protein abundance. The X-axis represents 
the tetraploid/diploid protein ratios with the Y representing the inverse 
(diploid/tetraploid), and reveals tetraploid enrichment of cyclin D1. (B) Raito of 
protein abundance (tetraploid/diploid), relative to signal intensity displaying cyclin 
D1 enrichment.  (C) Western blot validation and quantification of cyclin D1 in all 













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































4.5 Phosphoproteomics  
The SILAC experiments have attempted to quantify total protein differences 
between a diploid and tetraploid cell line pair. The total protein global differences 
between DC14 and TC13 were apparent but not extreme, and it was possible there 
would be a greater difference in the phosphoproteome (proportion of total protein 
phosphorylated) of the diploid and tetraploid cells. Phosphorylation is an immensely 
important process that regulates many biological systems and global quantitative 
phosphoproteomics is a powerful tool that allows the quantification and 
identification of current and novel phosphorylation sites between multiple samples. 
 
4.5.1 Principle of quantitative phosphoproteomics  
As the phosphopeptides present in the sample represent only a fraction of the total 
protein, they needed to be separated from the sample to produce an enriched 
phosphopeptide fraction that can be analysed by MS/MS (Macek et al., 2009). This 
approach involved use of a combination of strong cation exchange (SCX) 
chromatography and titanium dioxide (TiO2) enrichment. SCX is a form of ion 
exchange chromatography that utilises differences in molecular charge for 
separation. At pH 2.7, un-phosphorylated peptides have a charge of +2 due to 
protonation of the N-terminus amino group and the C-terminus arginine or lysine 
(Macek et al., 2009). If the peptide gains a negatively charged phosphate, the 
charge of the overall peptide charge will fall to +1. The phosphopeptide can then be 
eluted independently of the non-phosphorylated form by a salt gradient, as the 
phosphorylated species will be bound with less affinity (Macek et al., 2009). Further 
enrichment is achieved by mixing the separated phosphopeptides with TiO2 
spherical porous particles, which absorb organic phosphopeptides in acidic 
conditions and can then be de-absorbed in alkaline conditions (Macek et al., 2009). 
This combination of techniques provides a powerful phosphopeptide enrichment 
process permitting analysis of the phosphoproteome by mass spectrometry and 
peptide sequencing.  
 
 




4.5.2 Phosphoproteomic analysis of DC14 and TC13 
DC14 and TC13 cell lines, previously labelled with ‘heavy’ and ‘light’ lysine and 
arginine isotopes for conventional SILAC, were lysed, digested and their 
phosphopeptides enriched before relative quantification between the two samples 
(Figure 4.15). The analysis revealed that six TNIK phosphopeptides, implicated in 
WNT-pathway signalling were depleted in the tetraploid cell line. However, TNIK 
total protein levels were also depleted, suggesting the decrease in phosphorylation 
is a result of protein reduction rather that altered phosphorylation status. The 
experiment did not reveal any changes in phosphorylation that were not a result of 
differential protein expression and suggests the phosphoproteome was relatively 
similar between the two samples. 
  





Figure 4.15 Phospho-TNIK detection and total protein comparison 
(A) Phosphoproteomics revealed depleted phosphorylation of six TNIK peptides in 
TC13. (B) Total protein SILAC showed elevated protein amount in tetraploids is 





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































4.6 Discussion and Conclusions  
The primary aim of this of the study presented in this chapter was to utilise 
quantitative proteomics to explore differences in the proteome between diploid and 
tetraploid clones that may provide tetraploidy tolerance. The principle finding was 
cyclin D1 overexpression, which was validated by western blot and will be 
discussed in great detail in the following chapter.   
 
The SILAC assay performed well and good correlations were achieved between 
replicate experiments. The number of proteins covered in replicate experiments 
was 3,896 and although satisfactory, a greater depth would allow detection of less 
abundant proteins that may be contributing to tetraploidy tolerance.  
 
Although ‘hit’ validation was successful in all but one proteins investigated, 
demonstrating the sensitivity of the SILAC approach, in most cases the result only 
validated in the clones analysed and not other family members. In order for a ‘hit’ to 
fully validate, the enrichment or depletion was required to be specific to the 
tetraploids and in more than two individual clones. In order to reduce the probability 
of following up proteins that only show differences in expression between the 
diploid and tetraploid clones, as a result of clonal variation and not a specific ploidy 
effect, the whole isogenic family had to be analysed.  
 
This would have allowed the detection of proteins specifically up-regulated in 
multiple tetraploid clones and increase the likelihood of discovering proteins 
involved in tetraploidy tolerance. Importantly, this would also permit a diploid/diploid 
comparison, which would demonstrate the proteomic variability of two cloned 
diploids, providing a control for the diploid/tetraploid analysis. If the diploid/diploid 
comparison was similar to that of the diploid/tetraploid, this would suggest that 
most of the proteomic differences were due to clonal variation and not ploidy status.  
 
One possibility would be to compare all clones to a reference clone (e.g. DC8) and 
analyse in paired format through multiple independent SILAC runs. This analysis is 
possible, however to achieve a satisfactory proteome coverage for 8-10 clones 
would be immensely time-consuming, due to the low throughput nature of SILAC. 




Tandem Mass Tag (TMT) technology can address this problem and has very 
recently become available to our laboratory. In contrast to SILAC metabolic 
labelling, TMTs are used to label peptides after cell lysis, with up to 10 samples 
labelled with different TMTs before multiplexing. The TMT with a known mass 
dissociates from the peptides of each sample after collision induced dissociation 
(CID) detection. This provides a unique reporter low m/z peak for each sample that 
is relative to peptide abundance in each sample and, thus, comparative 
abundances can be calculated. This technology therefore allows accurate 
quantification of global proteomic changes in multiple samples in a single mass 
spectrometry experiment. This new technique would allow analysis of all ten 
members of the isogenic system and would provide a more thorough and detailed 
analysis.   
 
Phosphoproteomics revealed no significant changes in protein phosphorylation 
between DC14 and TC13, however based on the degree of clonal variability 
observed it would be wise to compare all clones. Although phosphorylation sites 
were enriched in the analysis, this was a result of increased total protein as 
opposed to a relative increase in phosphorylation. Differences in growth pathway 
signalling may have been overlooked by this analysis due to pathway saturation. 
High serum and growth factor levels may mask the activities of signalling pathways 
due to an excess of receptor stimulation (Gerlinger et al., 2012). A possible 
strategy that may be more effective at identifying differences in growth factor 
signalling involves starving the cells before analysis. After starvation for a defined 
period of time, cells could be stimulated with serum before analysis of 
phosphorylation status. This would yield information on the activity and strength of 
growth factor pathways in the two cell lines.  
 
Pathway analysis was performed using the SILAC hits an attempt to identify more 
global changes.  Previous research has shown that protein levels generally scale 
with gene copy number in aneuploid cells (Stingele et al., 2012, Pavelka et al., 
2010). The SILAC data presented in this chapter supports this observation, as the 
tetraploid median expression value for all proteins detected was 2-fold grater than 
diploid values. In addition, the total protein amount on a per cell basis shows a near 
doubling of protein in tetraploid clones.  





Gene ontology analysis of the 50 most enriched and most depleted proteins 
revealed several changes in biological processes and molecular pathway between 
the diploid and tetraploid clones. Pathways or processes commonly up-regulated in 
the tetraploid clones included organelle organisation and biogenesis, protein 
localisation, mitosis, chromatin and chromosome organisation and DNA packaging. 
These findings are in contrast to Stingele et al, who showed that similar pathways 
are down-regulated in trisomic and tetrasomic cell lines (Stingele et al., 2012). On 
the other hand, Stingele et al showed up-regulation in pathways implicated in 
endoplasmic reticulum regulation, carbon metabolism, mitochondrial metabolism, 
Golgi vesicles and lysomes. One similarity between the two investigations was the 
up-regulation of biosynthetic pathways in aneuploid and tetraploid cells. Stingele et 
al showed elevations in lipid membrane biogenesis, while the proteomics analysis 
identified elevations in tetraploid organelle synthesis. 
 
Pathway analysis for depleted proteins in the tetraploid clones revealed 
convergence on two biological systems involving oxidative-reduction processes 
and response to metal ions. These data might be suggestive of a suppression of 
metabolic pathways in tetraploids, in contrast to Stingele et al. The likely reason for 
this is that in the present study tetraploid cells were compared to diploids, whereas 
Stingele et al compared aneuploid cells possessing one extra chromosome to 
diploids. The global imbalances caused by a single chromosome defect may be 
different to those caused by tetraploidy, resulting in discrepancies between the two 
studies. However, as the late tetraploids are likely to be aneuploid, they may show 
are more aneuploid-like profile. Indeed, a study investigating aneuploid cells after a 
tetraploid intermediate, showed mRNA profiles were highly similar to trisomic cell 
lines (Durrbaum et al., 2014). The present study was designed to identify proteomic 
irregularities that could provide essential tetraploidy tolerance, which would be 
required in both early and late passages. Therefore, ‘hit’ calling parameters were 
set to identify protein differences in both sets of clones. This strategy may have 
excluded aneuploid specific differences in late clones. It is possible that some of 
the traits identified by Stingele et al are exclusively present in late tetraploids and 
therefore would not have been considered a hit. Nevertheless, many of the 
deregulated pathways in early and late tetraploids presented in this chapter were 




the complete opposite compared to Stingele et al, suggesting there are 
fundamental differences between the studies. Therefore, in addition to analysis of 
more clones, a more detailed analysis of enrichment and depletion profiles at 
multiple passages would be beneficial. This could provide insight as to how the 
proteome changes over time with increasing CIN and emerging aneuploidy. 
The most significant finding in this chapter was cyclin D1 overexpression in the 
tetraploid early clones. Validation of cyclin D1 revealed an elevation in the second 
generation clones only. These clones were derived from DC8 and the result might 
suggest that the second-generation tetraploid clones were derived from a subclonal 
population with high cyclin D1 expression. A low frequency subclonal cyclin D1 
tetraploid population in the DC8 cell line was unlikely to be detected by western 
blotting given the total tetraploid fraction is only 0.5%. Alternatively, as the age of 
TC3 and TC4 are unknown, they may have acutely expressed cyclin D1 before 
more efficient tolerance mechanisms were initiated (Figure 3.1). As cyclin D1 
expression reproducibly validated by western blot and has been implicated in p21 
sequestration (LaBaer et al., 1997), it was taken forward as the lead ‘hit’ and 
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Chapter 5. Cyclin D1 overexpression and tetraploidy 
tolerance  
5.1 Introduction 
Quantitative proteomics detected cyclin D1 overexpression in the early tetraploid 
clones. The aim of this chapter was to investigate if elevated cyclin D1 expression 
could provide tetraploid tolerance. Based on the previously discussed findings, 
(section 1.2.3.3), it was hypothesised that the observed elevations in tetraploid p21 
could be inhibited by high cyclin D1 expression in HCT-116 tetraploid clones. An 
elevation in Cyclin D1-CDK4 complexes could sequester heightened p21 protein 
levels, limiting CDK2-Cyclin E1 binding. Evidence for overexpression of cyclin D1 
being able to promote tetraploidy was provided by Casimiro et al, who showed that 
cyclin D1 overexpression in MEFs enriched the number of 8N polyploid cells from 
approximately 5% to 15% within 3 divisions (Casimiro et al., 2012).   . 
 
The primary objective of this chapter was to investigate how cyclin D1 is elevated 
and whether the expression corresponds spatially and temporally to p21 
expression in HCT-116 isogenic system. The binding of p21 to CDK4 and CDK2 
and the effect on the catalytic activity of the latter was also assessed. In addition, 
cyclin D1 overexpression was performed in RPE cells, which have an unperturbed 
G1/S control, to investigate if cyclin D1 could permit tetraploid tolerance. 
Furthermore, D-type cyclin expression was also explored in genome-doubled p53 
wild-type tumours.  
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5.2 Cyclin D1 characterisation in the isogenic HCT-116 system  
In order to investigate the role of cyclin D1 in the HCT-116 isogenic system, the 
protein was analysed by a variety of techniques. Expression, stability, localisation 
and complex formation were all analysed, before overexpression in parental HCT-
116 cells.   
5.2.1 Cyclin D1 expression is elevated relative to other cyclin members  
Quantitative proteomics revealed an elevation of cyclin D1 (Chapter 4) in the 
tetraploid clones and may provide tolerance by counteracting high p21 levels by 
sequestration. To investigate whether increased expression of cyclin D1 was 
specific, relative to other cyclins, the diploid and tetraploid clones were analysed by 
western blot for the expression of cyclin A1, B1, D1 and E1. The analysis clearly 
showed that only cyclin D1 was elevated in the tetraploids, indicating a specific 
deregulation that suggests that cyclin D1 might be implicated in the tetraploid 
tolerance phenotype (Figure 5.1A). 
5.2.2 Elevated p53 and p21 are not directly responsible for elevated cyclin 
D1 levels in tetraploid clones  
It is possible that the observed tetraploid increase in p53 and p21 is responsible for 
increased cyclin D1 levels, as p21 can stabilise cyclin D1 (LaBaer et al., 1997). To 
investigate the relationship between p53, p21 and cyclin D1 overexpression, TP53 
mRNA was silenced by siRNA (Figure 5.1B). As observed in previous experiments, 
p21 expression was solely p53-dependent (Figure 3.8H). It was also clear that a 
reduction in p53 or p21 resulted in a partial reduction of cyclin D1 (Figure 5.1B). 
This was obvious in the diploids and the tetraploids and most likely reflects the loss 
of p21-CDK4-Cyclin D1 complexes, although a role for p53-dependent regulation 
cannot be ruled out. Although cyclin D1 levels were reduced in all clones after p53 
and p21 loss, there was still an elevation in the tetraploid clones (Figure 5.1B). 
Therefore, the increased levels of p53 and p21 cannot be directly responsible for 
increased cyclin D1 expression in the tetraploid clones, suggesting other 
mechanisms are contributing.    




Figure 5.1 Cyclin expression levels and p53 knockdown  
(A) Comparison of all major cyclins in the diploid and tetraploid clones. 
Representative of two independent experiments (B) Western blot analysis after 
TP53 knockdown in clones. siTP53 oligos were incubated with cells for 72 hours 
before western blotting. GAPDH and actin were used as a loading control. (OE): 
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5.2.3 Tetraploid clones have elevated cyclin D1 mRNA expression and 
enhanced ERK pathway signalling  
The heightened levels of cyclin D1, observed in the tetraploid clones, could be 
explained by a corresponding increase in RNA levels.  CCND1 mRNA was 
quantified by Q-PCR, which revealed an increase in the transcript levels.  All 
tetraploid clones had elevated CCND1 mRNA and TC13 showed the greatest 
change of just over 2-fold (Figure 5.2). On average, the tetraploid clones had 1.64-
fold more CCND1 mRNA than the diploid clones (p = 0.0062; Figure 5.2B). As 
CCND1 was elevated, relative to GADPH, it is unlikely that the increase in the 
transcript was a function of genome-doubling.  CCND1 amplifications are common 
in human tumours and result in cyclin D1 overexpression (Musgrove et al., 2011). 
Previous studies in our lab investigating chromosome copy number showed that 
tetraploids had no gain of chromosome 11q (Dewhurst et al., 2014), suggesting 
other mechanisms are responsible for mRNA induction.  
 
CCND1 is a transcriptional target of many growth-signalling pathways, like 
RAS/ERK (Musgrove et al., 2011). To investigate whether the tetraploid clones had 
elevated ERK signalling, cells were serum-starved for 24 hours, before re-addition 
over a defined time-course. The activation of the pathway was determined by 
western blot analysis of total and phospho-ERK (Figure 5.2C). Three of the four 
tetraploid clones displayed enhanced signalling, compared to a diploid counterpart. 
This experiment was performed in diploid versus tetraploid-paired format (by 
random pair assignment), which allowed multiple time points to be analysed. All 
diploid clones showed an activation of the ERK pathway after serum addition, 
which was delayed when compared to tetraploids. Of note, clones TC13 and TC16 
still showed ERK signalling at time 0, 24 hours after serum starvation and addition 
of serum did not enhance the activity of the pathway any further. This suggests that 
under serum deprivation, the tetraploids can maintain a greater basal level of ERK 
pathway activation and an increase upon serum is not observed, as the pathway is 
already saturated. However, although TC17 had a similar basal level of signalling, 
serum addition produced a stronger response compared to DC8 clone. In contrast, 
TC35 showed no activation of the pathway compared to DC25. Together these 
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results provide evidence that ERK signalling may be enhanced in the tetraploid 
clones, which could account for the elevated CCND1 mRNA expression.   





Figure 5.2 Cyclin expresion levels and ERK signaling 
(A, B) CCND1 mRNA quantification. Error bars represent SD (B) Quantification of 
CCND1 mRNA pooled in diploids and tetraploids. (C) ERK pathway activation. 
Cells were serum starved for 24 hours before 10% serum addition. Cells were 
lysed, before immunoblotting for total and p-ERK. Upper band ERK1 (p44), lower 
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5.2.4 Cyclin D1 protein stability is enhanced in tetraploid clones  
The 1.6-fold elevation in CCND1 transcript does fully explain the 4.9-fold increase 
in protein measured in Figure 4.14 and suggests other mechanisms may be 
contributing to the overexpression. Given the importance of cyclin D1 
overexpression, resulting from stabilisation by post-translational mechanisms (Alao, 
2007), cyclin D1 stability was assessed in the diploid and tetraploid clones. I was 
hypothesised that increased protein stability in combination with enhanced mRNA 
expression might be accounting for the observed cyclin D1 elevation. Therefore, 
cells were treated with cycloheximide (CHX) and harvested at different time points, 
before western blotting for cyclin D1 (Figure 5.3).  
 
In all cases, cyclin D1 was more stable in the tetraploid clones. For technical 
reasons, analysis was performed in a paired format (diploid versus tetraploid). 
Comparison of DC8 vs TC13 and DC14 vs TC16 revealed that the greatest 
difference in protein stability was at 30 and 20 minutes respectively, with a rapid 
decline in diploid cyclin D1 in both cases. HCT-116 vs TC17 and DC25 vs TC35 
showed a more subtle difference, although cyclin D1 was consistently more stable 
in the tetraploid clones, with the greatest difference at 40 minutes. These findings 
suggest, in addition to an increase CCND1 mRNA, that cyclin D1 is stabilised at the 
protein level, resulting in elevated expression. A sharp increase in cyclin D1 is 
observed in three out of four diploid versus tetraploid comparisons after 
approximately 20 minutes of CHX-mediated inhibition of translation. One possible 
explanation for this observation is the activity of other regulatory mechanisms that 
were not investigated, as the primary objective was to assess cyclin D1 stability.  
 
The experiment was repeated analysing p53 stability (Appendix). The spike 
observed for cyclin D1 was not observed in the p53 analysis, suggesting this 
quality is specific to cyclin D1 regulation and not a technical artefact of the 
experiment. These data suggest the cyclin D1 is stabilised and may be a 
contributing factor fuelling the elevation in cyclin D1 that could counteract and 
sequester elevated p21.  
 
  





Figure 5.3 Cyclin D1 protein stability 
(A—D) A comparison of cyclin D1 protein stability between diploid and tetraploid 
clones.  Cells were treated with 50µg/ml cycloheximide and incubated at 37oC for 
the indicated times. Cells were lysed, before immunoblotting and western blotting 
for cyclin D1. For quantification, cyclin D1 protein was normalised to GADPH 
before expression as percentage relative to 0 minutes. Representative of two 
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5.2.5 Tetraploid clones display heightened cyclin D1 phosphorylation   
As previously discussed, in section 1.2.3.1, phosphorylation of cyclin D1 at Thr286 
by GSK3-β results in its nuclear export and its subsequent ubiquitin-mediated 
degradation by the PCF4 complex. Therefore, a possible mechanism of cyclin D1 
protein stabilisation might be mediated through reduced Thr286 phosphorylation 
and nuclear retention, or inactivation of the PCF4 complex. Analysis of the exome 
sequencing data revealed no mutations in members of the PCF4 complex 
(mechanism discussed in section 1.2.3.1), suggesting that the protein would be 
ubiquitinated efficiently. Phosphorylation of cyclin D1-Thr286 was significantly 
elevated (1.6-fold; p≤0.05) in the tetraploid clones, implying increased nuclear 
export, as opposed to nuclear retention by hypo-phosphorylation in the tetraploid 
clones (Figure 5.4A and B). This result implies stabilisation is maintained through 
another mechanism.  
  





Figure 5.4 Cyclin D1-Thr286 phosphorylation  
(A) Levels of cyclin D1 phospho-Thr286 in the diploid and tetraploid clones. (B) 
Quantification of the phosphorylated Thr 286 cyclin D1 fraction by densitometry. 
Error bars represent SD. Representative of two independent experiments. * p= 
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5.2.6 Tetraploid cyclin D1 expression is elevated in all cell cycle phases and 
co-localises with raised p21 in the cytoplasm and nucleus 
The increase in cyclin D1-Thr286 phosphorylation, observed in Figure 5.4, might 
result in more cytoplasmic cyclin D1. Increased cytoplasmic cyclin D1 tetraploids 
would challenge the hypothesis that elevated cyclin D1 is sequestering p21 from 
CDK2. Alternatively, the elevation could be a result if an increased S phase (Figure 
3.13). Cyclin D1-Thr286 phosphorylation occurs during S phase, rapidly reducing 
cyclin D1, as expression in this phase inhibits replication. Prolonged S phase may 
result in further tetraploid cyclin D1 reduction, compared to diploids. Low S phase 
cyclin D1 could free p21 and cause S phase arrest in tetraploids (Zhu et al., 2004).   
 
The distribution of cyclin D1 throughout the cell cycle was investigated by flow 
cytometry in the diploid and tetraploid clones. The analysis revealed an elevation of 
tetraploid cyclin D1 in all phases of the cell cycle (Figure 5.5A). The average fold 
change of tetraploid cyclin D1, relative to diploids, was 1.4 in G1, 1.6 in S and 1.4 
in G2/M (Figure 5.5B). Cyclin D1 levels were reduced in S phase, in both diploids 
and tetraploids by 32% and 19% respectively, relative to G1. This is a small but 
significant (p≤0.05) difference, suggesting that cyclin D1 export and degradation in 
the tetraploids is less efficient and elevated cyclin D1 transcends the cell cycle.  
 
To explore cyclin D1 subcellular distribution, cytoplasmic and nuclear fractionations 
were carried out in the diploid and tetraploid clones (Figure 5.5C). Purity of the 
distinct fractions was determined by mutual exclusivity of the nuclear protein 
histone H2B (Kanda et al., 1998). The levels of p21 were greater in both the 
nucleus and cytoplasm in tetraploid clones (Figure 5.5C), consistent with earlier 
experiments (Figure 3.9). In addition, p53 levels were higher in the tetraploid clones 
and again were exclusively nuclear (Figure 5.5B). Importantly, cyclin D1 levels 
were high in the nucleus and cytoplasm, suggesting that elevated p21 levels may 
be actively sequestered in the cytoplasm and nucleus.  
 
Taken together, these two experiments indicate that elevated nuclear p21 levels 
are accompanied by elevated cyclin D1 and despite an increased S phase, which 
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likely results in elevated cyclin D1-Thr286, nuclear cyclin D1 levels are still higher 
in tetraploid clones and expression is higher in all other cell cycle phases.   





Figure 5.5 Flow cytometry analysis and cyclin D1 localisation 
(A) All clones were stained for cyclin D1 analysed by flow cytometry. The median 
fluorescence intensity was calculated and plotted for each cell cycle phase.(B) Fold 
change in cyclin D1 median fluoresce intensity (MFI) relative to HCT-116 for all 
clones. Error bars represent SD, N=3. (C) Cellular fraction of the diploid and 
tetraploid clones. Actin served as loading control and histone H2B as a 
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5.2.7 Preliminary immunoprecipitations reveal elevated tetraploid p21-
CDK4-cyclinD1 complexes  
The previous data suggest that cyclin D1 is elevated in tetraploid clones and may 
sequester high p21 levels. To investigate the status of CDK4 and CDK2 complexes, 
in relation to cyclin D1 and p21 binding, immunoprecipitations (IPs) were performed. 
The rationale behind these experiments was that the presence of high CDK4-Cyclin 
D1-p21 complexes and low CDK2-Cyclin E1-p21 binding in the tetraploids, relative 
to the diploids, would provide evidence for p21 sequestration by cyclin D1.  
 
As expected, CDK4 IPs in the tetraploids showed equal protein levels (Figure 5.6A). 
CDK4-bound cyclin D1 was variable between clones and not specifically increased 
in the tetraploids as expected. The level of p21 binding was far greater in the 
tetraploids, although was also marginally detectable in diploid clones. This 
observation suggests that the high tetraploid p21 is in complex with CDK4. The 
same principle was applied for CDK2 (Figure 5.6B). Again, cyclin E1 was highly 
variable between all clones and not tetraploid-specific. The level of CDK2-
CyclinE1-p21 binding was elevated in the tetraploids, possibly suggesting inhibition 
of the kinase and disagrees with the aforementioned hypothesis. However the 
diploid clones also showed p21 binding to CDK2. This is in agreement with the 
hypothesis that most CDK2 is p21-bound and only a small, unbound fraction is 
required for proliferation (Planas-Silva and Weinberg, 1997).  
 
The activities of CDK4 and CDK2 were tested by kinase assays (Figure 5.6C). 
Endogenous CDK4 and CDK2 was immunoprecipitated from cycling cells 
incubated with 32P-labelled ATP and kinase activity on RB monitored. The CDK4 
assay in Figure 5.6C shows variability and no specific difference between the 
clones. DC8 and TC17 possessed the highest activity, whereas DC14 had the 
lowest. CDK2 activity was also variable but, as with CDK4, all clones showed more 
activity than the mock, suggesting activation.  Again, DC8 showed the greatest 
activity, with TC35 also exhibiting high levels. These results clearly demonstrate 
the degree of clonal variability in the isogenic system. Nevertheless, the kinase 
assays provided evidence for CDK4 and CDK2 activity in the tetraploids, despite 
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elevated p21 binding and support the hypothesis that p21-CDK association is non-
inhibitory in the tetraploids, possibly as a result of elevated cyclin D1.  





Figure 5.6 Preliminary CDK4 and CDK2 immunoprecipitations and kinase assays 
(A) CDK4 input and CDK4 IP. All clones were lysed and Immunoprecipitated of 
CDK4. Lysates were separated by SDS-PAGE before immunoblotting. 
Representative of three independent experiments. (B) CDK2 input and CDK2 IP. 
All clones were lysed and Immunoprecipitated of CDK4. Lysates were separated by 
SDS-PAGE before immunoblotting. Representative of two independent 
experiments.  (C) CDK4 kinase assay. Endogenous CDK4 was immunoprecipitated 
as above. CDK4 pull downs were incubated with radiolabeled 32P ATP substrate 
and full length RB. Signal was measured by radiography. (D) Kinase assay 
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5.2.8 Cyclin D1 overexpression in parental HCT-116 cells does not increase 
the basal tetraploid population  
Results in this chapter have indicated that cyclin D1 overexpression in tetraploid 
cells might inhibit the activity of p53-induced expression of p21. In addition, the 
elevated p21 expression, in the presence of increased cyclin D1 protein, appears to 
support increased CDK4-cyclin D1-p21 formation, which appears to maintain RB 
phosphorylation at critical residues required for G1/S transition, possibly by 
sheltering CDK2 from p21 inhibition. Conceivably, therefore, elevated Cyclin D1 
expression may provide insight into the tetraploidy tolerance mechanism. 
Consistent with this hypothesis, previous studies have shown that overexpression 
of cyclin D1 in MEFs results in an enhanced 8N tetraploid fraction, suggesting 
cyclin D1 can promote or at least be permissive for tetraploidization (Casimiro et al., 
2012).  
 
In order to investigate whether cyclin D1 could increase the fraction of newly 
generated tetraploids, the CCND1 gene was overexpressed by viral infection in the 
parental HCT-116 cells (Figure 5.7A), after which cells were allowed to expand, 
before propidium iodide staining and flow cytometry analysis (Figure 5.7B). The 
HCT-116 vector control cells displayed an average 8N fraction of 0.18% compared 
to 0.21% (p = 0.5626) of CCND1 overexpressing cells, showing no significant 
increase in the spontaneous formation of tetraploid cells (Figure 5.7C). Therefore, 
this indicates that HCT-116 cells do not behave the same way as MEFs. This could 
be due to the fact that MEFs are prone to genomic instability when successively 
passaged in culture, in contrast to HCT-116 cells. Therefore it is possible in MEFs 
CCND1 overexpression facilitates an already inherent mechanism. The degree of 
sensitivity in the current assay may also be unsatisfactory, and this topic is 
discussed in section 5.5.  
  




Figure 5.7 CCND1 overexpression in HCT-116 cells 
(A) Western blot analysis displaying the level of CCND1 overexpression. (B) 
Representative DNA ploidy plots for HCT-116 vector control and CCND1 
overexpression. Un-synchronised cells harvested in the exponential growth phase 
before staining with PI and analysis by flow cytometry.  (C) Percentage of 8N 
tetraploid control and CCND1 cells. Error bars represent SD, N=3.   
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5.3 Cyclin D1 overexpression in RPE pharmacologically-
induced tetraploids 
The work in the isogenic HCT-116 tetraploid system has revealed cyclin D1 as a 
protein possibly implicated in tetraploid tolerance within a p53+/+/p21+/+ background. 
However, due to the variable nature of the clones and their high mutational 
frequency, driven by the MSI of this cell line, definitively showing that cyclin D1 is 
providing a survival advantage has been challenging in this system (see section 
5.5). However, this work in combination with the defined role of cyclin D1 in p21 
regulation hints at the possible ability of the protein overriding the p53/p21-
dependent tetraploidy checkpoint. 
 
5.3.1 Generation of tetraploid RPEs 
In order to generate a more controlled system, the retinal pigment epithelial cell 
(RPE) line was used. RPEs are stable diploid cells, have a normal p53 response 
and undergo G1 arrest upon chemical induction of tetraploidy (Ganem et al., 2014). 
Therefore, inducing tetraploidy in RPE cells allows the investigation of mechanisms 
that can override the p53-dependent G1 tetraploidy checkpoint.  
 
To induce tetraploidy, cells were treated with 2µM dihydrocytochalasin B (DCB), a 
drug that inhibits actin polymerisation and contractile ring formation, inducing 
cytokinesis failure and formation of tetraploid (Fujiwara et al., 2005). DCB treatment 
results in a mixed population of diploid and tetraploid cells and distinguishing 
between them presents a technical challenge. A solution to this problem is to utilise 
the Fucci reporter system (Newman and Zhang, 2008). The Fucci reporter system 
expresses hCdt1-Cherry (cdt1) and hGem-green (geminin). Cdt1 is a member of 
the pre-recognition complex involved in origin licensing and is rapidly degraded and 
inhibited in S and G2/M phases by ubiquitination by geminin, a protein exclusively 
expressed in late S-G2/M (Newman and Zhang, 2008). Flow based cell-sorting 
analysis allows sorting of G1 (red) tetraploids from G2 (green) diploids and thus 
provides an elegant method to distinguish between different phases of the cell 
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cycle. Distinct populations of cells can be sorted before seeding and assessment of 
cell survival or other downstream assays (Figure 5.8).  
 
To investigate whether cyclin D1 overexpression can permit the survival of newly 
formed p53+/+/ p21+/+/ RB1+/+ RPE-Fucci tetraploid cells, cyclin D1 was stably 
overexpressed by viral infection and the stable cell lines were characterised (Figure 
5.8). Western blot analysis and immunofluorescence confirmed cyclin D1 
overexpression in the RPE cells (Figure 5.8A, B) and proliferation kinetics were 
investigated by construction of a growth curve (Figure 5.8C). All three conditions 
were in the lag phase until 12 hours. After this, cyclin D1 cells entered the 
exponential phase, although the controls remained in the lag phase for a further 12 
hours. The exponential doubling times between RPE-Fucci (15.03h), RPE-Control 
(14.86h) and CCND1 cells (16.25h) revealed no overwhelming difference. 
Therefore, cyclin D1 overexpression reduces the lag phase, resulting in an initial 
increase in cell number. As the control cells enter the exponential phase and 
proliferate at the same rate, the increase of cyclin D1-cells remains constant at 
~1.7-fold.  
 
In order to see if cyclin D1 overexpression increased the basal tetraploid fraction in 
the RPE-Fucci, RPE-Control and RPE-CCND1 cell lines, ploidy was determined by 
flow cytometry (Figure 5.9). RPE-Fucci had a basal >6N faction of 0.015% 
compared to 0.020% in the CCND1-overexpressing cells.  This finding suggests 
that tetraploidy is rare or poorly tolerated in the RPE cell line. This makes the 
model a good system to investigate if cyclin D1 overexpression can provide 
tetraploid tolerance after pharmacological induction, due to a low number of 
endogenous polyploid cells, which would only enhance the detection of viable 
DCB-induced tetraploid cells. 
 
  





Figure 5.8 Cyclin D1 overexpression and experimental strategy in RPE-Fucci 
(A) Western blot validation of CCND1 overexpression RPE-Fucci cells. (B) CCND1 
expression tests by immunofluorescence. (C) Growth curves for RPE-Fucci, control 
and CCND1 cells. Cells were plated and cell surface area coverage was 
calculated. Error bars represent SD (D) Experimental procedure used to isolate 
tetraploid cells. Cells were seeded before treatment with 2µM DCB to induce 
cytokinesis failure and tetraploidy. Cells were analysed by flow cytometry to 
determine ploidy, and the 4N peak containing cycling G2 diploids (black peak) and 
DCB induced G1 tetraploids (purple peak), was sorted to isolate the G1 tetraploids. 
This was achieved by selecting G1 mCherry positive 4N cells, before plating for 
downstream assays.  
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Figure 5.9 RPE baseline 8N fraction  
DNA ploidy plots for RPE-Fucci, RPE-Control and RPE-CCND.1 Un-synchronised 
cells were harvested in the exponential growth phase before stained with PI and 
subjected to ploidy analysis by flow cytometry. Representative of two independent 
experiments.   
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5.3.2 Cyclin D1 overexpression in DCB induced tetraploids promotes the 
bypass of G1 arrest and entry into G2 phase   
Induction of tetraploidy by DCB results in a 4N population of cells arrested at G1 
and this can be observed in the DNA ploidy plots which correspond to the sorted 
populations. DCB treatment produced a 4N G1 arrest in approximately 50% of cells, 
represented by an increased G2/M peak (Figure 5.8D). The percentage of cycling 
tetraploid cells can be determined by calculating the fraction of 8N cells within the 
total population (Figure 5.10A). An 8N population represents tetraploid cells that 
have passed through the G1 tetraploidy checkpoint, replicated their DNA and 
entered the G2/M phases of the cell cycle. The RPE-Fucci and RPE-control cells 
had an average 8N fraction of 2.4% and 2.6% respectively (p = 0.8303) (Figure 
5.10B). In contrast, the RPE-cyclin D1 cells possessed an average 8N of 13.8%, 
indicating a respective 5.7 (p= 0.0013) and 5.3 (p=0.0021) fold increase, compared 
to RPE-Fucci and RPE-control cells (Figure 5.10B). These data provide evidence 
that tetraploid cyclin D1-overexpressing cells are able to override the tetraploidy-
induced G1 arrest and enter the G2/M phases of the cell cycle more efficiently.  
 
These data also suggest that the difference is not simply due the shortened lag 
phase or elevated proliferation rate of CCND1 cells. The percentage of RPE-
FUCCI-CCND1 8N cells increases post DCB tetraploidization. Therefore, even if 
the RPE-FUCCI-CCND1 cells are cycling faster, and thus would result in more G1 
tetraploids being generated compared to controls, there is a relative increase in the 
8N fraction above the expected background. Therefore, the findings of this 
experiment are directly comparable and are not simply a function of differential 
growth kinetics.  
 
  





Figure 5.10 RPE 8N population quantification 16hrs post-DCB treatment 
(A) DNA ploidy plots showing the percentage of 8N cells post DCB treatment and a 
comparative quantification. (B) Quantification of average percentage of 8N cells 
from three independent experiments P= <0.01. Error bars representative of SD. 
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5.3.3 Cyclin D1 overexpression provides tetraploid tolerance  
The previous experiment quantified the number of tetraploid G2/M cells after a 
relatively short period of 16h hours. To investigate if cyclin D1-overexpressing RPE 
cells could propagate and tolerate the tetraploid phenotype over longer periods of 
time, cells from each condition were sorted by selecting G1 mCherry-positive cells, 
in order to specifically isolate G1 tetraploids from the 4N peak (Figure 5.8D). Cells 
were then seeded into multi-well plates before fixation and quantification of the 
green fluorescent G2/M cells. As p21 and p53 are key components of the 
tetraploidy checkpoint, they were silenced by siRNA after plating to act as positive 
to control, given that depletion of either protein would abrogate the checkpoint and 
allow G1 tetraploid cells to proliferate (Ganem et al., 2014). 
 
The G2/M fraction of the RPE-Fucci and RPE-control tetraploid cells under 
untransfected, mock and control siRNA conditions was between 2-4% of cells 
(Figure 5.11A). TP53 and CDKN1A knockdown resulted in an increase of G2/M 
cells, consistent with the involvement of p53 and p21 in the tetraploidy checkpoint, 
although a high level of variability between experiments was observed in the 
untransfected and control conditions. CCND1-overexpressing cells displayed a 
G2/M population ranging between 9-12% across the untransfected, mock and 
control siRNA conditions, representing an average increase of 4-fold compared to 
RPE-Fucci cells (Figure 5.11B). The vector control displayed a slight increase of 
1.5-fold relative to RPE-Fucci, however the fold change between RPE-CCND1 cells 
and RPE-control was highly significant under all conditions (2.6-fold on average). 
These data suggest that overexpression of cyclin D1 can override the tetraploidy 
checkpoint in RPE cells and sustain tetraploidy tolerance for at least 72 hours. 
Images obtained for the G2/M microscopy analysis (Figure 5.11C), clearly showed 
more G2/M cells in the CCND1 overexpressing cells.  
  




Figure 5.11 G2/M cells 72 hours post-DCB treatment 
(A) Percentage of cyclin D1 cells 72 hours post-DCB treatment and TP53 and 
CDKN1A controls. Cells were plated after sorting and reverse transfected with the 
indicated siRNAs. (B) Fold change of control vector and CCND1 overexpressing 
G2/M cells relative to RPE-control. Error bars representive of SD. Unpaired 
stsudents t-test  **, ***, ****p = ≤ 0.01, 0.01, 0.0001 respectively. (C) Microscopy 
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5.3.4 p53 and p21 are induced in RPE cells after tetraploidization by DCB 
treatment  
TP53 and CDKN1A knockdown produced average fold changes in G2/M cells of 
10-fold and 7.5-fold respectively, highlighting their importance in the response to 
tetraploidization (Figure 5.11A). To highlight this further and to investigate their 
expression dynamics, p53 and p21 were analysed by western blot after DCB-
induced tetraploidization. In the RPE-Fucci and control cells there was no detection 
of p53 or p21 in diploid untreated cells, however after DCB treatment there was a 
time-dependent increase in both proteins (Figure 5.12A). In the RPE-CCND1 cells 
the basal levels of p53 and p21 were greater but also increased in time-dependent 
manner. In Figure 5.11, Cyclin D1 expression was reduced below normal RPE-
Control cell line levels, shown in Figure 5.8A, which is consistent with a G1 arrest in 
the RPE-Fucci and control lines. The increase in cyclin D1 expression after 72 
hours in the RPE-CCND1 cells could be a direct effect of p21 increase and, thus, 
stabilisation (Figure 5.12A).  
 
In order to investigate if the same regulatory mechanisms were in place in the RPE 
cells as in the HCT-116 cells and specifically if there were any p21-CDK4-Cyclin 
D1 complexes forming, p21 was immunoprecipitated 72 hours after DCB treatment 
(Figure 5.12B). In the RPE-CCND1 cells there were more CDK4-Cyclin D1-p21 
complexes, whereas in the RPE-Fucci and control cells there was p21 bound to 
cyclin D1 but less bound to CDK4. This may suggest a more catalytically active 
CDK4 in the RPE-CCND1 cells contributing to the enhanced survival and 
proliferation, which is consistent with observations in the HCT-116 system.  
 
5.3.5 Cyclin D1 overexpression provides long-term tetraploid tolerance in 
RPE cells  
To test if the CCND1 overexpression could provide an advantage to the tetraploid 
cells in a long-term clonogenic assay, DCB generated tetraploids were seeded at 
low density and allowed to form colonies over a 12-day period (Figure 5.12C). 
Untreated diploids were also analysed to obtain the plating efficiency (PE) for each 
condition. The diploid PE was similar between all conditions with RPE-Fucci, RPE-
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control and RPE-Cyclin D1 displaying efficiencies of 25%, 19% and 18% 
respectively (Figure 5.12D). The tetraploid PE was calculated for each condition, 
12 days post-DCB treatment, revealing an increase in colony formation in the RPE-
CCND1 cells (D). The RPE-Fucci and control cells had plating efficiencies of 1.6% 
and 1.06% respectively, compared to 7.8% of RPE-CCND1 cells, representative of 
a 7.3-fold change relative to RPE-Control (p≤0.01). These data support the notion 
that tetraploidy is poorly tolerated and provides strong evidence that cyclin D1 
overexpression can significantly enhance tolerance to tetraploidy over a prolonged 
period of time.  
 
  




Figure 5.12 Molecular characterisation and survival benefit of the RPE system 
(A) p53, p21 and cyclin D1 status at 0, 16 and 72 hour time points. Representative 
of two independent experiments.  (B) p21 IP 72 hours post-DCB treatment showing 
complex formation with CDK4 and cyclin D1. Representative of two independent 
experiments. (C) DCB sorted tetraploid cells were plated in a long term 
clonogenicity assay for 12 days. Colonies were stained, counted and the surviving 
fraction was calculated. Error bars represent SD. Representative of two 
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5.4 D-type cyclin overexpression and tetraploid tolerance in 
human TGCTs 
As discussed in section 3.5, 65% of genome-doubled tumours are TP53 wild-type 
and understanding how tolerance is provided in this molecular setting is of great 
interest. One tumour group that show frequent genome-doubling and the absence 
of TP53 mutations are Testicular Germ Cell Tumours (TGCTs). TGCTs affect 
young male adults and are the most frequent solid cancers in Caucasian males. 
TGCT consist of two major histological subtypes comprising of seminoma and non-
seminomatous lesions. The two subtypes show marked differences in morphology 
but share many pathogenic genetic aberrations including hypertriploid karyotypes 
and gain of chromosome 12p (Gilbert et al., 2011).  Gain of 12p occurs in 
approximately 80% of clinical cases and contains the CCND2 locus.  
 
All three D-type cyclins (CCND1, CCND1 and CCND3) are closely related and 62% 
identical to each other. The greatest homology between the thee proteins is in the 
cyclin box domain which is required for CDK and CDK inhibitor binding (p21, p27 
and p57), suggesting the G1/S and p21 sequestration functions of these three 
cyclins are highly conserved (Gilbert et al., 2011).  Early stage TGCTs have been 
shown to be tetraploid and can become hypertriploid or hexaploid in later disease, 
providing evidence for tetraploidy as intermediate that precedes aneuploidy 
(Ottesen et al., 2004, Dewhurst et al., 2014). TP53 mutations are rare in TGCTs 
(approximately 7%), and therefore, I hypothesised that the tetraploidy checkpoint is 
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5.4.1 Genome doubled p53 wild-type TGCTs display elevated D-type cyclin 
copy number and expression  
The previous data in this chapter provided evidence that CCND1 overexpression 
can mediate tetraploid tolerance in a TP53 wild-type background. Due to the 
sequence homology and protein functions of CCND1 and CCND2, it was 
hypothesised that CCND2 overexpression would also provide tolerance in the 
presence of wild-type p53 wild-type and might permit tetraploidization tolerance in 
TGCTs. Due time constraints, the involvement of CCND2 was not investigated in 
our experimental systems, however the clinical samples were analysed 
bioinformatically.  
 
To explore whether D-type cyclins were associated with genome-doubled TP53 
wild-type tumours, 117 testicular TCGA data based tumours were analysed (42 
seminomas, 62 non-seminomas and 13 uncharacterised samples) for copy number 
and expression of CCND1, CCND2 and CCND3. Genome-doubling was calculated 
by applying a modified version of the ABSOLUTE algorithm (Carter et al., 2012).  
 
Genome-doubling occurred in all but one tumour, however there was only one 
tumour with a TP53 or CDKN2A non-synonymous mutation and none with RB1, 
while all three genes were expressed in the remaining tumours. No tumours 
displayed CDKN1A mutations, suggesting a functional p21 pathway. Five out of 
117 (4.2%) tumours displayed MDM2 copy number gains, possibly suggesting p53 
could be reduced by enhanced ubiquitination in this small fraction of tumours 
(Abdel-Fattah et al., 2000). Taken together, these results suggest that most of the 
analysed tumours are tetraploid with wild-type tetraploidy checkpoint components 
and imply that another tetraploidy tolerance mechanism exists.  
 
Copy number analysis revealed copy number gains in CCND2 (98%) and CCND3 
in a smaller proportion of tumours (4.2%), while CCND1 gains were not observed 
(Figure 5.13A-C). CCND2 mRNA expression correlated with gene copy number 
and showed a positive correlation in the seminoma subtype. The non-seminomas 
did not correlate as strongly, with some tumours displaying lower CCND2 
expression relative to copy number (Figure 5.14A). CCND1 expression correlated 
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with CCND2 in both subtypes and revealed the non-seminomas had greater 
CCND1 expression than the seminoma (Figure 5.14B). The CCND2 low tumours 
were also CCND1 low, demonstrating CCND1 is not compensating for low CCND2 
expression. Interestingly, when CCND3 expression correlated with CCND2, an 
inverse relationship was observed with CCND3 high cells expressing lower levels 
of CCND2 (Figure 5.14C). This finding may suggest that in non-seminoma tumours 
with lower CCND2 expression, despite elevated CCND2 copy number, CCND3 
expression may serve to compensate for CCND activity. These data, combined 
with the observation that cyclin D1 overexpression can provide tolerance to 
tetraploidy in vitro, strongly suggests that the D-type cyclins might contribute to 
tetraploidy tolerance in TGCTs. 
  







Figure 5.13 CCND1, CCND2 and CCND3 copy number in TGCT 
(A-B) Copy number analysis of CCND1, CCND2 and CCND3 in 117 seminoma and 
non-seminoma TGCTs.  TGCT SNP data and matched normal samples were 
downloaded from the TCGA database and processed as described in Materials and 
Methods.  
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Interestingly, correlation of CDKN1A and CCND1 mRNA expression revealed a 
significant positive correlation (p ≤ 0.0001) and was evident in both seminoma and 
non-seminoma TGCT subtypes (Figure 5.15A). A correlation between CDKN1B 
and CCND1 was observed in seminoma tumours but not non-seminoma, 
suggesting the effects seen are not a general function of CCND1 overexpression 
(Figure 5.15B).  Analysis of CCND2 and CDKN1A showed no significant correlation, 
although here was strong positive correlation when compared to CDKN1B (Figure 
5.15C and D). These findings further support the hypothesis that cyclin D1 
overexpression can circumvent high p21 expression and possibly provide 
tetraploidy tolerance.  
  




Figure 5.14 CCND1, CCND2 and CCND3 mRNA expression in TGCT 
(A) CCND2 mRNA expression correlated with copy number for seminoma and non-
seminoma sub-types. (B) CCND1 and CCND2 mRNA expression correlations for 
seminoma and non-seminoma sub-types. (C) CCND2 and CCND3 mRNA 
expression correlations for seminoma and non-seminoma subtypes. 
 
  





Figure 5.15 CDKN1A, CDKN1B and CCND1 expression  
mRNA expression correlation analysis of 117 TGCTs; seminoma and non-
seminoma histological subtypes. (A) CCND1 and CDKN1A (B) CCND1 and 
CDKN1B (C) CCND2 and CDKN1A (D) CCND2 and CDKN1B.  
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5.5 Discussion and Conclusions  
Quantitative proteomics (see Chapter 4) showed an elevation in cyclin D1, which 
validated in four out of six independently-derived tetraploid clones. The primary aim 
of this chapter was to investigate cyclin D1 as a mediator of tetraploid tolerance. 
The principle finding suggests that cyclin D1 overexpression can provide tolerance 
to pharmacologically-induced tetraploidy in vitro and overexpression of D-type 
cyclins are found in genome-doubled TP53+/+, CDKN1A+/+ and RB1+/+ human 
testicular tumours. Although not unequivocally proven, this notion is at minimum 
supported in the HCT116 system. These data suggest that D-type cyclins can 
override the activated tetraploidy checkpoint and constitute a possible mechanism 
used to tolerate tetraploidy in genome-doubled testicular germ cell tumours.  
 
Overexpression of cyclin D1 was specific to the tetraploid clones, as analysis of the 
other major cyclins showed no up-regulation at the protein level. Silencing of TP53, 
resulting in complete p53 and p21 loss, reduced the amount of cyclin D1 in the 
diploids and tetraploids by the same extent. However, after knockdown there was 
still more cyclin D1 in all tetraploid clones, suggesting that elevated and p53 and 
p21 levels were not solely responsible for elevated cyclin D1. In this experiment, 
DC8 cyclin D1 levels did not fall as dramatically after knockdown, indicative of less 
stabilisation by p21 or p53. This may suggest abnormal cyclin D1 regulation in DC8, 
which is the parental clone for the second-generation clones with high cyclin D1. 
Abnormal regulation of cyclin D1 in this clone may result in subclones with higher 
protein expression that could provide tetraploidy tolerance if a genome-doubling 
event occurs.  
 
After confirming protein overexpression of cyclin D1, we set out to investigate the 
reasons behind this event and looked at the most prominent mechanisms of cyclin 
regulation. CCND1 mRNA levels were consistently elevated in the tetraploid clones 
although no copy number gains were detected (Dewhurst et al., 2014). A possible 
reason for CCND1 mRNA elevation was enhanced ERK pathway signalling, which 
is implicated in CCND1 gene transcription. All but one of the tetraploid clones had 
more heightened signalling after 24 hours of serum starvation and showed 
prolonged activation up serum re-addition. Another mechanism resulting in cyclin 
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D1 overexpression was enhanced protein stability, as CHX experiments showed 
that cyclin D1 was more stable in the tetraploid clones. This finding suggests that 
the overall increase in cyclin D1 protein observed is a combination of increased 
mRNA expression and enhanced stability. An intriguing extension of this part of the 
study would involve knocking down p21 and repeating the experiment under these 
conditions. As p21 is required for complex formation, this experiment could show if 
the unbound cyclin D1 fraction was stabilised or if stability is specifically provided 
when the protein is a p21-bound complex.  
 
Cyclin D1 levels are high in G1 and G2 phases of the cell cycle and the protein 
helps drive proliferation by activating CDK4. However during S phase, cyclin D1 
levels are rapidly reduced by Thr286 phosphorylation and subsequent cytoplasmic 
degradation by the PCF4 complex to very low levels (Guo et al., 2005, Alao, 2007, 
Yang et al., 2006b, Gong et al., 2014). An elevation in cyclin D1-Thr286 was 
observed in the tetraploid clones, which may be caused by an increased S phase 
due to a doubled genome. Indeed, there were nearly 2-fold more tetraploid p21-
expressing S phase cells and as result may have even lower S phase cyclin D1 
compared to diploids.  When cyclin D1 levels were quantified in different phases of 
the cell cycle, there was a reduction in S phase relative to G1 and G2 phases but 
surprisingly levels did not fall extensively in either diploids or tetraploids as reported 
by others (Yang et al., 2006b, Okabe et al., 2006). In fact, tetraploid cyclin D1 
levels were found to be greater in all cell cycle phases. Thus, despite a longer S 
phase and elevated phosphorylation, cyclin D1 levels were still higher in the 
tetraploids. In addition, the level of S phase degradation was significantly less in 
the tetraploids.  These findings suggest that cyclin D1 is elevated in every cell cycle 
stage and, therefore, could provide protection from the inhibitory effects of p21. The 
high levels in S phase are surprising, however this could allow heightened 
tetraploid cyclin D1 to sequester elevated p21 during this phase, as if cyclin D1 was 
exported and degraded in the presence of high S phase p21, it could result in 
arrest (Zhu et al., 2004). It cannot be excluded that the cyclin D1 levels in the 
diploids and tetraploids are cytoplasmic during S phase and, therefore, unable to 
sequester nuclear p21. However, if cyclin D1 was cytoplasmic, it would likely be 
rapidly degraded by the proteasome, suggesting a proportion of the levels 
observed would be nuclear during S phase and could inhibit p21.  




In support of these findings, subcellular fractionation experiments revealed that 
nuclear cyclin D1 was higher in the tetraploids compared to diploids. There was no 
tetraploid cytoplasmic enrichment, suggesting that the increased S phase and 
cyclin D1-Thr286 was not enhancing tetraploid cyclin D1 nuclear export. This 
experiment suggests that although tetraploids have elevated nuclear p21, this is 
counteracted by increased cyclin D1. As cyclin D1 levels are high in every phase it 
is possible that nuclear p21 is sequestered in every cell cycle phase by nuclear 
cyclin D1. As the subcellular fractionation experiment do not measure co-
localisation directly or separate distribution relative cell cycle phases, it cannot be 
formally excluded that p21 and cyclin D1 are in different cellular compartments at 
different phases of the cell cycle. Alternatively, if the two proteins are in complex 
they may be co-localised but may not be distributed in both the nucleus and 
cytoplasm at given cell cycle phase. However, it is likely that if cyclin D1 is 
expressed then it will be equally distributed, which is why it is rapidly degraded if 
not required.  
 
Taken together, the above experiments provide evidence that cyclin D1 is high in 
all cell cycle phases and could therefore sequester the observed elevated p21. One 
possible issue with this hypothesis is that high cyclin D1 during S phase is 
inhibitory, acting as a backup mechanism if cells aberrantly overexpress the G1 
cyclin (Guo et al., 2005). Therefore, there must be mechanism in place to tolerate 
high S phase cyclin D1 levels in the tetraploid clones. In order to progress through 
S phase with high cyclin D1 it is likely that cancer cells with cyclin D1 
overexpression adapt the molecular mechanics S phase to accommodate high 
cyclin D1 and resist arrest (Guo et al., 2005). Parental HCT-116 cells do not have a 
CCND1 amplification but have elevated β-catenin levels, through loss of the APC 
tumour suppressor, leading to heightened cyclin D1 expression (Tetsu and 
McCormick, 1999).  Therefore, it is possible that HCT-116 cells have evolved a 
mechanism to replicate DNA with elevated cyclin D1. This molecular phenotype 
may have influenced why cyclin D1 was selected as a tolerance mechanism in 
tetraploid clones. Elevated cyclin D1 could have sequestered p21 and permitted 
progression past the G1/S checkpoint. As HCT-116 cells overexpress cyclin D1, 
they may have been inherently resistant to further cyclin D1 overexpression in S 
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phase, permitting progression of cyclin D1 high tetraploids though the cell cycle. 
Therefore, cyclin D1 can sequester p21 in all cell cycle phases and provide 
tetraploidy tolerance. 
 
The CDK2 IP showed that there was still p21 binding to the kinase. Previous 
studies have shown that most CDK2 is p21 bound and only a minor fraction of p21-
free CDK2 is sufficient for catalytic activity (Planas-Silva and Weinberg, 1997). 
Therefore, it is tempting to speculate that although more p21 is bound to CDK2 in 
the tetraploid clones, p21 binding to CDK4-cyclin D1, possibly as result of elevated 
cyclin D1, ensures enough p21 is sequestered to maintain a p21/CDK2-free 
fraction capable of S phase initiation. In support of this hypothesis, CDK2 kinases 
assays showed that tetraploid clones could phosphorylate RB at greater levels 
compared to DC14 and DC25, suggesting increased CDK2 catalytic activity. 
 
It was expected that a greater number of cyclin D1 in complex with CDK4 and p21 
would be present in tetraploid clones. However, the level of cyclin D1 binding was 
highly variable between all clones, as was cyclin E association with CDK2. It is 
generally accepted that the cyclin D is required for p21 binding to CDKs. Therefore, 
in order to have elevated p21-containing complexes in the tetraploid clones, cyclin 
D1-CDK4 association would also have to be elevated. This discrepancy may be of 
technical nature, through the dissociation of cyclin D1 from CDK4 during the 
immunoprecipitation process. Another explanation could be that there are more 
than one molecule of p21 is binding per CDK4-Cyclin D1 complex. The CDK4 
kinase assay supports the first possibility, as although activity is variable, activity is 
observed in all the tetraploid clones. However, more activity in the kinase assay 
could also be explained by the presence of more complexes.  
 
An important question that has not been answered from this work is that, although 
cyclin D1 is elevated in tetraploids, it has not been determined whether the cyclin is 
in excess, relative to p21. In order to explore this, a sequential IP strategy would 
need to be employed, as used by Quintanilla-Martinez et al (Quintanilla-Martinez et 
al., 2003). Confirming that cyclin D1 is in excess if of great importance, and if 
proved, would greatly strengthen the argument for the role of cyclin D1 in providing 
tetraploidy tolerance. 
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In order to investigate the functional significance of cyclin D1 in tetraploid survival, 
cyclin D1 knockdown could be performed. Complete knockdown of cyclin D1 is 
problematic, as loss of CDK4 activity and displacement of p21 to CDK2 would 
cause arrest in diploids and tetraploids. This strategy would, therefore, not reveal if 
the specific loss of elevated tetraploid cyclin D1 fraction could cause arrest and 
was responsible for tetraploid tolerance. Instead, the tetraploid arrest would result 
from the total loss of p21 sequestration. Cyclin D1 knockdown to diploid expression 
levels would demonstrate the function of the elevated cyclin D1 fraction. If at this 
level there were reduced tetraploid kinase activity and cell cycle arrest, this would 
suggest that the elevated levels of p21 are being sequestered by the enhanced 
cyclin D1 fraction, permitting Cyclin E/CDK2 activity for passage through the G1/S 
checkpoint. As titrating siRNA to achieve a defined and reproducible level of 
knockdown is technically challenging, instead cyclin D1 was overexpressed in 
HCT-116 cells to test whether cyclin D1 could provide survival benefit. 
Overexpression did not increase the basal tetraploid fraction. The fraction of 
tetraploid cells in the HCT-116 population is approximately 0.5% and cyclin D1 is 
likely to provide a survival benefit to only a fraction of this subpopulation, thus 
making detection by flow cytometry very difficult and thus creating a need for a 
more sensitive assay. This approach could be improved by sorting the tetraploid 
cells before single cell cloning and quantification of cloning efficiency and 
comparison to the normal HCT-116 rate of 6%. 
 
Equally important, p21 should be over-expressed in diploid HCT-116 cells to the 
levels of detected in tetraploids, in an attempt to prove that that level of p21 is 
growth inhibitory and a mechanism such as cyclin D1 is required to counteract it. In 
combination with titrated cyclin D1 knockdown experiments, as outlined above, this 
would provide further evidence that elevated cyclin D1 is essential for tetraploid 
proliferation and that diploid levels of cyclin D1 are insufficient to sequester 
tetraploid p21 levels. It has been previously shown that HCT-116 cells arrest in G1 
after DNA damage or after pharmacologically-induced cytokinesis failure, 
demonstrating that elevated p21 can cause G1 arrest in HCT-116 cells (Waldman 
et al., 1995, Stewart et al., 1999). Furthermore, 5-FU causes a G1 arrest through 
the induction of DNA and RNA damage (Sun et al., 2007). 5-FU-treated diploid 
clones showed similar p21 levels to untreated tetraploid p21. Therefore, since the 
Chapter 5 Results 
193 
 
levels of 5-FU-induced p21 in diploid clones are comparable to untreated tetraploid 
levels, which are cycling under these conditions, it is logical to speculate that 
tetraploid p21 levels would also be inhibitory in the absence of a tolerance 
mechanism.  
 
The aforementioned cyclin D1 knockdown experiments are challenging. Even if 
they could be achieved technically, they may fail to detect the role of cyclin D1 due 
to characteristics of the HCT-116 cell line. HCT-116 cells are highly mutagenic 
through genetic loss of mis-match repair enzymes, leading to microsatellite 
instability (de las Alas et al., 1997). Therefore, after the tetraploidization event the 
system could have equilibrated, masking the tolerance effects of cyclin D1. 
Specifically, it is possible that cyclin D1 may have provided the initial tolerance but 
soon after a more efficient genetic aberration was gained (e.g. through copy 
number alterations or non-convergent somatic mutations). Therefore, loss of cyclin 
D1 in this hypothetical scenario would have no effect on viability, even though 
cyclin D1 would have been the initial tetraploidy tolerance mechanism. In support of 
this hypothesis, Dewhurst et al performed CGH analysis of the tetraploid clones 
and showed copy number alterations at the earliest passage analysed (p5). 
Therefore, tetraploid clones can undergo genomic rearrangement soon after 
tetraploidization, which may lead to acquisition and selection of a more efficient 
tolerance mechanism.  
 
Due to the technical restraints presented by the HCT-116 system, the RPE-Fucci 
cell line was adopted to investigate whether cyclin D1 could provide a functional 
role in tetraploidy tolerance. There are multiple advantages of using this system 
over the HCT-116 cell line. Firstly, RPE cells have fully active cell cycle 
checkpoints and are known to arrest after induction of tetraploidy. Secondly, the 
RPE cell line has clean genetic background, in contrast to the MIN HCT-116 cell 
line. Cyclin D1 may have provided the initial tolerance to tetraploidy, however a 
complex array of mutations may have been selected soon after genome-doubling, 
masking the tolerance effect of cyclin D1 expression. The RPE cells paired with the 
Fucci system, which allows determination of cell cycle phase, made for a very 
powerful experimental system to investigate the role of cyclin D1 and tetraploidy in 
tolerance in greater detail.  




In light of these advantages, CCND1 was overexpressed in the RPE-Fucci system 
before sorting of DCB-induced tetraploid cells. This strategy allowed the 
comparison of newly formed CCND1-overexpressing tetraploid cells with CCND1- 
normal cells, which enabled the direct effects of cyclin D1 overexpression on 
tetraploidy tolerance to be monitored. Of note, overexpression of cyclin D1 alone 
did not cause an increase in >6N the basal faction. The percentage of >6N cells 
was more than 10-fold lower than HCT-116s at 0.015%, equating to an actual 
number of three cells in a population of 2x104. Therefore, as with HCT-116s, low 
tetraploid numbers and diploid competition may supress the outgrowth tetraploids 
and mask the tolerance effect of cyclin D1. 
 
The short-term assays showed 5.7-fold more CCND1 cells could start to cycle and 
enter G2/M within 16 hours of DCB treatment.  A reproducible survival benefit of 
around 2.5-fold, compared to vector control, 72 hours post-tetraploid induction was 
observed, with western blotting providing evidence of p53 and p21 activation. A 
limitation of this medium-term survival assay is that the different lag phases 
observed between the cell lines could have affected the result. The growth curve 
analysis predicted an approximately 1.7-fold increase in cell numbers after 60 
hours, compared to the RPE-Fucci. Therefore, it is likely that at 72 hours there are 
1.7-fold CCND1-overexpressing cells and this is just a function of a decreased lag 
phase. If there are more cells because of differential cell cycle kinetics, this could 
affect the result, as there would be more G2/M cells purely through enhanced 
growth. However, the fold change in survival was 2.5-fold. This implies the lag 
effect cannot fully account for the observed increase, implying cyclin D1 can 
specifically override the G1 arrest. 
 
More strikingly, the difference was 7.3-fold in a long-term clonogenic assay. This 
assay overcomes the problem of differential lag phases between cell lines. The 
previous short-term assay counts the number of G2/M cells as the endpoint, 
therefore, if more cells existed due to proliferation, this could mask the result and 
resemble an escape from G1 arrest. In the clonogenic assay, cells are seeded at 
low-density and colonies from single cells were allowed to form, which were 
counted at the end of the experiment. This means that the number colonies were 
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directly proportional to the number of cells that can escape the G1 arrest. The 
difference in lag time would only affect the size of colony. It could be argued that 
smaller diploids colonies would be below a counting threshold and therefore 
underestimated, however, given the experiment is long term and after the initial lag 
dip lids and tetraploids grow at the same rate, this effect is likely to be minimal as 
most colonies will breach the lower detection limit. Therefore this assay represents 
a cleaner and more precise method to measure survival. 
 
The clonogenic potential was similar between the CCND1 cells and controls, 
suggesting overexpression of CCND1 in the diploid state does not provide a 
significant advantage for colony formation. Therefore, the increased survival after 
tetraploidy induction is not due to a mechanism present in the diploids (e.g. CDK4-
cyclinD1 catalytic activity and enhanced proliferation rate) but specific to the 
tetraploid karyotype. This finding suggests that the effect seen in the CCND1-
overexpressing tetraploids is selected for when the cell enters a tetraploid state of 
high p53 and p21, as the overexpression provides a selective advantage.  
 
Finally, D-type cyclin expression was specifically investigated in genome-doubled 
human tumours by analysing the TCGA data set using a genome-doubling 
algorithm, as discussed in Sections 5.5, 2.2.20.3 and (Carter et al., 2012). 
Genome-doubled TGCTs showed CCND2 copy number and overexpression 
through chromosome 12p gain. Importantly, nearly all tumours were TP53, MDM2, 
CDKN1A and RB1 wild type, suggestive of a functional tetraploidy checkpoint. 
These findings, combined with the ability of CCND1 to bypass the p53/p21 
tetraploidy checkpoint in vitro, provide evidence that that D-type cyclins may 
mediate tolerance to genome-doubling events in human tumours. In addition to 
these findings, CCND1 expression strongly correlated with CDKN1A transcript 
levels in TGCTs, recapitulating the previous in vitro data obtained. Therefore this 
observation further supports the hypotheses that D-type cyclin and p21 expression 
is functionally related in p53/p21/RB wild-type tetraploid cells and tumours. 
Although the in vitro data strongly suggest that D-type cyclins are likely to provide 
tolerance in TGCTs, other genetic events cannot be excluded such as K-RAS gain 
on chr12p (Sheikine et al., 2012) 
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As discussed in section 1.5.2.2, tetraploidy is an intermediate of CIN and 
aneuploidy. Therefore, it is important to determine if chromosome 12p gain in 
TGCTs has preceded genome-doubling and could have therefore provided 
tolerance to the initial tetraploidization event. Most evidence presented in this 
thesis would suggest that copy number alterations occur after genome-doubling, as 
a result of CIN and therefore challenges the idea of 12p gain before genome-
doubling in TGCTs. Two major theories have been proposed regarding the origin of 
seminoma (Houldsworth et al., 1997, Skakkebaek et al., 1998). Based on genetic 
evidence, Chaganti and Houldsworth hypothesised that the 4N zygotene-
pachytene spermatocyte is the TGCT cell of origin (Houldsworth et al., 1997). This 
is the meiotic stage, where chromosome cross-over by homologous recombination 
is subject to a p53-dependent recombination checkpoint (Roeder, 1997). The 
authors propose that, during this stage of cellular development, aberrant chromatid 
exchange can lead to 12p copy number gain and CCND2 overexpression. The 
overexpression of CCND2 allows the cell to bypass the recombination checkpoint 
and also induces cell cycle re-entry with a 4N genome. Based on the data 
presented in the present study, it is possible that the newly formed tetraploid cell 
can also resist p53/p21-mediated arrest as result of CCND2 overexpression. In this 
context, the tetraploid cell could then undergo CIN, eventually resulting in the 
hypertriploid seminoma or hypotriploid non-seminoma tumours.  
 
A second theory, proposed by Skakkebaek and colleagues, argues that the cell of 
origin is the primordial germ cell (PGC), which undergoes abnormal cell division as 
result of in utero environmental factors, leading to carcinoma in situ (Skakkebaek et 
al., 1998). Importantly, this theory states that tetraploidization precedes 12p gain 
and therefore challenges the role of cyclin D2-mediated tetraploidy tolerance. 
PGCs migrate into the developing gonad after 5 weeks of gestation and 
differentiate into gonocytes. Mitchell et al recently showed that the most common 
subpopulation of germ cell neoplasia show a gonocyte expression profile, 
supporting the hypothesis that TGCTs arise from early germ cells in utero (Mitchell 
et al., 2014).   
 
PGCs and gonocytes possess a functional DNA damage-dependent p53 pathway 
that can be activated by DNA damage (Forand and Bernardino-Sgherri, 2009, Luo 
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et al., 2014). Therefore, it is likely that a genome-doubling event could induce a p53 
dependent arrest and, thus, a mechanism must be in place to tolerate such a 
situation. One explanation could be that, although CCND2 copy number may be 
diploid, D-type cyclin expression may be elevated during this developmental stage, 
which could in turn result in a greater chance of polyploid cells overriding the 
tetraploidy checkpoint (Gilbert et al., 2011, Beumer et al., 2000).  There is clearly a 
debate as to whether cyclin D2 is expressed prior to tetraploidization.  
 
An important extension of this work would be to determine the timing of CCND2 
copy number gains. This is not possible, bioinformatically, due to the inherent 
genetic characteristics of TGCTs. In order to use the copy number data to 
determine whether or not the gain of 12p is early or late, the arm level event has to 
fall into categories that match the expected: pre-genome-doubling, 2 -> 3 copies, 
which following genome-doubling becomes 6 copies, or post-genome-doubling, 4 -
> 5 copies. However in the TCGA data, the amplification on 12p rarely falls into one 
of these categories. An alternative is to investigate if the copy number mutations on 
12p may follow a pattern that indicates early genome-doubling. Mutations generally 
showing 1 copy suggests early genome-doubling, as mutations occur later and are 
therefore present on only one gene copy. Mutations generally occurring on two 
copies would suggest they were present prior to genome-doubling and, therefore, 
doubled with the genome. But unfortunately, in TGCT the total mutation numbers 
are so low that we cannot use this as an estimate. 
 
Taken together, these data suggest that D-type cyclins can provide tolerance to 
tetraploidy in a p53-independent manner both in vitro and in human tumours. In 
tumours, such as TGCTs, where there is relatively low frequency for p53/p21/RB 
inactivation, D-type cyclin overexpression may provide a mechanism of tetraploidy 
tolerance. This can promote the formation and subsequent selection of aneuploid 









Chapter 6. Discussion 
6.1 Molecular model  
The work in this thesis reinforces the central role for a p53 and p21 dependent 
arrest after a genome-doubling event. Furthermore, the data obtained in this work 
provides evidence that cyclin D1 overexpression can override the tetraploidy 
checkpoint and provide tetraploid tolerance, and is central in the proposed 
molecular model (Figure 6.1 and Figure 6.2) 
 
6.1.1 Tetraploidization results in p53 and p21 elevation 
The steady state levels of p53 and p21 were elevated and functional in the HCT116 
tetraploids, whilst in the RPE system a graded response was observed after 
genome doubling, resulting in G1 arrest. Therefore, this functional p53 response 
further supports the hypothesis that tetraploid cells activate the p53/p21 pathway to 
supress the outgrowth of pathogenic tetraploid clones.  
 
Previous studies also support the notion of p53 dependent response after a 
tetraploidization event. A heightened level of p53 in tetraploid cells has been 
reported in early work by Andreassen et al and others (Andreassen et al., 2001b, 
Di Leonardo et al., 1997). These groups showed p53 is induced in tetraploid cells 
resulting in p21 dependent G1 arrest, consistent with the findings in this thesis. A 
problem with earlier studies was the use of pharmacological agents to induce 
tetraploidy. Indeed, some studies suggested that the p53 and p21-dependent arrest 
observed by Andreassen et al was a result of off-target effects (as discussed in 
section 1.4.1). However, a more recent study disputed this and proposed that 
discrepancies between studies were due to differences in G1 length and graded 
p53 response (Ganem et al., 2014). Specifically, newly formed tetraploid cells 
cultured on fibronectin have a shorter G1 and thus p53 levels could not reach the 
required inhibitory threshold and ceased to arrest. Therefore, this important study 
provided some clarification as to how tetraploid cells elicit a p53 response after 
cytokinesis failure. These findings, together with the observed tetraploid p53 and 




p21 kinetics described in this thesis, support the concept of a p53 and p21 
response after spontaneous or pharmacological tetraploidization.  
 
A model outlining the p53 and p21 dependent response to a tetraploidization event 
is presented in Figure 6.1. Accordingly, after a tetraploidization event, high p21 
levels through p53 signalling will bind and inhibit CDK4 and CDK2, resulting in cell 
cycle arrest through RB-E2F stabilisation (Massague, 2004). The stoichiometric 
model dictates that if one p21 molecule is bound to CDK4, the kinase is active. This 
is the molecular state apparent in a cycling G1 cell, as cyclin D1 is equimolar or in 
excess relative to p21. In addition, CDK2 in this context will be active, as p21 will 
be sequestered into CDK4-CyclinD1-p21 complexes. However, if p21 levels are 
raised above a threshold, then more than one molecule can bind CDK4 resulting in 
kinase inhibition (Figure 6.1) (LaBaer et al., 1997). In addition, when CDK4-
CyclinD1 complexes are saturated with p21, a single p21 molecule is sufficient to 
inhibit CDK2 (Hengst et al., 1998).  Therefore, when p21 is induced by a p53 
dependent stress mechanism (e.g. tetraploidization) both G1 kinases are inactive, 
and the cell is arrested.  
 
Alternatively, the phosphorylation model predicts the posttranslational state of p21 
may be important in switching the CKI from a kinase inhibitor to an activator during 
G1, and states only one p21 molecule can bind CDK4 (James et al., 2008, 
Hukkelhoven et al., 2012). During G1, phosphorylation of p21 via mitogenic 
signalling can result in a conformational change, switching the CKI from a CDK2 
inhibitor to a CDK4 activator, promoting cell cycle progression. However, during 
periods of high p21 levels (i.e. stress), the system can become saturated and most 
p21 is in an inactive un-phosphorylated confirmation, and thus will inhibit CDK4 and 
CDK2. Regardless the model applied, CDK4 and CDK2 will be inhibited when p21 
is elevated after a tetraploidization event (Figure 6.1).  
 
  






Figure 6.1 Intracellular mechanism indicating a p53 dependent tetraploid arrest.  






















6.1.2 Cyclin D1 overexpression can sequester p21 and permit proliferation 
of tetraploid cells in the presence of a functional p53/21 axis 
Inactivating the p53/p21 response as previously described in section 6.1.1 is an 
efficient way for a newly formed tetraploid cell to resist a G1 cell cycle arrest and 
acquire tetraploid tolerance. However, 65% of genome-doubled tumours are p53 
wild type, as was the tetraploid HCT-116 system studied in this thesis 
(McGranahan et al., 2015). In the HCT-116 system, tetraploid cells possessed high 
p21 and showed no indication of G1 arrest, suggesting a mechanism was inhibiting 
the CKI, permitting CDK2-Cyclin E activity, cell cycle progression and tetraploid 
tolerance. Taken together, these observations suggest alternative tetraploid 
tolerance mechanisms exist in human tumours, and may act thorough disruption of 
p21 function.  
 
The work presented in this thesis proposes cyclin D1 overexpression can provide 
such a tolerance mechanism. Quantitative proteomics revealed the cyclin was 
significantly elevated in the HCT-116 tetraploids and provided long-term tolerance 
after pharmacological induction of tetraploidy in the RPE system, despite a 
simultaneous p53/21 response.  Furthermore, D-type cyclin overexpression was 
identified in p53, p21 and RB wild-type genome doubled testicular germ cell 
tumours (TGCTs), providing evidence the mechanism may exist in human tumours. 
Studies by LeBaer and Planas-silva et al support the hypothesis that cyclin D1 
overexpression could inhibit p21 and provide tetraploid tolerance. The two 
investigations demonstrated that cyclin D1 could bind and sequester p21, 
inactivating the cyclin kinase inhibitor (CKI) and allow progression from G1 to S 
phase (Planas-Silva and Weinberg, 1997, LaBaer et al., 1997). Quintanilla-
Martinez et al have shown that cyclin D1 overexpression in Mantal cell Lymphomas 
(MCL) may sequester the inhibitory effects of p27, resulting in aggressive tumours 
in the presence of CKIs (Quintanilla-Martinez et al., 2003).  
 
A more recent study directly supports the argument of cyclin D1 mediated tetraploid 
tolerance. Ganem et al showed that enhanced growth factor signalling, through 
activation of the AKT and ERK pathways, could override the tetraploidy checkpoint 
after DCB-induced cytokinesis failure. ERK and AKT signalling transcriptionally 




induce cyclin D1 expression (Musgrove et al., 2011, Diehl et al., 1998). Therefore, 
the mechanistic basis of Ganem et al’s observations could involve ERK/AKT-
dependent cyclin D1 overexpression, resulting in p21 sequestration. Interestingly, 
in the present study, ERK signalling was shown to be enriched in the tetraploid 
clones and was possibly contributing to cyclin D1 overexpression.  
 
Based on the findings from the current investigation and others, D-type cyclin 
overexpression can be integrated into the classical tetraploid checkpoint model, 
providing an elegant mechanism that can override the p53/p21 dependent 
tetraploidy checkpoint (Figure 6.2).  
 
With regard to the stoichiometric model, If a newly formed tetraploid cell possessed 
equimolar or excessive cyclin D1, high p21 levels could be sequestered from CDK2 
by unbound or complexed cyclin D1 resulting in active CDK4-CyclinD1-p21 
complexes, as a result correct stoichiometry (Figure 6.2) (Planas-Silva and 
Weinberg, 1997, Sherr and Roberts, 1999, Quintanilla-Martinez et al., 2003). 
Therefore, under these molecular conditions, CDK4 and CDK2 will be catalytically 
active, cell cycle progression can occur and the tetraploidy checkpoint is overridden 
(Figure 6.2). This mechanism can also protect the cell from future insults, such as 
elevations of p21 from enhanced rates of segregation errors and, thus, the 
mechanism can provide continuous tolerance and facilitate CIN and aneuploidy.  
 
The impact of p21 phosphorylation on this model remains to be discovered. If 
phosphorylation of p21 bound to CDK4 is required for kinase activation, high cyclin 
D1 levels will still sequester excess p21 from CDK2, but a fraction may be inactive, 
as the phosphorylation mechanism is saturated (Hukkelhoven et al., 2012). 
However, a proportion of CDK4-CyclinD1-p21 complexes may still be 
phosphorylated and active resulting in a p21 high cell with active CDK4 and CDK2. 
Even supposing CDK4 was inhibited in this situation through lack of p21 
phosphorylation, it has been shown that CDK2 can compensate for the loss of 
CDK4 (Wang et al., 2007). Therefore as long as cyclin D1 overexpression can 
shield CDK2 from p21 inhibition, tolerance can be provided. 
 




On the other hand, Stewart et al showed p21 elevations in newly formed tetraploid 
cells specifically inhibited CKD2-Cyclin E complexes (Stewart et al., 1999). 
Although p21 bound CDK4-Cyclin D1 complexes, their catalytic activity was not 
affected, suggesting phosphorylation status is redundant. Therefore, this study 
implies that after tetraploidization, the elevation in p21 is only inhibitory to CDK2. 
Applying these finding to the current model implies that in a high cyclin D1 scenario, 
there will be an elevation in active CDK4-Cyclin D1-p21 complexes, while CDK2 will 
be sheltered from p21 inhibition, activating both kinases.  
 
Therefore, crucially, regardless of whether the stoichiometric or phosphorylation 
model is applied, in a high cyclin D1 environment, CDK2 would always remain 
active, in contrast to a cyclin D1 low background where the kinase would be 
inhibited (Figure 6.2).  
 
  





Figure 6.2  Mechanism describing cyclin D1 mediated tetraploid tolerance  







































6.1.3 A cyclin D1-derived tetraploid cell could the tumour cell of origin.  
The previously described molecular model could contribute the development of a 
cancerous lesion from a normal diploid precursor, such as a diploid epithelial cell 
(Figure 6.3). The first step would require a cycling diploid cell to exhibit elevation in 
D-type cyclin expression. This could be a result of abnormal stochastic fluctuations 
in growth factor signalling, such as ERK or AKT, leading to pathway activation and 
cyclin D overexpression. Alternatively, subtle genetic lesions could result in cyclin D 
overexpression. Subsequently, when a cyclin D1-overexpressing cell undergoes a 
genome-doubling event, such as a failed cytokinesis, the normal p53/p21-
dependent G1 arrest could be overridden by elevated cyclin D-dependent inhibition 
of p21 by sequestration. This would permit CDK2-Cyclin E-dependent 
phosphorylation of RB, freeing E2F to induce S phase initiation genes. The 
tetraploid cells would then enter mitosis, where supernumerary centrosomes could 
lead to increased merotelic and syntelic attachment and, thus, resulting in 
generation of segregation errors and DNA damage. As the response to segregation 
errors is p21-driven, the elevated cyclin D1 levels can also permit proliferation of 
cells with elevated segregation errors, resulting in CIN and aneuploidy. The 
resulting CIN provides a mechanism for proliferating tetraploid cells to acquire 
additional genetic aberrations such as TP53, RB1 and CDKN1A loss, facilitating 











Figure 6.3 A route to tumorigenesis  
Model depicting how D-type cyclin overexpression can result in tetraploid tolerance, 





























6.2 Concluding remarks 
This thesis has sought to advance our understanding and knowledge regarding 
tetraploidy tolerance independent of mutations of the p53/p21 pathway. HCT-116 
tetraploid clones with elevated p53 and p21 were analysed by SILAC that revealed 
overexpression of cyclin D1, a protein known to sequester and inhibit the function 
of p21 (Sherr and Roberts, 1999). Overexpression of cyclin D1 provided a 
significant survival benefit for newly formed tetraploid clones, indicating that 
deregulation of cyclin D can override the p53-dependent tetraploidy checkpoint and 
provide tolerance. Furthermore, analysis of genome-doubled TP53 wild-type 
TGCTs showed elevations of all three D-type cyclins, providing evidence that their 
overexpression may provide tetraploidy tolerance in these tumours.  




Chapter 7. Appendix 
 
Figure 7.1 p53 protein stability  
A comparison of p53 protein stability between diploid and tetraploid clones.  Cells 
were treated with 50µg/ml cycloheximide and incubated at 37oC for the indicated 
times. Cells were lysed before immunoblotting and western blotting for p53. For 
quantification, p53 protein was normalised to GADPH before expression as 
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Figure 7.2 Total protein levels 
Diploid and tetraploid clones were counted before lysis in equal volumes 8M urea 
buffer. Total protein amounts were determined by Bradford assay and dived by the 




































Figure 7.3 Quantification of HCT-116 isogenic cell system centriole number  




































7.1 Small molecule modulation of G6PD 
7.1.1 Introduction  
The pentose phosphate pathway (PPP) is responsible for around 20% of cellular 
glucose oxidation (Wamelink et al., 2008). Like glycolysis, the PPP is oxygen-
independent, however in contrast, it does not require adenosine triphosphate (ATP). 
The primary products of this biosynthetic pathway are nicotinamide adenine 
dinucleotide phosphate (NADPH) and ribose-5-phosphate (R5-P). The oxidative 
branch of the pathway contains the rate-limiting enzyme, glucose-6-phospahe 
dehydrogenase (G6PD), which is mainly responsible for NADPH production and 
approximately 30% of ribose production; the non-oxidative branch produces the 
majority of the remaining ribose. NADPH is utilised for lipid synthesis and redox 
control, whereas R5-P is a precursor for nucleotide production (Wamelink et al., 
2008).  
 
A recent study has implicated G6PD and the oxidative PPP in the maintenance of 
genome stability after IR (Cosentino et al., 2011). The ataxia telangiectasia 
mutated kinase (ATM) senses DNA double strand breaks (DSBs) though chromatin 
disruption (Kastan, 2008). DSB-induced autophosphorylation activates the kinase, 
which then phosphorylates downstream targets such as p53-Ser15 and BRCA1 to 
induce arrest and DNA repair (Kastan, 2008). Aside from the classical function of 
ATM, the kinase has been shown to interact with the PPP. Due to subnormal 
NADPH levels in ATM-/- neuronal cells, Cosentino et al investigated the possibility 
that ATM may interact with the PPP (Cosentino et al., 2011). Activation of ATM by 
DSBs resulted in G6PD activation, via allosteric binding of hsp27 to G6PD, and 
heightened levels of NADPH and R5-P (Figure 7.4) (Cosentino et al., 2011). As the 
PPP provides R5-P, it was hypothesised that the activation of G6PD assists DNA 
repair by providing nucleotide precursors. These findings suggest treatment of 
cancer cells with a G6PD inhibitor prior to IR, could reduce their DNA repair 
capacity, increase DSBs and CIN, resulting in cell death through extreme genetic 
instability (Kops et al., 2004).  
 




Studies by Varshney at al demonstrated the effects of PPP inhibition in vitro and in 
vivo. BMG-1 glioma cells were treated with either 2-deoxy-glucose (2-DG), an 
inhibitor of glycolysis or 6-aminonicotinamide (6-AN), a G6PD competitive inhibitor, 
and both result in decreased PPP flux (Varshney et al., 2005). Single-agent or 
combined treatment before and during IR enhanced sensitivity. PPP-inhibited cells 
showed a significant decrease in survival factions, depleted GSH levels, elevated S 
phase arrest and increased micronuclei formation (inactive of S phase segregation 
errors). Furthermore, the group showed treatment of mice bearing Ehrlich ascites 
tumours with 6-AN and IR, resulted in complete regression in 80% of animals, 
whereas IR alone resulted in stable disease followed by progression (Varshney et 
al., 2004).  
 
Taken together, these studies show that classical DNA damage pathways interact 
with central glucose metabolism pathways to facilitate DNA repair and maintain 
genomic integrity. Inhibition of these pathways after DNA damage can lead to 
further genomic instability through saturation of repair pathways, resulting in lethal 
DNA damage and enhanced sensitivity. Therefore inhibition of the PPP in tumour 










Figure 7.4 ATM regulates the pentose phosphate pathway 
After DSB induction by a genotoxic agent of IR, ATM senses DNA damage and is 
activated. ATM phosphorylates hsp27, possibly via p38. Phosphorylated hsp27 can 
allosterically bind G6PD and activate the PPP rate-limiting enzyme. The activated 
PPP provides ribose-5-phosphate for nucleotide synthesis and DNA repair, 
reducing the extent of DNA damage. Elevated NADPH levels also reduce the 
extent damage caused by ROS after IR treatment.  
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7.1.2 G6PD compound screen 
High throughput screening (HTS) is a common drug discovery approach, used to 
identify novel bioactive molecules. A collaboration with the HTS screening facility 
was formed in order to discover inhibitors of G6PD. The enzyme was produced and 
purified, before estimation of its oligomeric species by size exclusion 
chromatography (SEC). The purified G6PD was used in an isolated molecular 
target (IMT) assay, optimised for HTS. Screen hits were validated in a secondary 
screen, before specific validation and testing.  
7.1.2.1 Recombinant G6PD purification  
The first step of the process was to produce stocks of catalytically active human 
recombinant G6PD. A collaboration was formed with Cancer Research Technology 
and they provided human G6PD expression vectors and assay design information. 
 
A human His-tagged G6PD (pHis:hG6PD) bacterial expression plasmid was freshly 
transformed into JM109DE3 E.coli cells. Protein expression was induced by 
autoinduction, as this produced a greater soluble protein fraction than IPTG-
induction based methods. His:hG6PD expression is controlled by the lac operon 
and the autoinduction method uses carefully formulated media to control 
recombinant expression. The autoinduction media contains carbon sources of 
energy, such as glucose and lactose. After glucose stocks are depleted and the 
bacterial population is near saturation, lactose is transported into the bacterial cell 
and production of its isomer allolactose inhibits the lac repressor initiating gene 
transcription of His:hG6PD (Blommel et al., 2007). By utilising endogenous 
metabolism to induce recombinant protein expression, a greater yield and soluble 
fraction was obtained. The soluble fraction was incubated with nickel beads, which 
have affinity for His-binding, and tagged proteins were bound and eluted with 
imidazole. Elution fractions were separated by SDS-PAGE to confirm G6PD 
expression and purification (Figure 7.5A). SDS-PAGE analysis showed clear 
protein expression within the region expected for a protein with molecular weight of 
59kD. Western blot analysis of fraction 3, using an anti-histidine antibody, 
confirmed the presence of purified recombinant G6PD (Figure 7.5B). 
  







Figure 7.5 Nickel bead purification of His-G6PD 
(A) SDS-PAGE of His-G6PD imidazole elution fractions and His-tagged GST 
control. Proteins were expressed in E. coli JM109DE3 cells, via the autoinduction 
method. His-tagged G6PD was purified using nickel beads. PGS and PGD 
bacterial pellet samples. F1: flow wash one, F2: flow wash two. KDa, kilodalton. (B) 
Protein purification was confirmed by Western blot analysis. Proteins were probed 
using an anti-His antibody. M (marker); E3 (G6PD eluate). 
  

















7.1.2.2 Size-exclusion chromatography and oligomeric species identification 
G6PD can exist in an active multimeric complex or an inactive/semi-activity 
monomer. SEC analysis was performed in order to determine purity and confirm 
the presence of catalytic higher order enzyme species.  
 
Gel filtration analysis of purified His:hG6PD resulted in a single well-defined elution 
profile, indicating a predominant oligomeric species with high purity and low 
contaminants (Figure 7.6A). Fractions were collected and samples were separated 
by SDS-PAGE to further check purity and perform protein quantification, using a 
BSA standard curve (Figure 7.6B). The most prevalent protein bands were present 
at 59kDa, which is the region where monomeric G6PD is expected to migrate 
based on its amino acid sequence. Fraction eight displayed the greatest 
concentration of 169µg/ml and correlated with the centre of the chromatogram peak.  
 
Gel filtration analysis was also used to estimate the molecular weight of the purified 
proteins. A protein standard was loaded and eluted from the gel filtration column, 
and elution times were recorded. Purified His:hG6PD underwent the same 
procedure and the elution profiles were overlaid. The overlay showed that G6PD 
was eluted slightly earlier than the 158kDa standard, suggesting the possible 
presence of a tetrameric G6PD (Figure 7.7A). Using the standard curve to calculate 
an approximate value, by plotting it against the ratio of the void volume (Vo) and 
elution volume (Ve) (Figure 7.7B), resulted in an estimated molecular mass of 
198kD, which is indicative of a tetramer. The calculated molecular mass did not 
precisely equate to the actual mass of a G6PD tetramer, as in the SEC process, 
proteins are separated by shape and size, which is not directly proportional to 
weight, and therefore the predictive value of this assay is limited. However, the 
predicted molecular weight of 198kD is closest to the actual weight (236kD) of the 
tetramer, providing satisfactory evidence for the production of a higher order 
tetrameric species.  











Figure 7.6 Size exclusion chromatography of purified G6PD 
(A) Chromatogram displaying purified His:hG6PD expressed in JM109DE3 E.coli 
cells. Nickel bead-separated fractions were pooled before separation by gel 
filtration. mAU; milli absorbance units (B) SEC fraction separated on a SDS-PAGE 
gel, alongside a BSA quantification curve and stained with coomassie blue.  
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Figure 7.7 SEC standard curve and G6PD molecular weight estimation 
(A) Overlay of protein standards (blue) and His:hG6PDH (red) purified from 
JM109DE3 cells on after gel filtration column (B) Standard curve and equation 
used to estimate molecular weight/oligomer species.  
  




7.1.3 Enzyme assay development  
In order to assess the ability of small molecules to modulate G6PD activity, an 
isolated molecular target assay was designed (Figure 7.8A). The reduction of 
NADP to NADPH was measured by fluorescence intensity, which is directly 
proportional to the rate of G6PD activity. Molecules that affected NADPH 
production could, therefore, be considered as ‘hits’. An array of test experiments 
was required to optimise the conditions for a large HTS compound screen; the 
basic assay procedure is outlined in Figure 7.8B. 
 
The specific reaction mixture conditions were first determined using purified 
recombinant His:hG6PD. Next, the SEC purified fractions were tested for activity 
and inhibition potential, to ensure the optimal factions was selected for the HTS 
procedure. All fractions could be inhibited with the known G6PD inhibitor, 5-
Dehydroepiandrosterone (DHEA), and factions six, seven and eight displayed the 
greatest activity (Figure 7.8C). Given that fraction eight displayed the greatest 
concentration, activity and showed good purity, it was selected for use in the 
primary screen and for further assay optimisation. This characterisation provided 
evidence for a physiologically relevant and catalytically active enzyme that would 
give the greatest possible chance of discovering small chemical molecules that 
could modulate G6PD activity.  
 
Enzyme inhibition was tested over a dose range to ensure the enzyme could be 
inhibited in a dose-dependent manner. Figure 7.9 demonstrates that the enzyme 
could be inhibited with DHEA, producing an IC50 of 10.02µM.  Importantly, there 
was very little difference between 96 and 384-well format, confirming 384-well 
plates could be used to assay the 20,000 compounds. As DHEA could inhibit 
G6PD in vitro, the compound was chosen to act a positive control and any 
compounds that inhibited G6PD to similar level would be considered ‘hits’, given 
that the sample compounds were 5-fold less concentrated.  
  





Figure 7.8 Assay reaction scheme 
A) Assay reaction outline. G6PD catalyses the irreversible oxidation of glucose-6-
phosphate (G6P) to 6-phosphoglucono-δ-lactone, resulting in the subsequent 
reduction of NADP+. (B) Outline of reaction strategy. Compounds were used at a 
20µM final concentration. NADPH is excited at 340nm and gives a 460nm emission 
(C) Fraction activity of 1ng SEC-purified His:hG6PD, in the presence of DMSO and 
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Figure 7.9 Inhibition of purified enzyme  
(A,B,C) Dose response curves and IC50 values of His:hG6PD. A range of DHEA 
doses were used in the assay to ensure a dose-dependent inhibition. Activity is 































































In order to assess whether the enzyme functioned as expected, without chemical 
modulation, and to determine an acceptable concentration for the primary screen, 
various enzyme concentrations were assayed (Figure 7.10A). Varying amounts of 
G6PD, ranging from 1-0.0625ng, were analysed and a dose-dependent relationship 
was observed, in the presence or absence of DHEA. The control/inhibition ratio 
remained constant at 2.5-fold for all enzyme amounts, except for the lowest 
concentration of 0.0625ng, where the ratio was reduced to 1.7-fold.  
 
The upper range limit of detection was 250,000 Fluorescence intensity (FI) units. In 
order to identify inhibitors of G6PD, the reaction baseline for a fixed incubation 
period was required to be approximately 125,000 FI units, allowing detection of a 
sufficient dynamic range of enzymatic activity. From the data, it was clear that 
0.5ng of G6PD per reaction provides this, giving a fluorescence value of 115,000 FI 
units, which provided the greatest dynamic range between DMSO control and 
inhibitor. 
 
Rapid reaction termination was required to achieve an endpoint value, ensuring 
that all values could be compared and normalised to the DMSO control. As well as 
efficient termination of the NADPH produced by the reaction over the selected 
incubation period, NADPH was required to remain stable over time to ensure 
accurate read-out values were obtained, as the experimental process inevitably 
resulted in over two-hour periods between reading the first and last plates. 
Fluctuations in signal during this time would otherwise be problematic resulting in 
poor accuracy. The reaction was terminated using SDS, as this detergent 
denatured the protein and ceased NADPH production (Hamilton et al., 2012). A 
final concentration of 0.083% SDS was sufficient for reaction fixation and 
termination (Figure 7.10B) There was a small decay of NADPH signal over a four-
hour period, however this was minimal and still allowed effective normalisation of 
plates.  
  





Figure 7.10 Enzyme dose and SDS termination  
(A) Enzymatic activity relative to amount of enzyme added to reaction (1 - 0.625ng)  
-/+ DHEA.  (B) SDS fixation of assay reaction with 0.083% SDS; 0.5 and 1ng of 
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It was essential that the screen was carried out at the optimal reaction temperature 
to ensure accurate valid results, as enzyme reactions are sensitive to temperature 
(Daniel and Danson, 2013). To investigate the effect of temperature on the assay, 
reactions were performed at room temperature (RT), 25oC and 37oC and data 
demonstrated an inverse correlation between temperature and catalytic activity 
(Figure 7.11A). From the data, it was decided that the screen would be performed 
at RT due to optimal activity and practical advantages.  
 
The inhibitor library used for the screen was the Chembridge DriverSet™, which 
contains 20,000 compounds dissolved in 100% DMSO. Therefore, the assay was 
tested for DMSO tolerance, by applying 1% and 10% DMSO to the assay reaction 
(Figure 7.11B). From the data, it was clear there was little difference in activity at 
either DMSO concentration, when compared to non-DMSO treated control. These 
data suggested that the reaction could be performed at 10% DMSO without 
compromising enzymatic activity and this concentration could be used to minimise 
the risk of compounds becoming insoluble in the reaction buffer.  
 
7.1.4 The screen  
In order to test assay quality, the z-factor was calculated (Figure 7.12A) (the value 
obtained was 0.67, which is regarded as an excellent assay). The z-factor takes 
into account the dynamic range (range between highest and lowest value) and the 
degree of separation between variability of controls. There was no overlap between 
positive control (inhibitor) and negative control (DMSO) variation, suggesting any 
effect comparable to the positive control in the screen was valid and not a result of 
noise. 
 
With a fully optimised, robust and reproducible assay a pilot screen was first 
performed with a small kinase inhibitor library. Figure 7.12B shows a heat map of 
the kinase library replicated four times in a single 384-well plate, with the last lane 
containing DHEA as a positive control. The result clearly demonstrates that many 
compounds auto-fluoresced, which is a limitation of the wavelength used for this 
assay. In light of these findings, it was decided for the primary screen that an 




enzyme-deficient screen would be performed to determine the intrinsic compound 
fluorescence and this could be subtracted from the screen endpoint value.  
 
  





Figure 7.11 Temperature and DMSO tolerance 
(A) Reactions were performed at room temperature, 25oC and 37oC in order to find 
the optimal temperature for the assay. (B) 1% or 10% DMSO was incubated in the 
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Figure 7.12 Pilot screen and z-factor 
A) Assay Z-factor shows satisfactory distance between DMSO control and DHEA 
inhibitor control. (B) Heat map representing a kinase inhibitor library replicated four 
times in one 384-well plate. Blue represents low signal fluorescence and red high, 
which is relative to enzymatic activity.  Many of the compounds showed auto 











7.1.5 Primary screen results  
The primary screen was performed in triplicate with or without enzyme. The non-
enzyme control screen provided autofluorescence data that was used to reduce the 
number of false positives. The library was screened in two parts, screening 10,000 
compounds per experiment. Figure 7.13A shows the variation across all sixty-two 
384-well plates. From the raw data, it is clear that four plates were incubated for an 
incorrect amount of time before fixation, however this error was corrected upon 
data normalisation.   
 
Analysis for potential inhibitors was performed on all compounds that had low 
autofluorescence values, with the data expressed as a percentage of DMSO 
control. Inhibitors were defined as compounds that reduced signal by ≥25%, 
relative to control. Using this rule, eleven inhibitors were discovered in the primary 
screen and were re-ordered to repeat in a secondary screen (Figure 7.13B). 
 
  







Figure 7.13 Primary screen results  
(A) Normalised values representing the signal variation across all plates. (B) Table 
of inhibitors identified from the primary screen, displaying chemical formula, 
physiochemical properties and normalised signal.  cLogP; Lipid solubility. LogSW; 






Mol Weight Mol Formula Mol Name cLogP LogSW RB tPSA hDon hAcc Signal relative to DMSO control 
260.3 C13 H12 N2 O2 S (2-methyl-5-nitrophenyl)[(5-methyl-2-thienyl)methylene]amine 3.6 -4.173 2 55.5 0 3 0.73909 
370.5 C17 H26 N2 O5 S 1-[(2,5-dimethoxyphenyl)sulfonyl]-4-(3-methylbutanoyl)piperazine 2.063 -3.663 2 76.15 0 6 0.73869 
394.2 C16 H9 Cl2 N3 O3 S 
5-(2-chloro-5-nitrobenzylidene)-2-[(2-chlorophenyl)imino]-1,3-thiazolidin-4-
one 5.18 -6.888 2 84.6 1 4 0.73667 
336.3 C15 H17 F5 N2 O 2,3,4,5,6-pentafluoro-N-(1-isopropyl-4-piperidinyl)benzamide 1.891 -3.267 2 32.34 1 2 0.73435 
303.4 C17 H21 N O2 S N-(2,4-dimethylphenyl)-2,4,6-trimethylbenzenesulfonamide 4.51 -5.264 2 46.17 1 2 0.73214 
258.3 C15 H15 F N2 O 2-(2-fluorophenyl)-N-[1-(4-pyridinyl)ethyl]acetamide 1.673 -1.213 4 41.99 1 2 0.73002 
285.4 C18 H23 N O2 5,5-dimethyl-2-{[(2-phenylpropyl)amino]methylene}-1,3-cyclohexanedione 3.49 -3.254 4 46.17 1 2 0.72975 
358.4 C21 H18 N4 O2 1-(3-methoxyphenyl)-5-methyl-N-1-naphthyl-1H-1,2,3-triazole-4-carboxamide 3.781 -5.042 3 69.04 1 4 0.71843 
387.5 C20 H25 N3 O3 S 1-[(4-sec-butylphenyl)sulfonyl]-4-(3-pyridinylcarbonyl)piperazine 3.304 -4.847 3 70.58 0 5 0.70806 
203.2 C11 H9 N O3 4-(4-hydroxybenzylidene)-3-methyl-5(4H)-isoxazolone 2.31 -2.076 1 58.89 1 4 0.70343 
387.2 C15 H12 Cl2 N2 O4 S 4-[(2,3-dichloro-4-methoxyphenyl)sulfonyl]-3,4-dihydro-2(1H)-quinoxalinone 2.921 -4.63 1 75.71 1 4 0.56594 




7.1.6 Secondary screen and hit validation  
The secondary screen employed the same methods as the primary and was 
carried out over a dose range of 0.01-60µM for each compound. Only 9126408 
(C15H12CL2N2O4S) validated in the secondary screen, displaying a dose-dependent 
relationship and was confirmed as a G6PD inhibitor (Figure 7.14A).  
 
The physiochemical properties presented provide evidence that the compound is 
soluble and has low toxicity odds. A LogSW (water solubility) value of 4.63 is 
suggestive of good solubility in water, while a CLogP value of 2.9 is indicative of 
good lipid solubility, suggesting that the compound could pass through lipid 
membranes (Sangester, 1989) (Figure 7.14A). Analogues of 9126408 were 
obtained (6731786 [C16H16N2O4S) and 9121326 [C15H13CLNO4S]) to investigate if 
they also showed activity (Figure 7.14B). Chemical analogues have similar 
molecular structures but differ by certain components (e.g. different functional 
groups) and are often used in drug discovery in order to investigate how a molecule 
interacts with its target, as well as to increase potency (McKinney et al., 2000). The 
two analogues tested did show activity against G6PD, suggesting a relationship 
between this class of compound and G6PD inhibition. A greater number of number 
of chloride atoms on each molecule correlated positively with potency suggesting 
these groups are important in the mechanism of inhibition. However, neither was as 
potent as the screen ‘hit’ and, therefore, were not taken forward and 9126408 
remained as the lead compound.  
 
Drugs designed to target a specific enzyme can have off-target effects, especially 
with proteins that share a similar structure and function. As G6PD is a 
dehydrogenase that oxidises glucose-6-phoshate permitting reduction of 
NADPNADPH, isocitrate dehydrogenase (IDH1) was chosen as a means to 
investigate target specificity.  IDH1 catalyses the production of α-ketoglutarate from 
isocitrate and also uses NADP as a co-factor in a dehydrogenation reaction, similar 
to the G6PD-mediated reaction (Smolkova and Jezek, 2012). Compound 9126408 
showed no activity against IDH1, providing preliminary evidence of target specificity 
Figure 7.14C. In order to investigate if the compound demonstrated activity against 
endogenous G6PD, human breast adenocarcinoma cells (MCF-7) were lysed by 




sonication to obtain a native extract with an intact and active G6PD. Native cell 
lysates were supplemented with NADP, glucose-6-phosphate and 9126408 or 
DHEA (Figure 7.14D). It was clear that endogenous G6PD could also be inhibited 
effectively, suggesting the compound may show efficacy in cell line systems.  
  





Figure 7.14 Hit validation of compound 9126408 
(A) Compound 9126408 structure, secondary screen result and physiochemical 
properties. Compound 9126408 was assayed with all primary hits in the secondary 
screen. (B) Analysis of 9126408 analogues in the G6PD assay. (C) IDH1 was 
incubated with a range of 9126408 to investigate compound specificity to G6PD. 
(D) MCF-7 native lysates were prepared by sonication to investigate if 9126408 
could inhibit endogenous G6PD. Error bars represent the SD (N=3) for all 
experiments.   
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387.2 C15H12Cl2N2O4S 4-[2,3-dichloro-4methoxyphenyl)sulfonyl]-3,4-
dihydro-2(1H)-quinoxalinone 
















































7.1.7 Discussion and Conclusions 
The aim of this chapter was to discover inhibitors of G6PD, as they may provide 
therapeutic benefit, and it was anticipated that the ‘hit’ compounds could be used 
for research in cell lines, in an attempt to improve the effect of radiotherapy. 
Recombinant tetrameric G6PD was successfully purified and its function assessed 
in an enzymatic assay. The assay was designed to be as robust as possible, in 
order to reproducibly screen 20,000 compounds. A number of inhibitors were 
identified in the primary screen and one inhibitor was validated. The validated 
inhibitor displayed a dose-dependent relationship with the enzyme and was more 
potent than its commercially available analogues. The compound showed no 
activity against an enzyme of similar catalytic function as G6PD (IDH1), suggesting 
a degree of specificity and showed activity against endogenous G6PD in cells. 
 
The primary screen used the Chembridge DriverSet™ consisting of 20,000 
compounds picked to provide high coverage of chemical space, covering all 
possible stoichiometric configurations in all possible topological isomers. Using a 
library such as this, increases the probability of discovering ‘hits’, as many classes 
of compounds are represented. The compounds in the library have been selected 
to ensure favourable physicochemical properties, such as solubility and lipophilicity, 
while undesirable chemical groups that may cause toxicity have been omitted.  
 
The primary screen identified a potential inhibitor of G6PD. The compound (no. 
9126408) displayed IC50 values comparable to the standard inhibitor DHEA 
(~10µM), providing a starting point for development. Analogues of the compound 
were commercially available and were obtained and tested in the assay, however 
showed inferior potency compared to 9126408. The physiochemical properties of 
the molecule were also promising, suggesting water and lipid solubility. A 
relationship between topological polar surface area and CLogP has been reported 
and can be used to predict potential compound toxicity. Compounds with a CLogP 
>3 and TPSA <75A2 appear to be 25x more likely to have off-target effects and 
cause toxicity (Allen et al., 2010). Compound 9126408 does not fall into this 
category, as both parameters were within the aforementioned limits, implying that 
the compound is less likely to have toxic off-target effects.  





A clear issue with 9126048 is a high IC50 of 10µM. This was expected, as HTS 
screening intends to find molecules that can be used as a foundation for further 
chemical optimisation. However, when used in the cell lysate system, the inhibition 
potential of the compound was reduced and in cell lines this is expected to fall even 
further. Therefore, the next stage of the process is to collaborate with medicinal 
chemists in order to perform structural activity relationship (SAR) analysis that can 
increase potency and further improve solubility. Increased efficacy and potency will 
also reduce the likelihood of cellular toxicity, as lower doses would suffice for 
activity.  
 
Future work on the compound would also involve determination of Michaelis-
Menten kinetics to understand whether the inhibition is competitive or allosteric 
(Strelow et al., 2004). As the assay was performed at Vmax, where enzyme 
substrate is in excess and not rate-limiting, this favours the discovery of allosteric 
inhibitors. In contrast to competitive inhibitors that bind active sites, allosteric 
inhibitors interact with sites that are less evolutionary conserved and therefore can 
display grater selectivity (May et al., 2007). This is demonstrated by the specific 
inhibition of G6PD by compound 9126048, by comparison to IDH1. In order to 
further increase confidence in the specificity of the compound to G6PD, a panel of 
oxidoreductases should be screened. This assay would best be performed after the 
SAR process, as a more potent molecule is less likely to interact with other 
enzymes (Hughes et al., 2011). After compound optimisation in vitro, cell lines 
should be treated to investigate whether the compound can reach its target and 
potentiate the effect of IR.  
 
The degree of compound autofluorescence was a major limitation in the presented 
assay. The primary screen was performed with and without enzyme in order to 
assess the level of background fluorescence. Background fluorescence could be 
subtracted from medium-to-low fluorescing compounds, however, highly 
fluorescent compounds that saturated the detection threshold were problematic, as 
the enzyme reaction combined with autofluorescence pushed the signal beyond the 
detection range and subtraction would result in incorrect results. Even with the 
removal of fluorescent compounds from the analysis, the secondary screen 




activators did not validate. It is likely that these compounds autofluoresced in the 
primary and not in the secondary screen. This may be due to bond rotations within 
the molecule leading to false positives results.  
 
In order to overcome this problem, the screen should be repeated using a different 
wavelength for excitation and emission, or using a non-fluorescence based 
approach. Large fractions of screening libraries contain heterocyclic molecules and 
compounds with conjugated bonds that are responsible for autofluorescence at 
short wavelengths (Thorne et al., 2010). Data has shown that screens performed in 
the blue spectral region (340/460nm) are likely to have a greater proportion of 
autofluorescent compounds; approximately 2-5% of the library (Thorne et al., 2010). 
Conversely, excitation in the red/orange (e.g. 540ex/590em) spectrum ensures 
background fluorescence is reduced to approximately 0.004-0.01% (Thorne et al., 
2010).  
 
During the course of this investigation, Hamilton et al synthesised a novel 
uncompetitive inhibitor of G6PD (Hamilton et al., 2012). The steroid based 
compound was a 10-fold more potent derivative of DHEA. In addition to good 
physiochemical properties, the DHEA derivatives could inhibit cellular G6PD in the 
low µM range. It will be interesting to see if these compounds can potentiate the 
effects of DNA damage and CIN after IR treatment, and if their potency can be 
further increased into the nM range.  
 
In conclusion, this chapter aimed to find novel inhibitors of G6PD that could be 
used in cell line systems to inhibit the function of the PPP. An inhibitor was 
discovered and preliminary experiments warrant further optimisation of the 
molecule by medicinal chemistry techniques. Compound autofluorescence may 
have masked a number of positive ‘hits’. A repeat screen exciting within the red 










7.1.8 Methods  
7.1.8.1 G6PD assay and screen  
The G6PD plasmid was kindly provided by Dr Dominic James (CRUK Patterson 
Institute). Protein purification, assay development and guidance were provided by 
Dr Ed McKenzie (Manchester University). 
 
7.1.8.2 Protein purification  
pHis: hG6PDH (Figure 7.15) plasmid was freshly transformed into JM109DE3 cells 
and plated into LB amp selection plate. A single colony was used to inoculate 5 ml 
LB amp and was incubated for 8 hours at 37oC. The 5ml starter culture was then 
used to inoculate a 500ml auto-induction broth (for 1L; 6g phosphate buffer pH 7.2 
6g Na2HPO4/3g KH2PO4, 20g trypton, 5g yeast extract, 5g NaCl,	   60 % v/v Glycerol, 
10 % w/v Glucose, 8 % w/v Lactose) and left overnight at 37oC with shaking 
(220rpm). Cells were harvested by centrifugation (4000rpm for 10mins) and 
resuspended in 20mL lysis buffer (50mM NaP, 0.3M NaCl, pH 8.0 and 1% Triton X-
100 supplemented with proteinase inhibitors). 
 
Samples were sonicated for six 30 second bursts on ice (setting 20%) and spun at 
20,000rpm for 30 minutes at 4oC. Lysates were incubated in batch to nickel-
sepharose beads (Qiagen) in the presence of 10mM imidazole for 2 hours at 4oC 
(on roller). Beads were pelleted and washed with increasing stringency buffers 
containing 10mM-50mM imidazole in lysis buffer-free detergent. Protein was eluted 
in 250mM imidazole and fractions 1-3 pooled. Proteins were further purified and 
analysed by gel filtration on a superdex200 (120ml column volume) column at 4oC. 
BioRad protein standards were used to determine molecular species of glucose-6-
phosphaste dehydrogenase (G6PD). Eluted sample was stored in 50mM NaP, 









Figure 7.15 pHis-G6PD plasmid map 
 
 
7.1.8.3 Enzyme reaction assay 
The following methods were adjusted for one assay reaction in a 96-well format, 
whereas ¼ of the indicted volume was used for 384-well format. 10µl of test 
compound or dimethyl sulfoxide (DMSO) (control) was dispensed into 
corresponding wells. Then, 50µl of G6PD assay base buffer 2.5x (50mM Tris pH 
8.0, MgCl2 25mM, BSA 0.0075% [w/v]), 10µl of 10x glucose-6-phosphate (500µM 
final concentration; Sigma-Aldrich) and 10µl of 10x G6PD recombinant enzyme 
were mixed to create a master mix and dispensed in wells. Finally, 20µl of 5x 
nicotinamide adenine dinucleotide phosphate (NADP) (50µM final concentration; 
Sigma-Aldrich) was added to start the reaction. After five minutes at room 
temperature the reaction was inhibited with sodium dodecyl sulfate (SDS) (Sigma-




Aldrich) at 0.083% final concentration. Endpoint fluorescence was analysed on a 
Pherastar (BMG Labtech) plate reader at Ex340/Em440nm.  
 
7.1.8.4 Screening procedure 
2.5µl of compound dissolved in DMSO (1µM final concentration) was dispended 
using a Biomek® FXP Laboratory Automation Workstation and stored at -80oC until 
screening. Compound plates were thawed for 20 minutes at room RT. Plates were 
centrifuged at 1,200rpm to ensure compounds were equally distributed in wells. 
Next, 17.5µl/well NAPD master-mix was applied to each well using WellMate liquid 
handlers. 5µl/well G6PDH (10X) enzyme was then added to start the reaction. 
Plates were incubated at room temperature for five minutes. To inhibit the reaction, 
5µl of SDS was applied to each well (final concentration 0.5%). Fluorescence 
intensity signal was immediately measured on the Pherastar Plate reader 
(Ex340/Em440nm). 
 
7.1.8.5 Isocitrate dehydrogenase assay 
1µg of human recombinant isocitrate dehydrogenase (Sigma-Aldrich) was 
incubated with NADP 5.2mM isocitrate (Sigma-Aldrich) in assay base buffer. 
Reactions were carried out a room temperature for five minutes before SDS fixing. 
Endpoint fluorescence was analysed on a Pherastar (BMG Labtech) plate reader at 
Ex340/Em440nm.  
 
7.1.8.6 Native extract assay    
MCF-7 cells were trypsinised and washed in cold PBS 4oC. Cells were sonicated 
six times for 10 seconds and cooled on ice. Lysates were centrifuged at 13,000rpm 
for 15 minutes (4oC). Protein concentrations were determined by Bradford assay 
and 25µg of lysate was incubated with 0.5mM NADP, 5mM G6P, 10mM Tris pH 7.5 
and 3mM MgCl2. Fluorescence was analysed on a Pherastar (BMG Labtech) plate 
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